Report text available as:

  • TXT
  • PDF   (PDF provides a complete and accurate display of this text.) Tip ?

115th Congress    }                                  {   Rept. 115-767
                        HOUSE OF REPRESENTATIVES
 2d Session       }                                  {          Part 1

======================================================================



 
   COORDINATED RESPONSE THROUGH INTERAGENCY STRATEGY AND INFORMATION 
                              SHARING ACT

                                _______
                                

 June 20, 2018.--Committed to the Committee of the Whole House on the 
              State of the Union and ordered to be printed

                                _______
                                

   Mr. Gowdy, from the Committee on Oversight and Government Reform, 
                        submitted the following

                              R E P O R T

                        [To accompany H.R. 5925]

      [Including cost estimate of the Congressional Budget Office]

    The Committee on Oversight and Government Reform, to whom 
was referred the bill (H.R. 5925) to codify provisions relating 
to the Office of National Drug Control, and for other purposes, 
having considered the same, report favorably thereon with an 
amendment and recommend that the bill as amended do pass.

                                CONTENTS

                                                                   Page
Summary and Purpose of Legislation...............................    41
Background and Need for Legislation..............................    41
Statement of Oversight Findings and Recommendations of the 
  Committee......................................................    49
Statement of General Performance Goals and Objectives............    49
Legislative History..............................................    49
Committee Consideration..........................................    50
Roll Call Votes..................................................    51
Explanation of Amendments........................................    51
Application of Law to the Legislative Branch.....................    52
Duplication of Federal Programs..................................    52
Disclosure of Directed Rule Makings..............................    52
Federal Advisory Committee Act...................................    52
Unfunded Mandates Statement......................................    53
Earmark Identification...........................................    53
Committee Estimate...............................................    53
New Budget Authority and Congressional Budget Office Cost 
  Estimate.......................................................    53
Section-by-Section Analysis......................................    55
Changes in Existing Law Made by the Bill, as Reported............    63
Correspondence...................................................   125

    The amendment is as follows:
  Strike all after the enacting clause and insert the 
following:

SECTION 1. SHORT TITLE.

  This Act may be cited as the ``Coordinated Response through 
Interagency Strategy and Information Sharing Act'' or the ``CRISIS 
Act''.

SEC. 2. OFFICE OF NATIONAL DRUG CONTROL.

  (a) Redesignation.--The Office of National Drug Control Policy shall 
be known as the ``Office of National Drug Control''.
  (b) References.--Any reference in any other Federal law, Executive 
order, rule, regulation, or delegation of authority, or any document of 
or relating to the Office of National Drug Control Policy is deemed to 
refer to the Office of National Drug Control.
  (c) Codification.--Subtitle I of title 31, United States Code, is 
amended by adding at the end the following new chapter:

             ``CHAPTER 10--OFFICE OF NATIONAL DRUG CONTROL

                         ``subchapter i--office

``Sec.
``1001. Definitions.
``1002. Office of National Drug Control.
``1003. Administration of the office.
``1004. National drug control program budget.
``1005. National drug control strategy.
``1006. Development of an annual national drug control assessment.
``1007. Monitoring and evaluation of national drug control program.
``1008. Coordination and oversight of the national drug control 
program.
``1009. Emerging threats taskforce, plan, media campaign.
``1010. National and international coordination.
``1011. Interdiction.
``1012. Treatment coordinator.
``1013. Critical information coordination.
``1014. Annual audit and investigation requirements.
``1015. Authorization of appropriations.

     ``subchapter ii--high intensity drug trafficking areas program

``1021. High intensity drug trafficking areas program.

         ``subchapter iii--drug-free communities support program

``1031. Establishment of drug-free communities support program.
``1032. Program authorization.
``1033. Information collection and dissemination with respect to grant 
recipients.
``1034. Technical assistance and training.
``1035. Supplemental grants for coalition mentoring activities.
``1036. Authorization for National Community Antidrug Coalition 
Institute.
``1037. Definitions.
``1038. Drug-free communities reauthorization.

                         ``SUBCHAPTER I--OFFICE

``Sec. 1001. Definitions

  ``In this chapter:
          ``(1) Agency.--The term `agency' has the meaning given the 
        term `executive agency' in section 102.
          ``(2) Appropriate congressional committees.--The term 
        `appropriate congressional committees' means--
                  ``(A) the Committee on the Judiciary, the Committee 
                on Appropriations, and the Caucus on International 
                Narcotics Control of the Senate; and
                  ``(B) the Committee on Oversight and Government 
                Reform, the Committee on the Judiciary, and the 
                Committee on Appropriations of the House of 
                Representatives.
          ``(3) Demand reduction.--The term `demand reduction' means 
        any activity conducted by a National Drug Control Program 
        Agency, other than an enforcement activity, that is intended to 
        reduce or prevent the use of drugs or support or provide 
        treatment and recovery efforts, including--
                  ``(A) education about the dangers of illicit drug 
                use;
                  ``(B) services, programs, or strategies to prevent 
                substance use disorder, including evidence-based 
                education campaigns, community-based prevention 
                programs, opioid diversion, collection and disposal of 
                unused prescription drugs, and services to at-risk 
                populations to prevent or delay initial use of an 
                illicit substance;
                  ``(C) substance use disorder treatment;
                  ``(D) illicit drug use research;
                  ``(E) drug-free workplace programs;
                  ``(F) drug testing, including the testing of 
                employees;
                  ``(G) interventions for illicit drug use and 
                dependence;
                  ``(H) expanding availability of access to health care 
                services for the treatment of substance use disorders;
                  ``(I) international drug control coordination and 
                cooperation with respect to activities described in 
                this paragraph;
                  ``(J) pre- and post-arrest criminal justice 
                interventions such as diversion programs, drug courts, 
                and the provision of evidence-based treatment to 
                individuals with substance use disorders who are 
                arrested or under some form of criminal justice 
                supervision, including medication assisted treatment;
                  ``(K) other coordinated and joint initiatives among 
                Federal, State, local, and Tribal agencies to promote 
                comprehensive drug control strategies designed to 
                reduce the demand for, and the availability of, illegal 
                drugs;
                  ``(L) international illicit drug use education, 
                prevention, treatment, recovery, research, 
                rehabilitation activities, and interventions for 
                illicit drug use and dependence; and
                  ``(M) research related to any of the activities 
                described in this paragraph.
          ``(4) Director.--The term `Director' means the Director of 
        the Office of National Drug Control.
          ``(5) Drug.--The term `drug' has the meaning given the term 
        `controlled substance' in section 102(6) of the Controlled 
        Substances Act (21 U.S.C. 802(6)).
          ``(6) Drug control.--The term `drug control' means any 
        activity conducted by a National Drug Control Program Agency 
        involving supply reduction or demand reduction.
          ``(7) Emerging threat.--The term `emerging threat' means the 
        occurrence of a new and growing trend in the use of an illicit 
        drug or class of drugs, including rapid expansion in the supply 
        of or demand for such drug.
          ``(8) Illicit drug use; illicit drugs; illegal drugs.--The 
        terms `illicit drug use', `illicit drugs', and `illegal drugs' 
        include the illegal or illicit use of prescription drugs.
          ``(9) Law enforcement.--The term `law enforcement' or `drug 
        law enforcement' means all efforts by a Federal, State, local, 
        or Tribal government agency to enforce the drug laws of the 
        United States or any State, including investigation, arrest, 
        prosecution, and incarceration or other punishments or 
        penalties.
          ``(10) National drug control program.--The term `National 
        Drug Control Program' means programs, policies, and activities 
        undertaken by National Drug Control Program Agencies pursuant 
        to the responsibilities of such agencies under the National 
        Drug Control Strategy, including any activities involving 
        supply reduction, demand reduction, or State, local, and Tribal 
        affairs.
          ``(11) National drug control program agency.--The term 
        `National Drug Control Program Agency' means any agency (or 
        bureau, office, independent agency, board, division, 
        commission, subdivision, unit, or other component thereof) that 
        is responsible for implementing any aspect of the National Drug 
        Control Strategy, including any agency that receives Federal 
        funds to implement any aspect of the National Drug Control 
        Strategy, but does not include any agency that receives funds 
        for drug control activity solely under the National 
        Intelligence Program or the Military Intelligence Program.
          ``(12) National drug control strategy; strategy.--The term 
        `National Drug Control Strategy' or `Strategy' means the 
        strategy developed and submitted to Congress under section 
        1005.
          ``(13) Nonprofit organization.--The term `nonprofit 
        organization' means an organization that is described in 
        section 501(c)(3) of the Internal Revenue Code of 1986 and 
        exempt from tax under section 501(a) of such Code.
          ``(14) Office.--The term `Office' means the Office of 
        National Drug Control.
          ``(15) State, local, and tribal affairs.--The term `State, 
        local, and Tribal affairs' means domestic activities conducted 
        by a National Drug Control Program Agency that are intended to 
        reduce the availability and use of illegal drugs, including--
                  ``(A) coordination and enhancement of Federal, State, 
                local, and Tribal law enforcement drug control efforts;
                  ``(B) coordination and enhancement of efforts among 
                National Drug Control Program Agencies and State, 
                local, and Tribal demand reduction and supply reduction 
                agencies;
                  ``(C) coordination and enhancement of Federal, State, 
                local, and Tribal law enforcement initiatives to 
                gather, analyze, and disseminate information and law 
                enforcement intelligence relating to drug control among 
                domestic law enforcement agencies; and
                  ``(D) other coordinated and joint initiatives among 
                Federal, State, local, and Tribal agencies to promote 
                comprehensive drug control strategies designed to 
                reduce the demand for, and the availability of, illegal 
                drugs.
          ``(16) Substance use disorder treatment.--The term `substance 
        use disorder treatment' means an evidence-based, professionally 
        directed, deliberate, and planned regimen including evaluation, 
        observation, medical monitoring, and rehabilitative services 
        and interventions such as pharmacotherapy, behavioral therapy, 
        and individual and group counseling, on an inpatient or 
        outpatient basis, to help patients with substance use disorder 
        reach recovery.
          ``(17) Supply reduction.--The term `supply reduction' means 
        any activity or program conducted by a National Drug Control 
        Program Agency that is intended to reduce the availability or 
        use of illegal drugs in the United States or abroad, 
        including--
                  ``(A) law enforcement outside the United States;
                  ``(B) domestic law enforcement;
                  ``(C) source country programs, including economic 
                development programs primarily intended to reduce the 
                production or trafficking of illicit drugs;
                  ``(D) activities to control international trafficking 
                in, and availability of, illegal drugs, including--
                          ``(i) accurate assessment and monitoring of 
                        international drug production and interdiction 
                        programs and policies; and
                          ``(ii) coordination and promotion of 
                        compliance with international treaties relating 
                        to the production, transportation, or 
                        interdiction of illegal drugs;
                  ``(E) activities to conduct and promote international 
                law enforcement programs and policies to reduce the 
                supply of drugs;
                  ``(F) activities to facilitate and enhance the 
                sharing of domestic and foreign intelligence 
                information among National Drug Control Program 
                Agencies, relating to the production and trafficking of 
                drugs in the United States and in foreign countries;
                  ``(G) activities to prevent the diversion of drugs 
                for their illicit use; and
                  ``(H) research related to any of the activities 
                described in this paragraph.

``Sec. 1002. Office of National Drug Control

  ``(a) Establishment of Office.--There is established in the Executive 
Office of the President an Office of National Drug Control, which 
shall--
          ``(1) lead national drug control efforts, including 
        developing and assessing implementation of evidence-based drug 
        control policy;
          ``(2) coordinate and oversee the implementation of the 
        national drug control policy, including the National Drug 
        Control Strategy;
          ``(3) assess and certify the adequacy of National Drug 
        Control Programs and the budget for those programs;
          ``(4) monitor and evaluate the effectiveness of national drug 
        control policy efforts, including the National Drug Control 
        Program Agencies' programs, by developing and applying specific 
        goals and performance measurements and tracking program-level 
        spending;
          ``(5) identify and respond to emerging threats related to 
        illicit drug use;
          ``(6) administer and evaluate grant programs in furtherance 
        of the National Drug Control Strategy; and
          ``(7) facilitate broad-scale information sharing and data 
        standardization among Federal, State, and local entities to 
        support the national drug control efforts.
  ``(b) Director of National Drug Control and Deputy Directors.--
          ``(1) Director.--
                  ``(A) In general.--There shall be at the head of the 
                Office a Director who shall hold the same rank and 
                status as the head of an executive department listed in 
                section 101 of title 5, United States Code.
                  ``(B) Appointment.--The Director shall be appointed 
                by the President, by and with the advice and consent of 
                the Senate, and shall serve at the pleasure of the 
                President.
          ``(2) Deputy director.--
                  ``(A) In general.--There shall be a Deputy Director 
                who shall report directly to the Director, be appointed 
                by the President, and serve at the pleasure of the 
                President.
                  ``(B) Responsibilities.--The Deputy Director shall--
                          ``(i) carry out the responsibilities 
                        delegated by the Director; and
                          ``(ii) be responsible for effectively 
                        coordinating with the Coordinators.
  ``(c) Responsibilities.--
          ``(1) Policies, goals, objectives, and priorities.--The 
        Director shall assist the President in directing national drug 
        control efforts, including establishing policies, goals, 
        objectives, and priorities for the National Drug Control 
        Program that are based on evidence-based research.
          ``(2) Consultation.--To formulate the National Drug Control 
        policies, goals, objectives, and priorities, the Director--
                  ``(A) shall consult with--
                          ``(i) State and local governments;
                          ``(ii) National Drug Control Program 
                        Agencies;
                          ``(iii) each committee, working group, 
                        council, or other entity established under this 
                        chapter, as appropriate;
                          ``(iv) the public;
                          ``(v) appropriate congressional committees; 
                        and
                          ``(vi) any other person in the discretion of 
                        the Director; and
                  ``(B) may--
                          ``(i) establish advisory councils;
                          ``(ii) acquire data from agencies; and
                          ``(iii) request data from any other entity.

``Sec. 1003. Administration of the office

  ``(a) Employment.--
          ``(1) Authority of the director.--The Director may select, 
        appoint, employ, and fix compensation of such officers and 
        employees of the Office as may be necessary to carry out the 
        functions of the Office under this chapter.
          ``(2) Prohibitions.--
                  ``(A) Generally.--No person shall serve as Director 
                or Deputy Director while serving in any other position 
                in the Federal Government.
                  ``(B) Prohibition on political campaigning.--Any 
                officer or employee of the Office who is appointed to 
                that position by the President, by and with the advice 
                and consent of the Senate, may not participate in 
                Federal election campaign activities, except that such 
                official is not prohibited by this paragraph from 
                making contributions to individual candidates.
  ``(b) Prohibition on the Use of Funds for Political Campaigns or 
Ballot Initiatives.--No funds authorized under this chapter may be 
obligated for the purpose of influencing any Federal, State, or local 
election or ballot initiative.
  ``(c) Personnel Detailed to Office.--
          ``(1) Evaluations.--Notwithstanding any provision of chapter 
        43 of title 5, the Director shall perform the evaluation of the 
        performance of any employee detailed to the Office for purposes 
        of the applicable performance appraisal system established 
        under such chapter for any rating period, or part thereof, that 
        such employee is detailed to such office.
          ``(2) Compensation.--
                  ``(A) Bonus payments.--Subject to the availability of 
                appropriations, the Director may provide periodic bonus 
                payments to any employee detailed to the Office.
                  ``(B) Restrictions.--An amount paid under this 
                paragraph to an employee for any period--
                          ``(i) shall not be greater than 20 percent of 
                        the basic pay paid or payable to such employee 
                        for such period; and
                          ``(ii) shall be in addition to the basic pay 
                        of such employee.
                  ``(C) Aggregate amount.--The aggregate amount paid 
                during any fiscal year to an employee detailed to the 
                Office as basic pay, awards, bonuses, and other 
                compensation shall not exceed the annual rate payable 
                at the end of such fiscal year for positions at level 
                III of the Executive Schedule.
  ``(d) Congressional Access to Information.--The location of the 
Office in the Executive Office of the President shall not be construed 
as affecting access by Congress, or any committee of the House of 
Representatives or the Senate, to any--
          ``(1) information, document, or study in the possession of, 
        or conducted by or at the direction of the Director; or
          ``(2) personnel of the Office.
  ``(e) Other Authorities of the Director.--In carrying out this 
chapter, the Director may--
          ``(1) use for administrative purposes, on a reimbursable 
        basis, the available services, equipment, personnel, and 
        facilities of Federal, State, and local agencies;
          ``(2) procure the services of experts and consultants in 
        accordance with section 3109 of title 5 relating to 
        appointments in the Federal Service, at rates of compensation 
        for individuals not to exceed the daily equivalent of the rate 
        of pay payable under level IV of the Executive Schedule under 
        section 5311 of such title; and
          ``(3) use the mails in the same manner as any other agency.
  ``(f) General Services Administration.--The Administrator of General 
Services shall provide to the Director, on a reimbursable basis, such 
administrative support services as the Director may request.

``Sec. 1004. National drug control program budget

  ``(a) Budget Recommendations.--Not later than July 1 of each year, 
the Director shall provide to the head of each National Drug Control 
Program Agency budget recommendations, including requests for specific 
initiatives that are consistent with the priorities of the President 
under the National Drug Control Strategy, which shall--
          ``(1) apply to the budget for the next fiscal year scheduled 
        for formulation under chapter 11, and each of the 4 subsequent 
        fiscal years; and
          ``(2) address funding priorities developed in the National 
        Drug Control Strategy.
  ``(b) Responsibilities of National Drug Control Program Agencies.--
          ``(1) In general.--For each fiscal year, the head of each 
        National Drug Control Program Agency shall transmit to the 
        Director a copy of the proposed drug control budget request of 
        such agency at the same time as that budget request is 
        submitted to their superiors (and before submission to the 
        Office of Management and Budget) in the preparation of the 
        budget of the President submitted to Congress under section 
        1105(a).
          ``(2) Submission of drug control budget requests.--The head 
        of each National Drug Control Program Agency shall ensure 
        timely development and submission to the Director of each 
        proposed drug control budget request transmitted pursuant to 
        this subsection, in such format as may be designated by the 
        Director with the concurrence of the Director of the Office of 
        Management and Budget.
          ``(3) Content of drug control budget requests.--A drug 
        control budget request submitted by the head of a National Drug 
        Control Program Agency under this subsection shall include all 
        requests for funds for any drug control activity undertaken by 
        such agency, including demand reduction, supply reduction, and 
        State, local, and Tribal affairs, including any drug law 
        enforcement activities. If an activity has both drug control 
        and nondrug control purposes or applications, such agency shall 
        estimate by a documented calculation the total funds requested 
        for that activity that would be used for drug control, and 
        shall set forth in its request the basis and method for making 
        the estimate.
  ``(c) Review and Certification of Budget Requests and Budget 
Submissions of National Drug Control Program Agencies.--
          ``(1) In general.--The Director shall review each drug 
        control budget request submitted to the Director under 
        subsection (b).
          ``(2) Review of budget requests.--
                  ``(A) Inadequate requests.--If the Director concludes 
                that a budget request submitted under subsection (b) is 
                inadequate, in whole or in part, to implement the 
                objectives of the National Drug Control Strategy with 
                respect to the agency or program at issue for the year 
                for which the request is submitted, the Director shall 
                submit to the head of the applicable National Drug 
                Control Program Agency a written description 
                identifying the funding levels and specific initiatives 
                that would, in the determination of the Director, make 
                the request adequate to implement those objectives.
                  ``(B) Adequate requests.--If the Director concludes 
                that a budget request submitted under subsection (b) is 
                adequate to implement the objectives of the National 
                Drug Control Strategy with respect to the agency or 
                program at issue for the year for which the request is 
                submitted, the Director shall submit to the head of the 
                applicable National Drug Control Program Agency a 
                written statement confirming the adequacy of the 
                request.
                  ``(C) Record.--The Director shall maintain a record 
                of each description submitted under subparagraph (A) 
                and each statement submitted under subparagraph (B).
          ``(3) Specific requests.--The Director shall not confirm the 
        adequacy of any budget request that requests a level of funding 
        that will not enable achievement of the goals of the National 
        Drug Control Strategy, including--
                  ``(A) requests funding for Federal law enforcement 
                activities that do not adequately compensate for 
                transfers of drug enforcement resources and personnel 
                to law enforcement and investigation activities;
                  ``(B) requests funding for law enforcement activities 
                on the borders of the United States that do not 
                adequately direct resources to drug interdiction and 
                enforcement;
                  ``(C) requests funding for drug treatment activities 
                that do not provide adequate results and accountability 
                measures;
                  ``(D) requests funding for drug treatment activities 
                that do not adequately support and enhance Federal drug 
                treatment programs and capacity; and
                  ``(E) requests funding for the operations and 
                management of the Department of Homeland Security that 
                does not include a specific request for funds for the 
                Office of Counternarcotics Enforcement to carry out its 
                responsibilities under section 878 of the Homeland 
                Security Act of 2002 (6 U.S.C. 458).
          ``(4) Agency response.--
                  ``(A) In general.--The head of a National Drug 
                Control Program Agency that receives a description 
                under paragraph (2)(A) shall include the funding levels 
                and initiatives described by the Director in the budget 
                submission for that agency to the Office of Management 
                and Budget.
                  ``(B) Impact statement.--The head of a National Drug 
                Control Program Agency that has altered its budget 
                submission under this paragraph shall include as an 
                appendix to the budget submission for that agency to 
                the Office of Management and Budget an impact statement 
                that summarizes--
                          ``(i) the changes made to the budget under 
                        this paragraph; and
                          ``(ii) the impact of those changes on the 
                        ability of that agency to perform its other 
                        responsibilities, including any impact on 
                        specific missions or programs of the agency.
                  ``(C) Congressional notification.--The head of a 
                National Drug Control Program Agency shall submit a 
                copy of any impact statement under subparagraph (B) to 
                the Senate, the House of Representatives, and the 
                appropriate congressional committees, at the time the 
                budget for that agency is submitted to Congress under 
                section 1105(a).
          ``(5) Certification of budget submissions.--
                  ``(A) In general.--At the time a National Drug 
                Control Program Agency submits its budget request to 
                the Office of Management and Budget, the head of the 
                National Drug Control Program Agency shall submit a 
                copy of the budget request to the Director.
                  ``(B) Review and certification of submissions.--The 
                Director shall review each budget submission submitted 
                under subparagraph (A) and submit to the appropriate 
                congressional committees one of the following:
                          ``(i) A written certification of the budget 
                        request for the agency indicating such request 
                        fully funds the National Drug Control Programs 
                        as necessary to achieve the goals of the 
                        National Drug Control Strategy, including a 
                        written statement explaining the basis for the 
                        determination that the budget provides 
                        sufficient resources for the agency to achieve 
                        the goals of the Strategy.
                          ``(ii) A written certification of the budget 
                        request for the agency indicating such request 
                        partially funds the National Drug Control 
                        Programs as necessary to achieve the goals of 
                        the Strategy, including a written statement 
                        explaining the basis for the determination and 
                        identifying the level of funding sufficient to 
                        achieve the goals of the Strategy.
                          ``(iii) A written decertification of the 
                        budget request for the agency indicating the 
                        Director is unable to determine whether such 
                        budget request for the agency fully funds or 
                        partially funds the National Drug Control 
                        Programs as necessary to achieve the goals of 
                        the National Drug Control Strategy, including a 
                        written statement identifying the additional 
                        information necessary for the Director to make 
                        a determination on such budget and the level of 
                        funding sufficient to achieve the goals of the 
                        Strategy.
                          ``(iv) A written decertification of the 
                        budget request for the agency indicating that 
                        such budget is insufficient to fund the 
                        National Drug Control Programs as necessary to 
                        achieve the goals of the Strategy, including a 
                        written statement explaining the basis for the 
                        determination that the budget is insufficient 
                        and identifying the level of funding sufficient 
                        to achieve the goals of the Strategy.
  ``(d) National Drug Control Program Budget Proposal.--For each fiscal 
year, following the transmission of proposed drug control budget 
requests to the Director under subsection (b), the Director shall, in 
consultation with the head of each National Drug Control Program Agency 
and the head of each major national organization that represents law 
enforcement officers, agencies, or associations--
          ``(1) develop a consolidated National Drug Control Program 
        budget proposal designed to implement the National Drug Control 
        Strategy and to inform Congress and the public about the total 
        amount proposed to be spent on all supply reduction, demand 
        reduction, State, local, and Tribal affairs, including any drug 
        law enforcement, and other drug control activities by the 
        Federal Government, which shall conform to the content 
        requirements set forth in subsection (b)(3) and include--
                  ``(A) for each National Drug Control Program Agency, 
                a list of whether the funding level is full, partial, 
                or insufficient to achieve the goals of the National 
                Drug Control Strategy or whether the Director is unable 
                to determine whether the budget request for the agency 
                fully funds or partially funds the agency's activities 
                and contributions as necessary to achieve the goals of 
                National Drug Control Strategy;
                  ``(B) a statement describing the extent to which any 
                budget of a National Drug Control Program Agency with 
                less than full funding hinders progress on achieving 
                the goals of the National Drug Control Strategy; and
                  ``(C) alternative funding structures that could 
                improve progress on achieving the goals of the National 
                Drug Control Strategy; and
          ``(2) submit the consolidated budget proposal to the 
        President and Congress.
  ``(e) Budget Estimate or Request Submission to Congress.--Whenever 
the Director submits any budget estimate or request to the President or 
the Office of Management and Budget, the Director shall concurrently 
transmit copies of that estimate or request to the appropriate 
congressional committees.
  ``(f) Reprogramming and Transfer Requests.--
          ``(1) In general.--No National Drug Control Program Agency 
        shall submit to Congress a reprogramming or transfer request 
        with respect to any amount of appropriated funds in an amount 
        exceeding $1,000,000 that is included in the National Drug 
        Control Program budget unless the request has been approved by 
        the Director. If the Director has not responded to a request 
        for reprogramming subject to this paragraph within 30 days 
        after receiving notice of the request having been made, the 
        request shall be deemed approved by the Director under this 
        paragraph and forwarded to Congress.
          ``(2) Appeal.--The head of any National Drug Control Program 
        Agency may appeal to the President any disapproval by the 
        Director of a reprogramming or transfer request under this 
        subsection.

``Sec. 1005. National drug control strategy

  ``(a) In General.--
          ``(1) Statement of drug policy priorities.--The Director 
        shall release a statement of drug policy priorities in the 
        calendar year of a Presidential inauguration following the 
        inauguration but not later than April 1.
          ``(2) National drug control strategy submitted by the 
        president.--Not later than the first Monday in February 
        following the year in which the term of the President 
        commences, the President shall submit to Congress a National 
        Drug Control Strategy.
  ``(b) Development of the National Drug Control Strategy.--
          ``(1) Promulgation.--The Director shall promulgate the 
        National Drug Control Strategy, which shall set forth a 
        comprehensive plan to reduce illicit drug use and the 
        consequences of such illicit drug use in the United States by 
        limiting the availability of and reducing the demand for 
        illegal drugs and promoting prevention, early intervention, 
        treatment, and recovery support for individuals with substance 
        use disorders.
          ``(2) State and local commitment.--The Director shall seek 
        the support and commitment of State, local, and Tribal 
        officials in the formulation and implementation of the National 
        Drug Control Strategy.
          ``(3) Strategy based on evidence.--The Director shall ensure 
        the National Drug Control Strategy is based on the best 
        available medical and scientific evidence regarding the 
        policies that are most effective in reducing the demand for and 
        supply of illegal drugs.
          ``(4) Process for development and submission of national drug 
        control strategy.--In developing and effectively implementing 
        the National Drug Control Strategy, the Director--
                  ``(A) shall consult with--
                          ``(i) the heads of the National Drug Control 
                        Program Agencies;
                          ``(ii) the United States Interdiction 
                        Coordinator;
                          ``(iii) the Interdiction Committee;
                          ``(iv) the appropriate congressional 
                        committees and any other committee of 
                        jurisdiction;
                          ``(v) State, local, and Tribal officials;
                          ``(vi) private citizens and organizations, 
                        including community and faith-based 
                        organizations, with experience and expertise in 
                        demand reduction;
                          ``(vii) private citizens and organizations 
                        with experience and expertise in supply 
                        reduction; and
                          ``(viii) appropriate representatives of 
                        foreign governments; and
                  ``(B) in satisfying the requirements of subparagraph 
                (A), shall ensure, to the maximum extent possible, that 
                State, local, and Tribal officials and relevant private 
                organizations commit to support and take steps to 
                achieve the goals and objectives of the National Drug 
                Control Strategy.
  ``(c) Contents of the National Drug Control Strategy.--
          ``(1) In general.--The National Drug Control Strategy 
        submitted under subsection (a)(2) shall include the following:
                  ``(A) A description of the current prevalence of 
                illicit drug use in the United States, including both 
                the availability of illicit drugs and the prevalence of 
                substance use disorders, which shall include the 
                following:
                          ``(i) Such description for the previous three 
                        years for any drug identified as an emerging 
                        threat under section 1009 and any other illicit 
                        drug identified by the Director as having a 
                        significant impact on the prevalence of illicit 
                        drug use.
                          ``(ii) A summary of the data and trends 
                        presented in the Drug Control Data Dashboard 
                        required under section 1013.
                  ``(B) A mission statement detailing the major 
                functions of the National Drug Control Program.
                  ``(C) A list of comprehensive, research-based, long-
                range, quantifiable goals for reducing illicit drug 
                use, including--
                          ``(i) the percentage of the total flow of 
                        illicit drugs to be interdicted during the time 
                        period covered by the Strategy; and
                          ``(ii) the number of individuals to receive 
                        treatment for substance use disorders.
                  ``(D) A description of how each goal listed in the 
                National Drug Control Strategy will be achieved, 
                including--
                          ``(i) a list of relevant National Drug 
                        Control Program Agencies and each such agency's 
                        related programs, activities, and available 
                        assets and the role of each such program, 
                        activity, and asset in achieving the goal;
                          ``(ii) a list of relevant stakeholders and 
                        each such stakeholder's role in achieving the 
                        goal;
                          ``(iii) an estimate of Federal funding and 
                        other resources needed to achieve each goal;
                          ``(iv) an identification of existing or new 
                        coordinating mechanisms needed to achieve the 
                        goal; and
                          ``(v) a description of the Office's role in 
                        facilitating the achievement of such goal.
                  ``(E) For each year covered by the Strategy, a 
                performance evaluation plan for each goal listed in the 
                National Drug Control Strategy for each National Drug 
                Control Program Agency, including--
                          ``(i) specific performance measures for each 
                        National Drug Control Program Agency and each 
                        such agency's related programs and activities;
                          ``(ii) annual and quarterly objectives and 
                        targets for each performance measure; and
                          ``(iii) an estimate of Federal funding and 
                        other resources needed to achieve each 
                        performance measure.
                  ``(F) A list identifying existing data sources or a 
                description of data collection needed to evaluate 
                performance, including a description of how the 
                Director will obtain such data.
                  ``(G) A list of anticipated challenges to achieving 
                the National Drug Control Strategy goals and planned 
                actions to address such challenges;
                  ``(H) A description of how each goal was determined, 
                including--
                          ``(i) a description of each required 
                        consultation and how such consultation was 
                        incorporated;
                          ``(ii) data, research, or other information 
                        used to inform the decision; and
                          ``(iii) a statement of whether the goal 
                        established in subparagraph (C)(i) will be 
                        adequate to disrupt drug trafficking 
                        organizations that supply the majority of 
                        foreign-sourced illicit drugs trafficked into 
                        the United States.
                  ``(I) A 5-year projection for program and budget 
                priorities.
                  ``(J) A review of international, State, local, and 
                private sector drug control activities to ensure that 
                the United States pursues coordinated and effective 
                drug control at all levels of government.
                  ``(K) Such statistical data and information as the 
                Director considers appropriate to demonstrate and 
                assess trends relating to illicit drug use, the effects 
                and consequences of illicit drug use (including the 
                effects on children), supply reduction, demand 
                reduction, drug-related law enforcement, and the 
                implementation of the National Drug Control Strategy.
          ``(2) Additional strategies.--
                  ``(A) In general.--The Director shall include in the 
                National Drug Control Strategy the additional 
                strategies required under this paragraph and shall 
                comply with the following:
                          ``(i) Provide a copy of the additional 
                        strategies to the appropriate congressional 
                        committees and to the Committee on Armed 
                        Services and the Committee on Homeland Security 
                        of the House of Representatives, and the 
                        Committee on Homeland Security and Governmental 
                        Affairs and the Committee on Armed Services of 
                        the Senate.
                          ``(ii) Issue the additional strategies in 
                        consultation with the head of each relevant 
                        National Drug Control Program Agency and any 
                        relevant official of a State, local or Tribal 
                        government, and the government of other 
                        countries.
                          ``(iii) Not change any existing agency 
                        authority or construe any strategy described 
                        under this paragraph to amend or modify any law 
                        governing interagency relationship but may 
                        include recommendations about changes to such 
                        authority or law.
                          ``(iv) Present separately from the rest of 
                        any strategy described under this paragraph any 
                        information classified under criteria 
                        established by an Executive order, or whose 
                        public disclosure, as determined by the 
                        Director or the head of any relevant National 
                        Drug Control Program Agency, would be 
                        detrimental to the law enforcement or national 
                        security activities of any Federal, State, 
                        local, or Tribal agency.
                  ``(B) Requirement for southwest border 
                counternarcotics.--
                          ``(i) Purposes.--The Southwest Border 
                        Counternarcotics Strategy shall--
                                  ``(I) set forth the Government's 
                                strategy for preventing the illegal 
                                trafficking of drugs across the 
                                international border between the United 
                                States and Mexico, including through 
                                ports of entry and between ports of 
                                entry on that border;
                                  ``(II) state the specific roles and 
                                responsibilities of the relevant 
                                National Drug Control Program Agencies 
                                for implementing that strategy; and
                                  ``(III) identify the specific 
                                resources required to enable the 
                                relevant National Drug Control Program 
                                Agencies to implement that strategy.
                          ``(ii) Specific content related to drug 
                        tunnels between the united states and mexico.--
                        The Southwest Border Counternarcotics Strategy 
                        shall include--
                                  ``(I) a strategy to end the 
                                construction and use of tunnels and 
                                subterranean passages that cross the 
                                international border between the United 
                                States and Mexico for the purpose of 
                                illegal trafficking of drugs across 
                                such border; and
                                  ``(II) recommendations for criminal 
                                penalties for persons who construct or 
                                use such a tunnel or subterranean 
                                passage for such a purpose.
                  ``(C) Requirement for northern border 
                counternarcotics strategy.--
                          ``(i) Purposes.--The Northern Border 
                        Counternarcotics Strategy shall--
                                  ``(I) set forth the strategy of the 
                                Federal Government for preventing the 
                                illegal trafficking of drugs across the 
                                international border between the United 
                                States and Canada, including through 
                                ports of entry and between ports of 
                                entry on the border;
                                  ``(II) state the specific roles and 
                                responsibilities of each relevant 
                                National Drug Control Program Agency 
                                for implementing the strategy;
                                  ``(III) identify the specific 
                                resources required to enable the 
                                relevant National Drug Control Program 
                                Agencies to implement the strategy;
                                  ``(IV) be designed to promote, and 
                                not hinder, legitimate trade and 
                                travel; and
                                  ``(V) reflect the unique nature of 
                                small communities along the 
                                international border between the United 
                                States and Canada, ongoing cooperation 
                                and coordination with Canadian law, 
                                enforcement authorities, and variations 
                                in the volumes of vehicles and 
                                pedestrians crossing through ports of 
                                entry along the international border 
                                between the United States and Canada.
                          ``(ii) Specific content related to cross-
                        border indian reservations.--The Northern 
                        Border Counternarcotics Strategy shall 
                        include--
                                  ``(I) a strategy to end the illegal 
                                trafficking of drugs to or through 
                                Indian reservations on or near the 
                                international border between the United 
                                States and Canada; and
                                  ``(II) recommendations for additional 
                                assistance, if any, needed by Tribal 
                                law enforcement agencies relating to 
                                the strategy, including an evaluation 
                                of Federal technical and financial 
                                assistance, infrastructure capacity 
                                building, and interoperability 
                                deficiencies.
          ``(3) Classified information.--Any contents of the National 
        Drug Control Strategy that involve information properly 
        classified under criteria established by an Executive order 
        shall be presented to Congress separately from the rest of the 
        National Drug Control Strategy.
          ``(4) Selection of data and information.--In selecting data 
        and information for inclusion under paragraph (1), the Director 
        shall ensure--
                  ``(A) the inclusion of data and information that will 
                permit analysis of current trends against previously 
                compiled data and information where the Director 
                believes such analysis enhances long-term assessment of 
                the National Drug Control Strategy; and
                  ``(B) the inclusion of data and information to permit 
                a standardized and uniform assessment of the 
                effectiveness of drug treatment programs in the United 
                States.
  ``(d) Annual Performance Supplement.--Not later than the first Monday 
in February of each year following the year in which the National Drug 
Control Strategy is submitted pursuant to subsection (a)(2), the 
Director shall submit to the appropriate congressional committees a 
supplement to the Strategy that shall include--
          ``(1) annual and quarterly quantifiable and measurable 
        objectives and specific targets to accomplish long-term 
        quantifiable goals specified in the Strategy; and
          ``(2) for each year covered by the Strategy, a performance 
        evaluation plan for each goal listed in the Strategy for each 
        National Drug Control Program Agency, including--
                  ``(A) specific performance measures for each National 
                Drug Control Program Agency and each such agency's 
                related programs and activities;
                  ``(B) annual and quarterly objectives and targets for 
                each performance measure; and
                  ``(C) an estimate of Federal funding and other 
                resources needed to achieve each performance measure.
  ``(e) Submission of Revised Strategy.--The President may submit to 
Congress a revised National Drug Control Strategy that meets the 
requirements of this section--
          ``(1) at any time, upon a determination of the President, in 
        consultation with the Director, that the National Drug Control 
        Strategy in effect is not sufficiently effective; or
          ``(2) if a new President or Director takes office.
  ``(f) Failure of President to Submit National Drug Control 
Strategy.--If the President does not submit a National Drug Control 
Strategy to Congress in accordance with subsection (a)(2), not later 
than five days after the first Monday in February following the year in 
which the term of the President commences, the President shall send a 
notification to the appropriate congressional committees--
          ``(1) explaining why the Strategy was not submitted; and
          ``(2) specifying the date by which the Strategy will be 
        submitted.

``Sec. 1006. Development of an annual national drug control assessment

  ``(a) Timing.--Not later than the first Monday in February of each 
year, the Director shall submit to the President, Congress, and the 
appropriate congressional committees, a report assessing the progress 
of each National Drug Control Program Agency toward achieving the 
annual goals, objectives, and targets contained in the National Drug 
Control Strategy applicable to the prior fiscal year.
  ``(b) Process for Development of the Annual Assessment.--Not later 
than November 1 of each year, the head of each National Drug Control 
Program Agency shall submit, in accordance with guidance issued by the 
Director, to the Director an evaluation of progress by the agency with 
respect to drug control program goals using the performance measures 
for the agency developed under this section, including progress with 
respect to--
          ``(1) success in achieving the goals of the National Drug 
        Control Strategy;
          ``(2) success in reducing domestic and foreign sources of 
        illegal drugs;
          ``(3) success in expanding access to and increasing the 
        effectiveness of substance use disorder treatment;
          ``(4) success in protecting the borders of the United States 
        (and in particular the Southwestern border of the United 
        States) from penetration by illegal narcotics;
          ``(5) success in reducing crime associated with drug use in 
        the United States;
          ``(6) success in reducing the negative health and social 
        consequences of drug use in the United States; and
          ``(7) implementation of drug treatment and prevention 
        programs in the United States and improvements in the adequacy 
        and effectiveness of such programs.
  ``(c) Contents of the Annual Assessment.--The Director shall include 
in the annual assessment required under subsection (a)--
          ``(1) a summary of each evaluation received by the Director 
        under subsection (b);
          ``(2) a summary of the progress of each National Drug Control 
        Program Agency toward the drug control program goals of the 
        agency using the performance measures for the agency developed 
        under this section;
          ``(3) an assessment of the effectiveness of each Drug Control 
        Program agency and program in achieving the National Drug 
        Control Strategy for the previous year, including a specific 
        evaluation of whether the applicable goals, measures, 
        objectives, and targets for the previous year were met;
          ``(4) for National Drug Control Program Agencies that 
        administer grant programs, an evaluation of the effectiveness 
        of each grant program, including an accounting of the funds 
        disbursed by the program in the prior year and a summary of how 
        those funds were used by the grantees and sub-grantees during 
        that period;
          ``(5) a detailed accounting of the amount of funds obligated 
        by each National Drug Control Program Agency in carrying out 
        the responsibilities of that agency under the Strategy, 
        including the information submitted to the Director under 
        section 1007(b);
          ``(6) an assessment of the effectiveness of any Emerging 
        Threat Response Plan in effect for the previous year, including 
        a specific evaluation of whether the objectives and targets 
        were met and reasons for the success or failure of the previous 
        year's plan;
          ``(7) a detailed accounting of the amount of funds obligated 
        during the previous fiscal year for carrying out the media 
        campaign under section 1009(d), including each recipient of 
        funds, the purpose of each expenditure, the amount of each 
        expenditure, any available outcome information, and any other 
        information necessary to provide a complete accounting of the 
        funds expended; and
          ``(8) the assessments required under this subsection shall be 
        based on the Performance Measurement System describe in 
        subsection (d).
  ``(d) Performance Measurement System.--The Director shall include in 
the annual assessment required under subsection (a) a national drug 
control performance measurement system, that--
          ``(1) develops annual, 2-year, and 5-year performance 
        measures, objectives, and targets for each National Drug 
        Control Strategy goal and objective established for reducing 
        drug use, availability, and the consequences of drug use;
          ``(2) describes the sources of information and data that will 
        be used for each performance measure incorporated into the 
        performance measurement system;
          ``(3) identifies major programs and activities of the 
        National Drug Control Program Agencies that support the goals 
        and annual objectives of the National Drug Control Strategy;
          ``(4) evaluates the contribution of demand reduction and 
        supply reduction activities implemented by each National Drug 
        Control Program Agency in support of the National Drug Control 
        Strategy;
          ``(5) monitors consistency between the drug-related goals, 
        measures, targets, and objectives of the National Drug Control 
        Program Agencies and ensures that each agency's goals and 
        budgets support, and are fully consistent with, the National 
        Drug Control Strategy; and
          ``(6) coordinates the development and implementation of 
        national drug control data collection and reporting systems to 
        support policy formulation and performance measurement, 
        including an assessment of--
                  ``(A) the quality of current drug use measurement 
                instruments and techniques to measure supply reduction 
                and demand reduction activities;
                  ``(B) the adequacy of the coverage of existing 
                national drug use measurement instruments and 
                techniques to measure the illicit drug user population, 
                and groups that are at risk for illicit drug use;
                  ``(C) the adequacy of the coverage of existing 
                national treatment outcome monitoring systems to 
                measure the effectiveness of substance use disorder 
                treatment in reducing illicit drug use and criminal 
                behavior during and after the completion of substance 
                use disorder treatment; and
                  ``(D) the actions the Director shall take to correct 
                any deficiencies and limitations identified pursuant to 
                subparagraphs (A), (B), and (C).
  ``(e) Modifications.--A description of any modifications made during 
the preceding year to the national drug performance measurement system 
described in subsection (d) shall be included in each report submitted 
under subsection (a).
  ``(f) Annual Report on Consultation.--The Director shall include in 
the annual assessment required under subsection (a)--
          ``(1) a detailed description of how the Office has consulted 
        with and assisted State, local, and Tribal governments with 
        respect to the formulation and implementation of the National 
        Drug Control Strategy and other relevant issues; and
          ``(2) a general review of the status of, and trends in, 
        demand reduction activities by private sector entities and 
        community-based organizations, including faith-based 
        organizations, to determine their effectiveness and the extent 
        of cooperation, coordination, and mutual support between such 
        entities and organizations and Federal, State, local, and 
        Tribal government agencies.
  ``(g) Performance-budget Coordinator.--
          ``(1) Designation.--The Director shall designate or appoint a 
        United States Performance-Budget Coordinator to--
                  ``(A) ensure the Director has sufficient information 
                about the performance of each National Drug Control 
                Program Agency, the impact Federal funding has had on 
                the goals in the Strategy, and the likely contributions 
                to the goals of the Strategy based on funding levels of 
                each National Drug Control Program Agency, to make an 
                independent assessment of the budget request of each 
                agency under section 1004;
                  ``(B) advise the Director on agency budgets, 
                performance measures and targets, and additional data 
                and research needed to make informed policy decisions 
                in the National Drug Control Budget and Strategy; and
                  ``(C) other duties as may be determined by the 
                Director with respect to measuring or assessing 
                performance or agency budgets.
          ``(2) Determination of position.--The Director shall 
        determine whether the coordinator position is a career or 
        noncareer position in the Senior Executive Service.

``Sec. 1007. Monitoring and evaluation of national drug control program

  ``(a) In General.--The Director shall monitor implementation of the 
National Drug Control Program and the activities of the National Drug 
Control Program Agencies in carrying out the goals and objectives of 
the National Drug Control Strategy including--
          ``(1) conducting program and performance audits and 
        evaluations; and
          ``(2) requesting assistance from the Inspector General of the 
        relevant agency in such audits and evaluations.
  ``(b) Accounting of Funds Expended.--Not later than December 1 of 
each year and in accordance with guidance issued by the Director, the 
head of each National Drug Control Program Agency shall submit to the 
Director a detailed accounting of all funds expended by the agency for 
National Drug Control Program activities during the previous fiscal 
year and shall ensure such detailed accounting is authenticated by the 
Inspector General for such agency prior to submission to the Director.
  ``(c) Notification.--The Director shall notify any National Drug 
Control Program Agency if its activities are not in compliance with the 
responsibilities of the agency under the National Drug Control 
Strategy, transmit a copy of each such notification to the President 
and the appropriate congressional committees, and maintain a copy of 
each such notification.
  ``(d) Recommendations.--The Director shall make such recommendations 
to the President and the appropriate congressional committees as the 
Director determines are appropriate regarding changes in the 
organization, management, and budgets of the National Drug Control 
Program Agencies, and changes in the allocation of personnel to and 
within those agencies, to implement the policies, goals, priorities, 
and objectives established under section 1002(c)(1) and the National 
Drug Control Strategy.
  ``(e) Authorization, Development, and Implementation of a Coordinated 
Tracking System.--
          ``(1) Establishment.--The Director, shall establish a 
        coordinated tracking system of federally-funded initiatives and 
        grant programs which shall--
                  ``(A) be the central repository of all relevant 
                grants;
                  ``(B) identify duplication, overlap, or gaps in 
                funding to provide increased accountability of 
                federally-funded grants for substance abuse treatment, 
                prevention, and enforcement;
                  ``(C) identify impediments that applicants currently 
                have in the grant application process with applicable 
                agencies; and
                  ``(D) be developed and maintained by the Office with 
                the support of designated National Drug Control Program 
                Agencies, and any other agency determined by the 
                Director.
          ``(2) Performance metrics.--The Director shall identify 
        metrics and achievable goals for grant recipients in 
        furtherance of the Strategy. Such metrics should be used to 
        measure how effective each federally funded initiative is in 
        achieving the objectives of the Strategy and to enable 
        comparisons of federally funded initiatives to identify those 
        that are the most cost effective.
          ``(3) Grant application standardization.--The Director, in 
        consultation with the head of each National Drug Control 
        Program Agency, shall develop a plan for coordinating and 
        standardizing drug control grant application processes and 
        develop a joint application to be used by all National Drug 
        Control Program Agencies to reduce the administrative burden 
        and improve oversight of Federal funds.
          ``(4) Central portal.--The Director shall maintain on the 
        public, electronic portal of the Office a list all drug control 
        grant award opportunities available in a central location. The 
        head of each National Drug Control Program Agency shall provide 
        a complete list of all drug control program grant award 
        opportunities to the Director and annually update such list.
          ``(5) Report to congress.--The Director shall include in the 
        assessment submitted to Congress under section 1006 an 
        assessment on progress under this section and the feasibility 
        of block grants of Federal funding to States.

``Sec. 1008. Coordination and oversight of the national drug control 
                    program

  ``(a) In General.--The Director shall coordinate and oversee the 
implementation by the National Drug Control Program Agencies of the 
policies, goals, objectives, and priorities established under section 
1002(c)(1) and the fulfillment of the responsibilities of such agencies 
under the National Drug Control Strategy and make recommendations to 
National Drug Control Program Agency heads with respect to 
implementation of National Drug Control Programs.
  ``(b) Detailing Employees to Other Agencies.--
          ``(1) Request.--The Director may request the head of an 
        agency or program of the Federal Government to place agency 
        personnel who are engaged in drug control activities on 
        temporary detail to another agency in order to implement the 
        National Drug Control Strategy.
          ``(2) Agency compliance.--The head of the agency shall comply 
        with such a request.
          ``(3) Maximum number of detailees.--The maximum number of 
        personnel who may be detailed to another agency (including the 
        Office) under this subsection during any fiscal year is--
                  ``(A) for the Department of Defense, 50; and
                  ``(B) for any other agency, 10.
  ``(c) Directing Federal Funding.--The Director may transfer funds 
made available to a National Drug Control Program Agency for National 
Drug Control Strategy programs and activities to another account within 
such agency or to another National Drug Control Program Agency for 
National Drug Control Strategy programs and activities, except that--
          ``(1) the authority under this subsection may be limited in 
        an annual appropriations Act or other provision of Federal law;
          ``(2) the Director may exercise the authority under this 
        subsection only with the concurrence of the head of each 
        affected agency;
          ``(3) in the case of an interagency transfer, the total 
        amount of transfers under this subsection may not exceed 3 
        percent of the total amount of funds made available for 
        National Drug Control Strategy programs and activities to the 
        agency from which those funds are to be transferred;
          ``(4) funds transferred to an agency under this subsection 
        may only be used to increase the funding for programs or 
        activities authorized by law;
          ``(5) the Director shall--
                  ``(A) submit to the appropriate congressional 
                committees and any other applicable committees of 
                jurisdiction, a reprogramming or transfer request in 
                advance of any transfer under this subsection in 
                accordance with the regulations of the affected agency 
                or agencies; and
                  ``(B) annually submit to the appropriate 
                congressional committees a report describing the effect 
                of all transfers of funds made pursuant to this 
                subsection or section 1004(f) during the 12-month 
                period preceding the date on which the report is 
                submitted; and
          ``(6) funds may only be used for--
                  ``(A) expansion of demand reduction activities;
                  ``(B) interdiction of illicit drugs on the high seas, 
                in United States territorial waters, and at United 
                States ports of entry by officers and employees of Drug 
                Control Program Agencies and domestic and foreign law 
                enforcement officers;
                  ``(C) accurate assessment and monitoring of 
                international drug production and interdiction programs 
                and policies;
                  ``(D) activities to facilitate and enhance the 
                sharing of domestic and foreign intelligence 
                information among Drug Control Program Agencies related 
                to the production and trafficking of drugs in the 
                United States and foreign countries; and
                  ``(E) activities to prevent the diversion of 
                prescription drugs for illicit use and research related 
                to any of these activities.
  ``(d) Directing Federal Funding to Respond to Emerging Threats.--
          ``(1) In general.--The Director may transfer funds made 
        available to a National Drug Control Program Agency for 
        National Drug Control Strategy programs and activities to 
        another account within such agency or to another National Drug 
        Control Program Agency for National Drug Control Strategy 
        programs and activities to implement the provisions of a plan 
        developed under section 1009, except that--
                  ``(A) the authority under this subsection may be 
                limited in an annual appropriations Act or other 
                provision of Federal law;
                  ``(B) in the case of an interagency transfer, the 
                total amount of transfers under this subsection may not 
                exceed 10 percent of the total amount of funds made 
                available for National Drug Control Strategy programs 
                and activities to the agency from which those funds are 
                to be transferred;
                  ``(C) funds transferred to an agency under this 
                subsection may only be used to increase the funding for 
                programs or activities authorized by law;
                  ``(D) no transfer of funds under this subsection may 
                result in a reduction in total Federal expenditures for 
                substance use disorder treatment;
                  ``(E) the Director shall--
                          ``(i) submit to the appropriate congressional 
                        committees and any other applicable committees 
                        of jurisdiction, a reprogramming or transfer 
                        request in advance of any transfer under this 
                        subsection in accordance with the regulations 
                        of each affected agency; and
                          ``(ii) annually submit to the appropriate 
                        congressional committees a report describing 
                        the effect of all transfers of funds made 
                        pursuant to this subsection or section 1004(f) 
                        during the 12-month period preceding the date 
                        on which the report is submitted; and
                  ``(F) funds may only be used for--
                          ``(i) expansion of demand reduction 
                        activities;
                          ``(ii) interdiction of illicit drugs on the 
                        high seas, in United States territorial waters, 
                        and at United States ports of entry by officers 
                        and employees of Drug Control Program agencies 
                        and domestic and foreign law enforcement 
                        officers;
                          ``(iii) accurate assessment and monitoring of 
                        international drug production and interdiction 
                        programs and policies;
                          ``(iv) activities to facilitate and enhance 
                        the sharing of domestic and foreign 
                        intelligence information among Drug Control 
                        Program Agencies related to the production and 
                        trafficking of drugs in the United States and 
                        foreign countries; and
                          ``(v) activities to prevent the diversion of 
                        prescription drugs for illicit use and research 
                        related to any of these activities.
          ``(2) Inadequacy of transfer.--In the event the authority 
        under this subsection is inadequate to implement the provisions 
        of a plan developed under section 1009, the Director shall 
        submit a request for funding to Congress as soon as the 
        Director becomes aware of the need for additional funding.
  ``(e) Fund Control Notices.--
          ``(1) In general.--The Director may issue to the head of a 
        National Drug Control Program Agency a fund control notice to 
        ensure compliance with the National Drug Control Program 
        Strategy. A fund control notice may direct that all or part of 
        an amount appropriated to the National Drug Control Program 
        Agency account be obligated by--
                  ``(A) months, fiscal year quarters, or other time 
                periods; and
                  ``(B) activities, functions, projects, or object 
                classes.
          ``(2) Unauthorized obligation or expenditure prohibited.--An 
        officer or employee of a National Drug Control Program Agency 
        shall not make or authorize an expenditure or obligation 
        contrary to a fund control notice issued by the Director.
          ``(3) Disciplinary action for violation.--In the case of a 
        violation of paragraph (2) by an officer or employee of a 
        National Drug Control Program Agency, the head of the agency, 
        upon the request of and in consultation with the Director, may 
        subject the officer or employee to appropriate administrative 
        discipline, including, when circumstances warrant, suspension 
        from duty without pay or removal from office.
          ``(4) Congressional notice.--Not later than 5 days after 
        issuance of a fund control notice, the Director shall submit a 
        copy of such fund control notice to the appropriate 
        congressional committees and make such notice publicly 
        available.
          ``(5) Restrictions.--The Director shall not issue a fund 
        control notice to direct that all or part of an amount 
        appropriated to the National Drug Control Program Agency 
        account be obligated, modified, or altered in any manner 
        contrary, in whole or in part, to a specific appropriation or 
        statute.
  ``(f) Exclusions.--The authorities described under subsections (c), 
(d), and (e) do not apply to any program under subchapter II or III.
  ``(g) Foreign Assistance Act Participation.--The Director may 
participate in the drug certification process pursuant to section 490 
of the Foreign Assistance Act of 1961 (22 U.S.C. 2291j) and section 706 
of the Department of State Authorization Act for Fiscal Year 2003 (22 
U.S.C. 229j-l).
  ``(h) Certifications of Policy Changes to Director.--
          ``(1) In general.--Subject to paragraph (2), the head of a 
        National Drug Control Program Agency shall, unless exigent 
        circumstances require otherwise, notify the Director in writing 
        regarding any proposed change in policies relating to the 
        activities of that agency under the National Drug Control 
        Program prior to implementation of such change. The Director 
        shall promptly review such proposed change and certify to the 
        head of that agency in writing whether such change is 
        consistent with the National Drug Control Strategy.
          ``(2) Exception.--If prior notice of a proposed change under 
        paragraph (1) is not practicable--
                  ``(A) the head of the National Drug Control Program 
                Agency shall notify the Director of the proposed change 
                as soon as practicable; and
                  ``(B) upon such notification, the Director shall 
                review the change and certify to the head of that 
                agency in writing whether the change is consistent with 
                the National Drug Control Strategy.
  ``(i) Work in Conjunction With Assistant for National Security 
Affairs.--The Director shall, in any matter affecting national security 
interests, work in conjunction with the Assistant to the President for 
National Security Affairs.

``Sec. 1009. Emerging threats taskforce, plan, media campaign

  ``(a) Emerging Threats Task Force.--
          ``(1) Emerging and continuing threats coordinator.--The 
        Director shall designate or appoint a United States Emerging 
        and Continuing Threats Coordinator to perform the duties of 
        that position described in this section and such other duties 
        as may be determined by the Director. The Director shall 
        determine whether the coordinator position is a career or 
        noncareer position in the Senior Executive Service.
          ``(2) Establishment and monitoring.--The Emerging and 
        Continuing Threats Coordinator (referred to in this section as 
        the `Coordinator') shall monitor evolving and emerging drug 
        threats in the United States and shall serve as Chair of an 
        Emerging Threats Task Force (in this section, referred to as 
        the `task force'). The Director shall appoint other members of 
        the Task force, which shall include representatives from--
                  ``(A) National Drug Control Program Agencies or other 
                agencies;
                  ``(B) State, local, and Tribal governments;
                  ``(C) the Director of the Fusion Center established 
                in section 1013; and
                  ``(D) other entities as determined to be necessary by 
                the Director.
          ``(3) Information review and sharing.--
                  ``(A) In general.--The task force shall disseminate 
                and facilitate the sharing with Federal, State, local, 
                and Tribal officials and other entities as determined 
                by the Director of pertinent information and data 
                relating to the following:
                          ``(i) Recent trends in drug supply and 
                        demand.
                          ``(ii) Fatal and nonfatal overdoses.
                          ``(iii) Demand for and availability of 
                        evidence-based substance use disorder 
                        treatment, including the extent of the unmet 
                        treatment need, and treatment admission trends.
                          ``(iv) Recent trends in drug interdiction, 
                        supply, and demand from State, local, and 
                        Tribal law enforcement agencies.
                          ``(v) Other subject matter as determined 
                        necessary by the Director.
                  ``(B) Contract, agreement, and other authority.--The 
                Director may award contracts, enter into interagency 
                agreements, manage individual projects, and conduct 
                other operational activities in support of the 
                identification of emerging threats and in support of 
                the development, implementation, and assessment of 
                Emerging Threat Response Plans.
                  ``(C) Data analysis activities.--In support of the 
                task force, the National Drug Control Fusion Center is 
                authorized to conduct and provide to the task force the 
                results of data analysis activities that the task force 
                requests to aid in their review of recent trends in the 
                data disseminated under subparagraph (A).
          ``(4) Criteria to identify emerging drug threats.--Not later 
        than 60 days after the date on which a task force first meets, 
        the task force shall develop and recommend to the Director 
        criteria to be used to identify an emerging drug threat or the 
        termination of an emerging drug threat designation based on 
        information gathered by the task force in paragraph (2), 
        statistical data, and other evidence.
          ``(5) Meetings.--The task force shall meet in person not less 
        frequently than quarterly and at additional meetings if 
        determined to be necessary by and at the call of the Chair to--
                  ``(A) identify and discuss evolving and emerging drug 
                trends in the United States using the criteria 
                established in paragraph (3);
                  ``(B) formulate the plan described in subsection (c);
                  ``(C) oversee implementation of the plan described in 
                subsection (c); and
                  ``(D) provide such other advice to the Coordinator 
                and Director concerning strategy and policies for 
                emerging drug threats and trends as the task force 
                determines to be appropriate.
  ``(b) Designation.--
          ``(1) In general.--The Director, in consultation with the 
        Coordinator, the task force, and the head of each National Drug 
        Control Program Agency, may designate an emerging drug threat 
        in the United States.
          ``(2) Standards for designation.--The Director, in 
        consultation with the Coordinator, shall promulgate and make 
        publicly available standards by which a designation under 
        paragraph (1) and the termination of such designation may be 
        made. In developing such standards, the Director shall consider 
        the recommendations of the task force and other criteria the 
        Director considers to be appropriate.
          ``(3) Public statement required.--The Director shall publish 
        a public written statement on the portal of the Office 
        explaining the designation of an emerging drug threat or the 
        termination of such designation and shall notify the 
        appropriate congressional committees of the availability of 
        such statement when a designation or termination of such 
        designation has been made.
  ``(c) Plan.--
          ``(1) Public availability of plan.--Not later than 60 days 
        after making a designation under subsection (b), the Director 
        shall publish and make publicly available an Emerging Threat 
        Response Plan and notify the President and the appropriate 
        congressional committees of such plan's availability.
          ``(2) Timing.--Not less frequently than every 90 days after 
        the date on which the plan is published under paragraph (1), 
        the Director shall update the plan and report on implementation 
        of the plan, until the Director issues the public statement 
        required under subsection (b)(3) to terminate the emerging 
        threat designation.
          ``(3) Contents of an emerging threat response plan.--The 
        Director shall include in the plan--
                  ``(A) a comprehensive strategic assessment of the 
                emerging drug threat, including the current 
                availability of, demand for, and effectiveness of 
                evidence-based prevention, treatment, and enforcement 
                programs and efforts to respond to the emerging drug 
                threat;
                  ``(B) comprehensive, research-based, long-range, 
                quantifiable goals for addressing the emerging drug 
                threat, including for reducing the supply of the 
                emerging drug threat and for expanding the availability 
                and effectiveness of evidence-based substance use 
                disorder treatment and prevention programs to reduce 
                the demand for the emerging drug threat;
                  ``(C) performance measures pertaining to the plan's 
                goals, including quantifiable and measurable objectives 
                and specific targets;
                  ``(D) the level of funding needed to implement the 
                plan, including whether funding is available to be 
                reprogrammed or transferred to support implementation 
                of the plan or whether additional appropriations are 
                necessary to implement the plan;
                  ``(E) an implementation strategy for the education 
                and public awareness campaign under subsection (d), 
                including goals as described under subparagraph (B) and 
                performance measures, objectives, and targets, as 
                described under subparagraph (C); and
                  ``(F) any other information necessary to inform the 
                public of the status, progress, or response of an 
                emerging drug threat.
          ``(4) Implementation.--
                  ``(A) In general.--Not later than 90 days after the 
                date on which a designation is made under subsection 
                (b), the Director, in consultation with the President, 
                the appropriate congressional committees, and the head 
                of each National Drug Control Program Agency, shall 
                issue guidance on implementation of the plan described 
                in subsection (c) to the National Drug Control Program 
                Agencies and any other relevant agency determined to be 
                necessary by the Director.
                  ``(B) Coordinator's responsibilities.--The 
                Coordinator shall--
                          ``(i) direct the implementation of the plan 
                        among the agencies identified in the plan, 
                        State, local, and Tribal governments, and other 
                        relevant entities;
                          ``(ii) facilitate information-sharing between 
                        agencies identified in the plan, State, local, 
                        and Tribal governments, and other relevant 
                        entities; and
                          ``(iii) monitor implementation of the plan by 
                        coordinating the development and implementation 
                        of collection and reporting systems to support 
                        performance measurement and adherence to the 
                        plan by agencies identified in plan, where 
                        appropriate.
                  ``(C) Reporting.--Not later than 180 days after 
                designation under subsection (b) and in accordance with 
                paragraph (2)(C), the head of each agency identified in 
                the plan shall submit to the Coordinator a report on 
                implementation of the plan.
  ``(d) Education and Public Awareness Campaign for Emerging Drug 
Threats.--
          ``(1) In general.--Not later than 90 days after a designation 
        under subsection (b), the Director shall establish and 
        implement an evidence-based substance use prevention education 
        and public awareness campaign to inform the public about the 
        dangers of any drug designated as an emerging drug threat. Such 
        campaign shall--
                  ``(A) educate the public about the dangers of such 
                drug, including patient and family education about the 
                characteristics and hazards of such drugs and methods 
                to safeguard against such dangers, including the safe 
                disposal of such drugs;
                  ``(B) support evidence-based prevention programs 
                targeting audiences' attitudes, perceptions, and 
                beliefs concerning substance use and intentions to 
                initiate or continue such use;
                  ``(C) increase awareness of the negative consequences 
                of drug use;
                  ``(D) encourage individuals affected by substance use 
                disorders to seek treatment and provide such 
                individuals with information on how to recognize 
                addiction issues, what forms of evidence-based 
                treatment options are available, and how to access such 
                treatment; and
                  ``(E) combat the stigma of addiction and substance 
                use disorders, including the stigma of treating such 
                disorders with medication-assisted treatment therapies.
          ``(2) Consultation.--For the planning of the campaign under 
        paragraph (1), the Secretary shall consult with--
                  ``(A) the head of any appropriate National Drug 
                Control Program Agency to obtain advice on evidence-
                based scientific information for policy, program 
                development, and evaluation;
                  ``(B) experts in evidence-based media campaigns, 
                education, evaluation, and communication;
                  ``(C) experts on the designated drug;
                  ``(D) State, local, and Tribal government officials 
                and relevant agencies;
                  ``(E) the public;
                  ``(F) appropriate congressional committees; and
                  ``(G) any other affected person.
          ``(3) Gifts and donations.--
                  ``(A) In general.--The Director may accept gifts and 
                donations (in cash or in kind, including voluntary and 
                uncompensated services or property), which shall be 
                available until expended, for the purpose of supporting 
                the education and outreach campaign authorized in this 
                section, including the media campaign.
                  ``(B) Ethics guidelines.--The Director shall 
                establish written guidelines setting forth the criteria 
                to be used in determining whether a gift or donation 
                should be declined under this section because the 
                acceptance of the gift or donation would--
                          ``(i) reflect unfavorably upon the ability of 
                        the Director or the Office, or any employee of 
                        the Office, to carry out responsibilities or 
                        official duties under this chapter in a fair 
                        and objective manner; or
                          ``(ii) compromise the integrity or the 
                        appearance of integrity of programs or services 
                        provided under this chapter or of any official 
                        involved in those programs or services.
                  ``(C) Annual report required.--Not later than the 
                first Monday in the February of each year, the Director 
                shall submit to the appropriate congressional 
                committees an annual report that identifies the sources 
                of any gift or donation accepted by the Office or any 
                contractor acting on behalf of the Office, under this 
                subsection, including the value of each gift and 
                donation provided by each source of the gift.
          ``(4) Implementation.--
                  ``(A) In general.--For any campaign established under 
                this subsection, the Director shall ensure the 
                following:
                          ``(i) Implementation is evidence-based, meets 
                        accepted standards for public awareness 
                        campaigns, and uses available resources in a 
                        manner to make the most progress toward 
                        achieving the goals identified in the emerging 
                        threats plan and paragraph (1).
                          ``(ii) Information disseminated through the 
                        campaign is accurate.
                          ``(iii) The Director approves the strategy of 
                        the campaign, all material distributed through 
                        the campaign, and the use of any Federal funds 
                        used for the campaign.
                          ``(iv) The campaign is designed using 
                        strategies found to be most effective at 
                        achieving such goals, which may include--
                                  ``(I) a media campaign, as described 
                                in subparagraph (B);
                                  ``(II) local, regional, or population 
                                specific messaging;
                                  ``(III) establishing partnerships and 
                                promoting coordination among community 
                                stakeholders, including public, 
                                nonprofit organizations, and for profit 
                                entities;
                                  ``(IV) providing support, training, 
                                and technical assistance to establish 
                                and expand school and community 
                                prevention programs;
                                  ``(V) creating websites to publicize 
                                and disseminate information;
                                  ``(VI) conducting outreach and 
                                providing educational resources for 
                                parents;
                                  ``(VII) establishing State or 
                                regional advisory councils to provide 
                                input and recommendations to raise 
                                awareness regarding the drug designated 
                                as an emerging drug threat;
                                  ``(VIII) collaborating with law 
                                enforcement; and
                                  ``(IX) support for school-based 
                                public health education classes to 
                                improve teen knowledge about the 
                                effects of such designated drug.
                  ``(B) Media campaign.--Any campaign implemented under 
                this subsection may include a media component, which--
                          ``(i) shall be designed to prevent the use of 
                        the drug designated as an emerging drug threat 
                        and to achieve the goals of paragraph (1);
                          ``(ii) shall be carried out through 
                        competitively awarded contracts to entities 
                        providing for the professional production and 
                        design of such campaign; and
                          ``(iii) may include the use of television, 
                        radio, Internet, social media, and other 
                        commercial marketing venues and may be targeted 
                        to specific age groups based on peer-reviewed 
                        social research.
                  ``(C) Required notice for communication from the 
                office.--Any communication, including an advertisement, 
                paid for or otherwise disseminated by the Office 
                directly or through a contract awarded by the Office 
                shall include a prominent notice informing the audience 
                that the communication was a paid for by of the Office.
          ``(5) Evaluation.--
                  ``(A) Performance evaluation.--The Director shall 
                include an evaluation of the campaign in the annual 
                assessment under section 1006, which shall include the 
                following:
                          ``(i) A performance evaluation of the 
                        campaign, including progress toward meeting the 
                        goals, objectives, measures, and targets 
                        identified in the emerging threats plan.
                          ``(ii) A description of all policies and 
                        practices to eliminate the potential for waste, 
                        fraud, abuse, and to ensure Federal funds are 
                        used responsibly.
                          ``(iii) A list of all contracts or other 
                        agreements entered into to implement the 
                        campaign.
                          ``(iv) The results of any financial audit of 
                        the campaign.
                          ``(v) A description of any evidence used to 
                        develop the campaign.
                  ``(B) Independent evaluation.--Not later than 180 
                days after establishing a campaign under paragraph (1) 
                and not less than frequently than every two years 
                thereafter, the Director shall--
                          ``(i) designate an independent entity to 
                        evaluate the effectiveness of the campaign with 
                        meeting the goals established in the emerging 
                        threat plan and paragraph (1); and
                          ``(ii) submit the results of the independent 
                        evaluation to the appropriate congressional 
                        committees.
          ``(6) Funding prohibitions.--None of the amounts made 
        available under this subsection may be obligated for any of the 
        following:
                  ``(A) To supplant current anti-drug community-based 
                coalitions.
                  ``(B) To supplant pro bono public service time 
                donated by national and local broadcasting network for 
                other public services campaigns.
                  ``(C) For partisan political purposes, or express 
                advocacy in support of or to defeat any clearly 
                identified candidate, clearly identified ballot 
                initiative, or clearly identified legislative or 
                regulatory proposal.
                  ``(D) For any advocacy in support of any particular 
                company, industry association, or advocacy group or the 
                explicit policy positions held by such groups.
                  ``(E) To direct any individuals to a specific type of 
                substance use disorder treatment, treatment facility, 
                medical provider, or form of medication assisted 
                treatment.
                  ``(F) To fund any advertising that features any 
                elected officials, persons seeking elected office, 
                cabinet level officials, or other Federal officials 
                employed pursuant to section 213 of Schedule C of title 
                5, Code of Federal Regulations.
  ``(e) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office to carry out this section, $25,000,000 for 
each of fiscal years 2019 through 2023.

``Sec. 1010. National and international coordination

  ``(a) Dissemination of Research and Information to States.--The 
Director shall ensure that drug control research and information is 
effectively disseminated by National Drug Control Program Agencies to 
State and local governments and nongovernmental entities involved in 
demand reduction by--
          ``(1) encouraging formal consultation between any such agency 
        that conducts or sponsors research, and any such agency that 
        disseminates information in developing research and information 
        product development agendas;
          ``(2) encouraging such agencies (as appropriate) to develop 
        and implement dissemination plans that specifically target 
        State and local governments and nongovernmental entities 
        involved in demand reduction; and
          ``(3) supporting the substance abuse information 
        clearinghouse administered by the Administrator of the 
        Substance Abuse and Mental Health Services Administration and 
        established in section 501(d)(16) of the Public Health Service 
        Act by--
                  ``(A) encouraging all National Drug Control Program 
                Agencies to provide all appropriate and relevant 
                information; and
                  ``(B) supporting the dissemination of information to 
                all interested entities.
  ``(b) Standards.--
          ``(1) Development.--The Director shall coordinate the 
        development of evidence-based standards developed by National 
        Drug Control Program Agencies and other relevant agencies and 
        non-Federal entities to State, local, and Tribal governments 
        and nongovernmental entities related to drug control policies, 
        practices, and procedures, such as the investigation of drug-
        related deaths, by--
                  ``(A) encouraging appropriate agencies and State, 
                local, and Tribal governments to develop data standards 
                for drug control practices and procedures and related 
                statistical data;
                  ``(B) encouraging information sharing between 
                appropriate agencies and State, local, and Tribal 
                governments of relevant drug control information and 
                data;
                  ``(C) establishing a working group of agencies, 
                State, local, and Tribal governments, and other 
                relevant stakeholders to discuss and develop such 
                standards; and
                  ``(D) facilitating collaboration among agencies, non-
                Federal entities, States, local, and Tribal 
                governments, and nongovernmental agencies.
          ``(2) Implementation.--The Director shall promote the 
        implementation of the standards described in paragraph (1) by--
                  ``(A) encouraging adoption by providing the standards 
                to State and local governments through the internet, 
                annual publications or periodicals, and other widely-
                disseminated means; and
                  ``(B) facilitating the use and dissemination of such 
                standards among State and local governments by--
                          ``(i) providing technical assistance to 
                        State, local, and Tribal governments seeking to 
                        adopt or implement such standards; and
                          ``(ii) coordinating seminars and training 
                        sessions for State, local, and Tribal 
                        governments seeking to adopt or implement such 
                        standards.
  ``(c) Private Sector.--
          ``(1) In general.--The Director or the head of a National 
        Drug Control Program (as designated by the Director) shall 
        coordinate with the private sector to promote private research 
        and development of medications to treat or prevent addiction, 
        including research and development for non-addictive pain 
        management medication, abuse deterrent formulations, 
        medication-assisted treatment, and other addiction research 
        determined to be necessary by the Director by--
                  ``(A) encouraging the sharing of information 
                regarding evidence-based treatment addiction findings 
                and related data between agencies and the private 
                sector, as appropriate;
                  ``(B) encouraging collaboration between appropriate 
                agencies and the private sector; and
                  ``(C) providing private sector entities with relevant 
                statistical data and information to enhance research as 
                permissible.
          ``(2) Working group.--The Director may establish a working 
        group of National Drug Control Program Agencies, State, local, 
        and Tribal governments, and the private sector stakeholders to 
        discuss and disseminate best practices, research and 
        development, and other related issues, as appropriate.
  ``(d) Model Acts Program.--
          ``(1) In general.--The Director shall provide for or shall 
        enter into an agreement with a nonprofit organization to--
                  ``(A) advise States on establishing laws and policies 
                to address illicit drug use issues; and
                  ``(B) revise such model State drug laws and draft 
                supplementary model State laws to take into 
                consideration changes in illicit drug use issues in the 
                State involved.
          ``(2) Authorization of appropriations.--There is authorized 
        to be appropriated to carry out this subsection $1,250,000 for 
        each of fiscal years 2019 through 2023.
  ``(e) Drug Court Training and Technical Assistance Program.--
          ``(1) Grants authorized.--The Director may make a grant to a 
        nonprofit organization for the purpose of providing training 
        and technical assistance to drug courts.
          ``(2) Authorization of appropriations.--There is authorized 
        to be appropriated to carry out this subsection $2,000,000 for 
        each of fiscal years 2019 through 2023.
  ``(f) International Coordination.--The Director shall facilitate 
international drug control coordination efforts.
  ``(g) State, Local, and Tribal Affairs Coordinator.--The Director 
shall designate or appoint a United States State, Local, and Tribal 
Affairs Coordinator to perform the duties of the Office outlined in 
this section and section 1005 and such other duties as may be 
determined by the Director with respect to coordination of drug control 
efforts between agencies and State, local, and Tribal governments. The 
Director shall determine whether the coordinator position is a career 
or noncareer position in the Senior Executive Service.

``Sec. 1011. Interdiction

  ``(a) United States Interdiction Coordinator.--
          ``(1) In general.--The Director shall designate or appoint a 
        United States Interdiction Coordinator to perform the duties of 
        that position described in paragraph (2) and such other duties 
        as may be determined by the Director with respect to 
        coordination of efforts to interdict illicit drugs from 
        entering the United States.
          ``(2) Responsibilities.--The United States Interdiction 
        Coordinator shall be responsible to the Director for--
                  ``(A) coordinating the interdiction activities of the 
                National Drug Control Program Agencies to ensure 
                consistency with the National Drug Control Strategy;
                  ``(B) on behalf of the Director, developing and 
                issuing, on or before March 1 of each year and in 
                accordance with paragraph (4), a National Interdiction 
                Command and Control Plan to ensure the coordination and 
                consistency described in subparagraph (A);
                  ``(C) assessing the sufficiency of assets committed 
                to illicit drug interdiction by the relevant National 
                Drug Control Program Agencies; and
                  ``(D) advising the Director on the efforts of each 
                National Drug Control Program Agency to implement the 
                National Interdiction Command and Control Plan.
          ``(3) Staff.--The Director shall assign such permanent staff 
        of the Office as he considers appropriate to assist the United 
        States Interdiction Coordinator to carry out the 
        responsibilities described in paragraph (2), and may request 
        that appropriate National Drug Control Program Agencies detail 
        or assign staff to assist in carrying out such activities.
          ``(4) National interdiction command and control plan.--
                  ``(A) Purposes.--The National Interdiction Command 
                and Control Plan--
                          ``(i) shall set forth the Government's 
                        strategy for drug interdiction;
                          ``(ii) shall state the specific roles and 
                        responsibilities of the relevant National Drug 
                        Control Program Agencies for implementing that 
                        strategy;
                          ``(iii) shall identify the specific resources 
                        required to enable the relevant National Drug 
                        Control Program Agencies to implement that 
                        strategy; and
                          ``(iv) may include recommendations about 
                        changes to existing agency authorities or laws 
                        governing interagency relationships.
                  ``(B) Consultation with other agencies.--Before the 
                submission of the National Drug Control Strategy or 
                annual supplement required under section 1005(d), as 
                applicable, the United States Interdiction Coordinator 
                shall issue the National Interdiction Command and 
                Control Plan, in consultation with the other members of 
                the Interdiction Committee described in subsection (c).
                  ``(C) Report to congress.--On or before March 1 of 
                each year, the Director, through the United States 
                Interdiction Coordinator, shall provide to the 
                appropriate congressional committees, to the Committee 
                on Armed Services and the Committee on Homeland 
                Security of the House of Representatives, and to the 
                Committee on Homeland Security and Governmental Affairs 
                and the Committee on Armed Services of the Senate, a 
                report that includes--
                          ``(i) a copy of that year's National 
                        Interdiction Command and Control Plan;
                          ``(ii) information for the previous 10 years 
                        regarding the number and type of seizures of 
                        drugs by each National Drug Control Program 
                        Agency conducting drug interdiction activities 
                        and statistical information on the geographic 
                        areas of such seizures; and
                          ``(iii) information for the previous 10 years 
                        regarding the number of air and maritime patrol 
                        hours undertaken by each National Drug Control 
                        Program Agency conducting drug interdiction 
                        activities and statistical information on the 
                        geographic areas in which such patrol hours 
                        took place.
                  ``(D) Classified annex.--The report submitted 
                pursuant to subparagraph (C) may include a classified 
                annex.
  ``(b) Interdiction Committee.--
          ``(1) In general.--The Interdiction Committee shall meet to--
                  ``(A) discuss and resolve issues related to the 
                coordination, oversight, and integration of 
                international, border, and domestic drug interdiction 
                efforts in support of the National Drug Control 
                Strategy;
                  ``(B) review the annual National Interdiction Command 
                and Control Plan, and provide advice to the Director 
                and the United States Interdiction Coordinator 
                concerning that plan; and
                  ``(C) provide such other advice to the Director 
                concerning drug interdiction strategy and policies as 
                the committee determines is appropriate.
          ``(2) Chair.--The Director shall designate one of the members 
        of the Interdiction Committee to serve as chair.
          ``(3) Meetings.--The members of the Interdiction Committee 
        shall meet, in person and not through any delegate or 
        representative, at least once per calendar year, before March 
        1. At the call of the Director or the chair, the Interdiction 
        Committee may hold additional meetings, which shall be attended 
        by the members in person, or through such delegates or 
        representatives as the members may choose.
          ``(4) Report.--Not later than September 30 of each year, the 
        chair of the Interdiction Committee shall submit to the 
        Director and to the appropriate congressional committees a 
        report describing the results of the meetings and any 
        significant findings of the committee during the previous 12 
        months. Such report may include a classified annex.

``Sec. 1012. Treatment coordinator

  ``(a) United States Treatment Coordinator.--
          ``(1) In general.--The Director shall designate or appoint a 
        United States Treatment Coordinator to perform the 
        responsibilities of that position described in paragraph (2) 
        and such other duties as may be determined by the Director with 
        respect to coordination of efforts to expand the availability 
        of substance use disorder treatment with the goal of 
        eliminating the unmet treatment need.
          ``(2) Responsibilities.--The United States Treatment 
        Coordinator shall be responsible to the Director for--
                  ``(A) coordinating the activities of the National 
                Drug Control Program Agencies undertaken to expand the 
                availability of evidence-based substance use disorder 
                treatment to ensure consistency with the National Drug 
                Control Strategy;
                  ``(B) on behalf of the Director, developing and 
                issuing, on or before March 1 of each year and in 
                accordance with paragraph (4), a National Treatment 
                Plan to ensure the coordination and consistency 
                described in subparagraph (A);
                  ``(C) assessing the sufficiency of Federal resources 
                directed to substance use disorder treatment by the 
                relevant National Drug Control Program Agencies;
                  ``(D) encouraging the adoption by all substance use 
                disorder treatment providers of evidence-based 
                standards to guide all aspects of treatment provided; 
                and
                  ``(E) advising the Director on the efforts of each 
                National Drug Control Program Agency to implement the 
                National Treatment Plan.
          ``(3) Staff.--The Director shall assign such permanent staff 
        of the Office of the United States Treatment Coordinator as the 
        Director determines to be appropriate to assist the United 
        States Treatment Coordinator to carry out the responsibilities 
        described in paragraph (2), and may request that appropriate 
        National Drug Control Program Agencies detail or assign staff 
        to assist in carrying out such responsibilities.
          ``(4) National treatment plan.--
                  ``(A) Purposes.--The National Treatment Plan--
                          ``(i) shall identify the unmet need for 
                        treatment for evidence-based substance use 
                        disorders including opioid use disorders, and 
                        set forth the Government's strategy for closing 
                        the gap between available and needed treatment 
                        through all sources;
                          ``(ii) shall describe the specific roles and 
                        responsibilities of the relevant National Drug 
                        Control Program Agencies for implementing that 
                        strategy;
                          ``(iii) shall identify the specific resources 
                        required to enable the relevant National Drug 
                        Control Program Agencies to implement that 
                        strategy;
                          ``(iv) shall identify the resources, 
                        including private sources, required to 
                        eliminate the unmet need for evidence-based 
                        substance use disorder treatment; and
                          ``(v) may include recommendations about 
                        changes to existing agency authorities or laws 
                        governing interagency relationships.
                  ``(B) Consultation with other agencies.--Before the 
                submission of the National Treatment Strategy or annual 
                supplement required under section 1005(d), as 
                applicable, the United States Treatment Coordinator 
                shall issue the National Treatment Plan, in 
                consultation with the other members of the Interdiction 
                Committee described in subsection (b).
                  ``(C) Report to congress.--On or before March 1 of 
                each year, the Director, through the United States 
                Treatment Coordinator, shall provide to the appropriate 
                congressional committees a report that includes a copy 
                of that year's National Treatment Plan;
  ``(b) Treatment Committee.--
          ``(1) In general.--The Treatment Committee shall meet to--
                  ``(A) review and discuss the adequacy of evidence-
                based substance use disorder treatment as well as the 
                unmet need for treatment;
                  ``(B) review and discuss the status of the 
                implementation of the National Treatment Plan; and
                  ``(C) provide such other advice to the Director 
                concerning substance use disorder treatment initiatives 
                as the committee determines is appropriate.
          ``(2) Chair.--The Director shall designate one of the members 
        of the Treatment Committee to serve as chair.
          ``(3) Meetings.--The members of the Treatment Committee shall 
        meet, in person and not through any delegate or representative, 
        at least once per calendar year, before March 1. At the call of 
        the Director or the chair, the Treatment Committee may hold 
        additional meetings, which shall be attended by the members in 
        person, or through such delegates or representatives as the 
        members may choose.
          ``(4) Report.--Not later than September 30 of each year, the 
        chair of the Treatment Committee shall submit to the Director 
        and to the appropriate congressional committees a report 
        describing the results of the meetings and any significant 
        findings of the committee during the previous 12 months. Such 
        report may include a classified annex.

``Sec. 1013. Critical information coordination

  ``(a) National Drug Control Fusion Center.--
          ``(1) Establishment.--The Director shall, in consultation 
        with the head of each National Drug Control Program Agency, 
        designate an agency to establish a National Drug Control Fusion 
        Center (referred to in this section as the `Center'). The 
        Center shall operate under the authority of the Director and 
        shall work with the National Drug Control Program Agencies to 
        collect, compile, analyze, and facilitate the sharing of data 
        on the use of illicit drugs, treatment for substance use 
        disorder, and interdiction of illicit drugs. The Center shall 
        be considered a `statistical agency or unit', as that term is 
        defined in section 502 of the Confidential Information 
        Protection and Statistical Efficiency Act of 2002 (44 U.S.C. 
        3501 note) and shall have the necessary independence to ensure 
        any data or information acquired by an agency under a pledge of 
        confidentiality and for exclusively statistical purposes is 
        used exclusively for statistical purposes.
          ``(2) Center director.--There shall be at the head of the 
        Center a Center Director who shall be appointed by the Director 
        from among individuals qualified and distinguished in data 
        governance and statistical analysis.
          ``(3) Data compilation.--The Director, acting through the 
        Center Director, shall do the following:
                  ``(A) Coordinate data collection activities among the 
                National Drug Control Program Agencies.
                  ``(B) Collect information not otherwise collected by 
                National Drug Control Program Agencies as necessary to 
                inform the National Drug Control Strategy.
                  ``(C) Compile and analyze any data required to be 
                collected under this chapter.
                  ``(D) Disseminate technology, as appropriate, to 
                States and local jurisdictions to enable or improve the 
                collection of data on drug use, including the 
                recordation of the occurrence of fatal and non-fatal 
                drug overdoses.
                  ``(E) Compile information collected by National Drug 
                Control Program Agencies on grants issued through any 
                National Drug Control Program, including for any grant 
                the following:
                          ``(i) The recipient.
                          ``(ii) The amount.
                          ``(iii) The intended purpose.
                          ``(iv) Any evidence of the efficacy of the 
                        outcomes achieved by the program funded through 
                        the grant.
                          ``(v) Any assessments of how the grant met 
                        its intended purpose.
          ``(4) Toxicology screening.--
                  ``(A) Establishment.--The Center Director may 
                establish a toxicology screening program that engages 
                in--
                          ``(i) secondary analysis of urine samples 
                        that would otherwise be discarded by--
                                  ``(I) hospitals and drug treatment 
                                programs;
                                  ``(II) correctional facilities, 
                                booking sites, probation programs, drug 
                                courts, and related facilities; and
                                  ``(III) coroners and medical 
                                examiners; and
                          ``(ii) analysis of other physical samples, as 
                        determined by the Center Director to be 
                        valuable for understanding the prevalence of 
                        any illicit drug.
                  ``(B) De-identification of information.--The Center 
                Director shall ensure that no samples have any 
                personally identifiable information prior to 
                collection.
                  ``(C) Limitation on use.--No data obtained from 
                analysis conducted under this paragraph may be used as 
                evidence in any proceeding.
                  ``(D) State program.--The Center Director may 
                establish a program that enables States and local 
                jurisdictions to submit up to 20 urine samples per year 
                for toxicology analysis for the purposes of identifying 
                substances present in individuals who have suffered 
                fatal drug overdoses.
          ``(5) Authority to contract.--The Director may award 
        contracts, enter into interagency agreements, manage individual 
        projects, and conduct other operational activities under this 
        subsection.
  ``(b) Critical Drug Control Information and Evidence Plan.--
          ``(1) In general.--Not later than the first Monday in 
        February of each year, the Director shall submit to Congress a 
        systematic plan for increasing data collection to enable real-
        time surveillance of drug control threats, developing analysis 
        and monitoring capabilities, and identifying and addressing 
        policy questions relevant to the National Drug Control Policy, 
        Strategy, and Program. Such plan shall be made available on the 
        public online portal of the Office, shall cover at least a 4-
        year period beginning with the first fiscal year following the 
        fiscal year in which the plan is submitted and published, and 
        contain the following:
                  ``(A) A list of policy-relevant questions for which 
                the Director and each National Drug Control Program 
                Agency intends to develop evidence to support the 
                National Drug Control Program and Strategy.
                  ``(B) A list of data the Director and each National 
                Drug Control Program Agency intends to collect, use, or 
                acquire to facilitate the use of evidence in drug 
                control policymaking and monitoring.
                  ``(C) A list of methods and analytical approaches 
                that may be used to develop evidence to support the 
                National Drug Control Program and Strategy and related 
                policy.
                  ``(D) A list of any challenges to developing evidence 
                to support policymaking, including any barriers to 
                accessing, collecting, or using relevant data.
                  ``(E) A description of the steps the Director and the 
                head of each National Drug Control Program Agency will 
                take to effectuate the plan.
                  ``(F) Any other relevant information as determined by 
                the Director.
          ``(2) Consultation.--In developing the plan required under 
        paragraph (1), the Director shall consult with the following:
                  ``(A) The public.
                  ``(B) Any evaluation or analysis units and personnel 
                of the Office.
                  ``(C) Office officials responsible for implementing 
                privacy policy.
                  ``(D) Office officials responsible for data 
                governance.
                  ``(E) The appropriate congressional committees.
                  ``(F) Any other individual or entity as determined by 
                the Director.
  ``(c) Evidence-based Policy.--
          ``(1) Harm reduction programs.--When developing the national 
        drug control policy, any policy of the Director, including 
        policies relating to syringe exchange programs for intravenous 
        drug users, shall be based on the best available medical and 
        scientific evidence regarding the effectiveness of such policy 
        in promoting individual health, preventing the spread of 
        infectious disease and the impact of such policy on drug 
        addiction and use. In making any policy relating to harm 
        reduction programs, the Director shall consult with the 
        National Institutes of Health and the National Academy of 
        Sciences.
          ``(2) Fund restriction for the legalization of controlled 
        substances.--The Director shall ensure that no Federal funds 
        appropriated to the Office shall be expended for any study or 
        contract relating to the legalization (for a medical use or any 
        other use) for which a listing in schedule I is in effect under 
        section 202 of the Controlled Substances Act (21 U.S.C. 812).
  ``(d) Drug Control Data Dashboard.--
          ``(1) Establishment.--The Director, in consultation with the 
        Center Director, shall establish and maintain a data dashboard 
        on the online portal of the Office to be known as the `Drug 
        Control Data Dashboard'. The Director shall ensure the user 
        interface of the dashboard is constructed with modern design 
        standards. To the extent practicable, the data made available 
        on the dashboard shall be publicly available in a machine-
        readable format and searchable by year, agency, drug, and 
        location.
          ``(2) Data.--The data included in the Drug Control Data 
        Dashboard shall be updated not less frequently than quarterly 
        and shall include, at a minimum, the following:
                  ``(A) For each substance identified under section 
                1005(c)(1)(A)(i)--
                          ``(i) the total amount seized and disrupted 
                        in the calendar year and each of the previous 3 
                        calendar years;
                          ``(ii) the known and estimated flows into the 
                        United States from all sources in the calendar 
                        year and each of the previous 3 calendar years;
                          ``(iii) the total amount of known flows that 
                        could not be interdicted or disrupted in the 
                        calendar year and each of the previous 3 
                        calendar years;
                          ``(iv) the known and estimated levels of 
                        domestic production in the calendar year and 
                        each of the previous three calendar years, 
                        including the levels of domestic production if 
                        the drug is a prescription drug, as determined 
                        under the Federal Food, Drug, and Cosmetic Act, 
                        for which a listing is in effect under section 
                        202 of the Controlled Substances Act (21 U.S.C. 
                        812); and
                          ``(v) the average street price for the 
                        calendar year and the highest known street 
                        price during the preceding 10-year period.
                  ``(B) For the calendar year and each of the previous 
                three years data sufficient to show, disaggregated by 
                State and, to the extent feasible, by region within a 
                State, county, or city, the following:
                          ``(i) The number of fatal and non-fatal 
                        overdoses caused by each drug identified under 
                        subparagraph (A)(i).
                          ``(ii) The prevalence of substance use 
                        disorders.
                          ``(iii) The number of individuals who have 
                        received substance use disorder treatment, 
                        including medication assisted treatment, for a 
                        substance use disorder, including treatment 
                        provided through publicly-financed health care 
                        programs.
                          ``(iv) The extent of the unmet need for 
                        substance use disorder treatment, including the 
                        unmet need for medication-assisted treatment.
                  ``(C) Data sufficient to show the extent of 
                prescription drug diversion, trafficking, and misuse in 
                the calendar year and each of the previous 3 calendar 
                years.
                  ``(D) Any quantifiable measures the Director 
                determines to be appropriate to detail progress toward 
                the achievement of the goals of the National Drug 
                Control Strategy.
  ``(e) Access to Information.--
          ``(1) In general.--Upon the request of the Director, the head 
        of any National Drug Control Program Agency shall cooperate 
        with and provide to the Director any statistics, studies, 
        reports, and other information prepared or collected by the 
        agency concerning the responsibilities of the agency under the 
        National Drug Control Strategy that relate to--
                  ``(A) drug control; or
                  ``(B) the manner in which amounts made available to 
                that agency for drug control are being used by that 
                agency.
          ``(2) Protection of intelligence information.--
                  ``(A) In general.--The authorities conferred on the 
                Office and the Director by this chapter shall be 
                exercised in a manner consistent with provisions of the 
                National Security Act of 1947 (50 U.S.C. 401 et seq.). 
                The Director of National Intelligence shall prescribe 
                such regulations as may be necessary to protect 
                information provided pursuant to this chapter regarding 
                intelligence sources and methods.
                  ``(B) Duties of director.--The Director of National 
                Intelligence and the Director of the Central 
                Intelligence Agency shall, to the maximum extent 
                practicable in accordance with subparagraph (A), render 
                full assistance and support to the Office and the 
                Director.
          ``(3) Required reports from national drug control agencies.--
        The head of each National Drug Control Program Agency shall 
        submit to the Director such information and reports as 
        requested from such National Drug Control Program Agency by the 
        Director, which shall include from the appropriate National 
        Drug Control Program Agencies:
                  ``(A) Not later than July 1 of each year, the head of 
                a designated National Drug Control Program Agency shall 
                submit to the Director and the appropriate 
                congressional committees an assessment of the quantity 
                of illegal drug cultivation and manufacturing in the 
                United States on lands owned or under the jurisdiction 
                of their respective agencies that was seized or 
                eradicated by their personnel during the preceding 
                calendar year.
                  ``(B) Not later than July 1 of each year, the head of 
                a designated National Drug Control Program Agency shall 
                submit to the Director and the appropriate 
                congressional committees information for the preceding 
                year regarding--
                          ``(i) the number and type of seizures of 
                        drugs by each component of the agency seizing 
                        drugs, as well as statistical information on 
                        the geographic areas of such seizures; and
                          ``(ii) the number of air and maritime patrol 
                        hours primarily dedicated to drug supply 
                        reduction missions undertaken by each component 
                        of the agency.
                  ``(C) Not later than July 1 of each year, the head of 
                a designated National Drug Control Program Agency shall 
                submit to the Director and the appropriate 
                congressional committees information for the preceding 
                year regarding the number of air and maritime patrol 
                hours primarily dedicated to drug supply reduction 
                missions undertaken by each component of the agency.
                  ``(D) Not later than July 1 of each year, the head of 
                a designated National Drug Control Program Agency shall 
                submit to the Director and the appropriate 
                congressional committees information for the preceding 
                year regarding the number and type of--
                          ``(i) arrests for drug violations;
                          ``(ii) prosecutions for drug violations by 
                        United States Attorneys; and
                          ``(iii) seizures of drugs by each component 
                        of the Department of Justice seizing drugs, as 
                        well as statistical information on the 
                        geographic areas of such seizures.
  ``(f) Data Exchange Standards for Improved Interoperability.--
          ``(1) Interagency and intergovernmental designation and use 
        of data exchange standards working group.--The Director shall 
        establish a working group of National Drug Control Program 
        Agencies, State, local and Tribal government health and law 
        enforcement agencies, and data governance experts to develop 
        consensus data exchange standards for necessary categories of 
        information that allow effective electronic exchange of 
        information between States, between State agencies, between 
        States and National Drug Control Program Agencies, and any 
        other drug control relevant data exchange.
          ``(2) Data exchange standards must be nonproprietary and 
        interoperable.--The data exchange standards designated under 
        paragraph (1) shall, to the extent practicable, be 
        nonproprietary and interoperable.
          ``(3) Other requirements.--In designating data exchange 
        standards under this subsection, the working group shall, to 
        the extent practicable, incorporate--
                  ``(A) interoperable standards developed and 
                maintained by an international voluntary consensus 
                standards body, as defined by the Office of Management 
                and Budget;
                  ``(B) interoperable standards developed and 
                maintained by intergovernmental partnerships; and
                  ``(C) interoperable standards developed and 
                maintained by Federal entities with authority over 
                contracting and financial assistance.
          ``(4) Data exchange standards for federal reporting.--
                  ``(A) Designation.--The Director may, in consultation 
                with the working group established under this section, 
                National Drug Control Program Agencies, and State, 
                local, and Tribal governments, designate data exchange 
                standards to govern Federal reporting and exchange 
                requirements for National Drug Control Programs, as 
                appropriate.
                  ``(B) Requirements.--The data exchange reporting 
                standards required by subparagraph (A) shall, to the 
                extent practicable--
                          ``(i) incorporate a widely accepted, 
                        nonproprietary, searchable, machine-readable 
                        format;
                          ``(ii) be consistent with and implement 
                        applicable accounting principles;
                          ``(iii) be implemented in a manner that is 
                        cost-effective and improves program efficiency 
                        and effectiveness; and
                          ``(iv) be capable of being continually 
                        upgraded as necessary.
                  ``(C) Incorporation of nonproprietary standards.--In 
                designating data exchange standards under this 
                paragraph, the Director shall, to the extent 
                practicable, incorporate existing nonproprietary 
                standards.
                  ``(D) Rule of construction.--Nothing in this 
                paragraph shall be construed to require a change to 
                existing data exchange standards for Federal reporting 
                about a program referred to in this section, if the 
                head of the agency responsible for administering the 
                program finds the standards to be effective and 
                efficient.
          ``(5) Termination.--The working group established under 
        paragraph (1) shall terminate not earlier than 60 days after 
        the public notification of termination by the Director.
  ``(g) Annual Data Collection and Dissemination Requirements.--
          ``(1) In general.--The Director shall collect and 
        disseminate, as appropriate, such information as the Director 
        determines is appropriate, but not less than the information 
        described in this subsection. To the extent practicable, the 
        data shall be publicly available in a machine-readable format 
        on the Drug Control Data Dashboard, be searchable by year, 
        agency, drug, and location, and cover not less than the 
        previous 10-year period.
          ``(2) Preparation and dissemination of information.--The 
        Director shall prepare and disseminate the following:
                  ``(A) An assessment of current illicit drug use 
                (including inhalants and steroids) and availability, 
                impact of illicit drug use, and treatment availability, 
                which assessment shall include--
                          ``(i) estimates of drug prevalence and 
                        frequency of use as measured by national, 
                        State, and local surveys of illicit drug use 
                        and by other special studies of nondependent 
                        and dependent illicit drug use;
                          ``(ii) illicit drug use in the workplace and 
                        the productivity lost by such use; and
                          ``(iii) illicit drug use by arrestees, 
                        probationers, and parolees.
                  ``(B) An assessment of the reduction of illicit drug 
                availability, for each drug identified under section 
                1005(c)(1)(A)(i), as measured by--
                          ``(i) the quantities of such drug available 
                        for consumption in the United States;
                          ``(ii) the amount of such drug entering the 
                        United States;
                          ``(iii) the number of illicit drug 
                        manufacturing laboratories seized and destroyed 
                        of each relevant drug and the number of 
                        hectares cultivated and destroyed domestically 
                        and in other countries of each relevant drug;
                          ``(iv) the number of metric tons of such drug 
                        seized; and
                          ``(v) changes in the price and purity of such 
                        drug.
                  ``(C) An assessment of the reduction of the 
                consequences of illicit drug use and availability, 
                which shall include--
                          ``(i) the cost of treating substance use 
                        disorder in the United States, such as the 
                        quantity of illicit drug-related services 
                        provided;
                          ``(ii) the annual national health care cost 
                        of illicit drug use; and
                          ``(iii) the extent of illicit drug-related 
                        crime and criminal activity.
                  ``(D) A determination of the status of drug treatment 
                in the United States, by assessing--
                          ``(i) public and private treatment 
                        utilization; and
                          ``(ii) the number of illicit drug users the 
                        Director estimates meet diagnostic criteria for 
                        treatment.
                  ``(E) A summary of the efforts made to coordinate 
                with private sector entities to conduct private 
                research and development of medications to treat 
                addiction by--
                          ``(i) screening chemicals for potential 
                        therapeutic value;
                          ``(ii) developing promising compounds;
                          ``(iii) conducting clinical trials;
                          ``(iv) seeking Food and Drug Administration 
                        approval for drugs to treat addiction;
                          ``(v) marketing the drug for the treatment of 
                        addiction;
                          ``(vi) urging physicians to use the drug in 
                        the treatment of addiction; and
                          ``(vii) encouraging insurance companies to 
                        reimburse the cost of the drug for the 
                        treatment of addiction.

``Sec. 1014. Annual audit and investigation requirements

  ``(a) Periodic Government Accountability Office Audits of Programs 
and Operations.--Not later than December 31, 2019, and every 3 years 
thereafter, the Comptroller General shall--
          ``(1) conduct and supervise an audit and investigation 
        relating to the programs and operations of--
                  ``(A) the Office; or
                  ``(B) certain programs within the Office, including--
                          ``(i) the High Intensity Drug Trafficking 
                        Areas Program; and
                          ``(iii) the media campaign under section 
                        1009(d); and
          ``(2) submit to the Director and the appropriate 
        congressional committees a report containing an evaluation of 
        and recommendations on the--
                  ``(A) policies and activities of the programs and 
                operations subject to the audit and investigation;
                  ``(B) economy, efficiency, and effectiveness in the 
                administration of the reviewed programs and operations; 
                and
                  ``(C) policy or management changes needed to prevent 
                and detect fraud and abuse in such programs and 
                operations.

``Sec. 1015. Authorization of appropriations

  ``There are authorized to be appropriated to carry out this chapter, 
except as otherwise specified, to remain available until expended, 
$18,400,000 for each of fiscal years 2019 through 2023.

     ``SUBCHAPTER II--HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM

``Sec. 1021. High intensity drug trafficking areas program

  ``(a) Establishment.--
          ``(1) In general.--There is established in the Office a 
        program to be known as the High Intensity Drug Trafficking 
        Areas Program (in this section referred to as the `Program').
          ``(2) Purpose.--The purpose of the Program is to reduce drug 
        trafficking and drug production in the United States by--
                  ``(A) facilitating cooperation among Federal, State, 
                local, and Tribal law enforcement agencies to share 
                information and implement coordinated enforcement 
                activities;
                  ``(B) enhancing law enforcement intelligence sharing 
                among Federal, State, local, and Tribal law enforcement 
                agencies;
                  ``(C) providing reliable law enforcement intelligence 
                to law enforcement agencies needed to design effective 
                enforcement strategies and operations; and
                  ``(D) supporting coordinated law enforcement 
                strategies which maximize use of available resources to 
                reduce the supply of illegal drugs in designated areas 
                and in the United States as a whole.
  ``(b) Designation.--
          ``(1) In general.--The Director, in consultation with the 
        Attorney General, the Secretary of the Treasury, the Secretary 
        of Homeland Security, heads of the National Drug Control 
        Program Agencies, and the Governor of each applicable State, 
        may designate any specified area of the United States as a high 
        intensity drug trafficking area.
          ``(2) Activities.--After making a designation under paragraph 
        (1) and in order to provide Federal assistance to the area so 
        designated, the Director may--
                  ``(A) obligate such sums as are appropriated for the 
                Program;
                  ``(B) direct the temporary reassignment of Federal 
                personnel to such area, subject to the approval of the 
                head of the agency that employs such personnel;
                  ``(C) take any other action authorized under this 
                chapter to provide increased Federal assistance to 
                those areas; and
                  ``(D) coordinate activities under this section 
                (specifically administrative, recordkeeping, and funds 
                management activities) with State, local, and Tribal 
                officials.
  ``(c) Petitions for Designation.--The Director shall establish and 
maintain regulations under which a coalition of interested law 
enforcement agencies from an area may petition for designation as a 
high intensity drug trafficking area (in this section referred to as 
the `HIDTA'). Such regulations shall provide for a regular review by 
the Director of the petition, including a recommendation regarding the 
merit of the petition to the Director by a panel of qualified, 
independent experts.
  ``(d) Factors for Consideration.--In considering whether to designate 
an area under this section as a high intensity drug trafficking area, 
the Director shall consider, in addition to such other criteria as the 
Director considers to be appropriate, the extent to which--
          ``(1) the area is a significant center of illegal drug 
        production, manufacturing, importation, or distribution;
          ``(2) State, local, and Tribal law enforcement agencies have 
        committed resources to respond to the drug trafficking problem 
        in the area, thereby indicating a determination to respond 
        aggressively to the problem;
          ``(3) drug-related activities in the area are having a 
        significant harmful impact in the area, and in other areas of 
        the country; and
          ``(4) a significant increase in allocation of Federal 
        resources is necessary to respond adequately to drug-related 
        activities in the area.
  ``(e) Organization of High Intensity Drug Trafficking Areas.--
          ``(1) Executive board and officers.--To be eligible for funds 
        appropriated under this section, each high intensity drug 
        trafficking area shall be governed by an Executive Board. The 
        Executive Board shall designate a chairman, vice chairman, and 
        any other officers to the Executive Board that it determines 
        are necessary.
          ``(2) Responsibilities.--The Executive Board of a high 
        intensity drug trafficking area shall be responsible for--
                  ``(A) providing direction and oversight in 
                establishing and achieving the goals of the high 
                intensity drug trafficking area;
                  ``(B) managing the funds of the high intensity drug 
                trafficking area;
                  ``(C) reviewing and approving all funding proposals 
                consistent with the overall objective of the high 
                intensity drug trafficking area; and
                  ``(D) reviewing and approving all reports to the 
                Director on the activities of the high intensity drug 
                trafficking area.
          ``(3) Board representation.--None of the funds appropriated 
        under this section may be expended for any high intensity drug 
        trafficking area, or for a partnership or region of a high 
        intensity drug trafficking area, if the Executive Board for 
        such area, region, or partnership, does not apportion an equal 
        number of votes between representatives of participating 
        agencies and representatives of participating State, local, and 
        Tribal agencies. Where it is impractical for an equal number of 
        representatives of agencies and State, local, and Tribal 
        agencies to attend a meeting of an Executive Board in person, 
        the Executive Board may use a system of proxy votes or weighted 
        votes to achieve the voting balance required by this paragraph.
          ``(4) No agency relationship.--The eligibility requirements 
        of this section are intended to ensure the responsible use of 
        Federal funds. Nothing in this section is intended to create an 
        agency relationship between individual high intensity drug 
        trafficking areas and the Federal Government.
  ``(f) Use of Funds.--The Director shall ensure that not more than 5 
percent of Federal funds appropriated for the Program are expended for 
drug treatment programs and not more than 5 percent of the Federal 
funds appropriated for the Program are expended for drug prevention 
programs.
  ``(g) Counterterrorism Activities.--
          ``(1) Assistance authorized.--The Director may authorize use 
        of resources available for the Program to assist Federal, 
        State, local, and Tribal law enforcement agencies in 
        investigations and activities related to terrorism and 
        prevention of terrorism, especially but not exclusively with 
        respect to such investigations and activities that are also 
        related to drug trafficking.
          ``(2) Limitation.--The Director shall ensure--
                  ``(A) that assistance provided under paragraph (1) 
                remains incidental to the purpose of the Program to 
                reduce drug availability and carry out drug-related law 
                enforcement activities; and
                  ``(B) that significant resources of the Program are 
                not redirected to activities exclusively related to 
                terrorism, except on a temporary basis under 
                extraordinary circumstances, as determined by the 
                Director.
  ``(h) Role of Drug Enforcement Administration.--The Director, in 
consultation with the Attorney General, shall ensure that a 
representative of the Drug Enforcement Administration is included in 
the Intelligence Support Center for each high intensity drug 
trafficking area.
  ``(i) Emerging Threat Response Fund.--
          ``(1) In general.--Subject to the availability of 
        appropriations, the Director may expend up to 10 percent of the 
        amounts appropriated under this section on a discretionary 
        basis, in accordance with the criteria established under 
        paragraph (2)--
                  ``(A) to respond to any emerging drug trafficking 
                threat in an existing high intensity drug trafficking 
                area;
                  ``(B) to establish a new high intensity drug 
                trafficking area; or
                  ``(C) to expand an existing high intensity drug 
                trafficking area.
          ``(2) Consideration of impact.--In allocating funds under 
        this subsection, the Director shall consider--
                  ``(A) the impact of activities funded on reducing 
                overall drug traffic in the United States, or 
                minimizing the probability that an emerging drug 
                trafficking threat will spread to other areas of the 
                United States; and
                  ``(B) such other criteria as the Director considers 
                appropriate.
  ``(j) Annual Hidta Program Budget Submissions.--As part of the 
documentation that supports the President's annual budget request for 
the Office, the Director shall submit to Congress a budget 
justification that includes--
          ``(1) the amount proposed for each HIDTA, conditional upon a 
        review by the Office of the request submitted by such HIDTA and 
        the performance of such HIDTA, with supporting narrative 
        descriptions and rationale for each request;
          ``(2) a detailed justification that explains--
                  ``(A) the reasons for the proposed funding level and 
                how such funding level was determined based on a 
                current assessment of the drug trafficking threat in 
                each high intensity drug trafficking area;
                  ``(B) how such funding will ensure that the goals and 
                objectives of each such area will be achieved; and
                  ``(C) how such funding supports the National Drug 
                Control Strategy; and
          ``(3) the amount of HIDTA funds used to investigate and 
        prosecute organizations and individuals trafficking in each 
        major illicit drug, as identified by the Director, in the prior 
        calendar year, and a description of how those funds were used.
  ``(k) Hidta Annual Evaluation Report.--As part of each National Drug 
Control Evaluation assessment under section 1006, the Director shall 
include, for each designated high intensity drug trafficking area, a 
report that--
          ``(1) describes--
                  ``(A) the specific purposes for the high intensity 
                drug trafficking area; and
                  ``(B) the specific long-term and short-term goals and 
                objectives for the high intensity drug trafficking 
                area;
          ``(2) includes an evaluation of the performance of the high 
        intensity drug trafficking area in accomplishing the specific 
        long-term and short-term goals and objectives identified under 
        subparagraph (1)(B);
          ``(3) assesses the number and operation of all federally 
        funded drug enforcement task forces within such high intensity 
        drug trafficking area;
          ``(4) describes--
                  ``(A) each Federal, State, local, and Tribal drug 
                enforcement task force operating in such high intensity 
                drug trafficking area;
                  ``(B) how such task forces coordinate with each 
                other, with any high intensity drug trafficking area 
                task force, and with investigations receiving funds 
                from the Organized Crime and Drug Enforcement Task 
                Force;
                  ``(C) what steps, if any, each such task force takes 
                to share information regarding drug trafficking and 
                drug production with other federally funded drug 
                enforcement task forces in the high intensity drug 
                trafficking area;
                  ``(D) the role of the high intensity drug trafficking 
                area in coordinating the sharing of such information 
                among task forces;
                  ``(E) the nature and extent of cooperation by each 
                Federal, State, local, and Tribal participant in 
                ensuring that such information is shared among law 
                enforcement agencies and with the high intensity drug 
                trafficking area;
                  ``(F) the nature and extent to which information 
                sharing and enforcement activities are coordinated with 
                joint terrorism task forces in the high intensity drug 
                trafficking area; and
                  ``(G) any recommendations for measures needed to 
                ensure that task force resources are utilized 
                efficiently and effectively to reduce the availability 
                of illegal drugs in the high intensity drug trafficking 
                areas; and
          ``(5) in consultation with the Director of National 
        Intelligence--
                  ``(A) evaluates existing and planned law enforcement 
                intelligence systems supported by such high intensity 
                drug trafficking area, or utilized by task forces 
                receiving any funding under the Program, including the 
                extent to which such systems ensure access and 
                availability of law enforcement intelligence to 
                Federal, State, local, and Tribal law enforcement 
                agencies within the high intensity drug trafficking 
                area and outside of such area;
                  ``(B) evaluates the extent to which Federal, State, 
                local, and Tribal law enforcement agencies 
                participating in each high intensity drug trafficking 
                area are sharing law enforcement intelligence 
                information to assess current drug trafficking threats 
                and design appropriate enforcement strategies; and
                  ``(C) identifies the measures needed to improve 
                effective sharing of information and law enforcement 
                intelligence regarding drug trafficking and drug 
                production among Federal, State, local, and Tribal law 
                enforcement participating in a high intensity drug 
                trafficking area, and between such agencies and similar 
                agencies outside the high intensity drug trafficking 
                area.
  ``(l) Coordination of Law Enforcement Intelligence Sharing With 
Organized Crime Drug Enforcement Task Force Program.--
          ``(1) Drug enforcement intelligence sharing.--The Director, 
        in consultation with the Attorney General, shall ensure that 
        any drug enforcement intelligence obtained by the Intelligence 
        Support Center for each high intensity drug trafficking area is 
        shared, on a timely basis, with the drug intelligence fusion 
        center operated by the Organized Crime Drug Enforcement Task 
        Force of the Department of Justice.
          ``(2) Certification.--Before the Director awards any funds to 
        a high intensity drug trafficking area, the Director shall 
        certify that the law enforcement entities participating in that 
        HIDTA are providing laboratory seizure data to the national 
        clandestine laboratory database at the El Paso Intelligence 
        Center.
  ``(m) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office to carry out this section $280,000,000 for 
each fiscal years 2019 through 2023.
  ``(n) Specific Purposes.--
          ``(1) In general.--The Director shall ensure that, of the 
        amounts appropriated for a fiscal year for the Program, at 
        least 2.5 percent is used in high intensity drug trafficking 
        areas with severe neighborhood safety and illegal drug 
        distribution problems.
          ``(2) Required uses.--The funds used under paragraph (1) 
        shall be used to ensure the safety of neighborhoods and the 
        protection of communities, including the prevention of the 
        intimidation of witnesses of illegal drug distribution and 
        related activities and the establishment of or support for 
        programs that provide protection or assistance to witnesses in 
        court proceedings.
          ``(3) Best practice models.--The Director shall work with the 
        HIDTAs to develop and maintain best practice models to assist 
        State, local, and Tribal governments in addressing witness 
        safety, relocation, financial and housing assistance, or any 
        other services related to witness protection or assistance in 
        cases of illegal drug distribution and related activities. The 
        Director shall ensure dissemination of the best practice models 
        to each HIDTA.

        ``SUBCHAPTER III--DRUG-FREE COMMUNITIES SUPPORT PROGRAM

``Sec. 1031. Establishment of drug-free communities support program

  ``(a) Establishment.--The Director shall establish a program to 
support communities in the development and implementation of 
comprehensive, long-term plans and programs to prevent and treat 
substance use and misuse among youth.
  ``(b) Program.--In carrying out the Program, the Director shall--
          ``(1) make and track grants to grant recipients;
          ``(2) provide for technical assistance and training, data 
        collection, and dissemination of information on state-of-the-
        art practices that the Director determines to be effective in 
        reducing substance use; and
          ``(3) provide for the general administration of the Program.
  ``(c) Administration.--The Director shall appoint an Administrator to 
carry out the Program.
  ``(d) Contracting.--The Director may employ any necessary staff and 
may enter into contracts or agreements with national drug control 
agencies, including interagency agreements, to delegate authority for 
the execution of grants and for such other activities necessary to 
carry out this chapter.

``Sec. 1032. Program authorization

  ``(a) Grant Eligibility.--To be eligible to receive an initial grant 
or a renewal grant under this subchapter, a coalition shall meet each 
of the following criteria:
          ``(1) Application.--The coalition shall submit an application 
        to the Administrator in accordance with section 1033(a)(2).
          ``(2) Major sector involvement.--
                  ``(A) In general.--The coalition shall consist of 1 
                or more representatives of each of the following 
                categories:
                          ``(i) Youth.
                          ``(ii) Parents.
                          ``(iii) Businesses.
                          ``(iv) The media.
                          ``(v) Schools.
                          ``(vi) Organizations serving youth.
                          ``(vii) Law enforcement.
                          ``(viii) Religious or fraternal 
                        organizations.
                          ``(ix) Civic and volunteer groups.
                          ``(x) Health care professionals.
                          ``(xi) State, local, or tribal governmental 
                        agencies with expertise in the field of 
                        substance use prevention or substance use 
                        disorders (including, if applicable, the State 
                        authority with primary authority for substance 
                        use and misuse).
                          ``(xii) Other organizations involved in 
                        reducing the prevalence of substance use and 
                        misuse or substance use disorders.
                  ``(B) Elected officials.--If feasible, in addition to 
                representatives from the categories listed in 
                subparagraph (A), the coalition shall have an elected 
                official (or a representative of an elected official) 
                from--
                          ``(i) the Federal Government; and
                          ``(ii) the government of the appropriate 
                        State and political subdivision thereof or the 
                        governing body or an Indian tribe (as that term 
                        is defined in section 4(e) of the Indian Self-
                        Determination Act (25 U.S.C. 450b(e))).
                  ``(C) Representation.--An individual who is a member 
                of the coalition may serve on the coalition as a 
                representative of not more than 1 category listed under 
                subparagraph (A).
          ``(3) Commitment.--The coalition shall demonstrate, to the 
        satisfaction of the Administrator--
                  ``(A) that the representatives of the coalition have 
                worked together on substance use and misuse reduction 
                initiatives, which, at a minimum, includes initiatives 
                that target drugs described in section 1037(6)(A), for 
                a period of not less than 6 months, acting through 
                entities such as task forces, subcommittees, or 
                community boards; and
                  ``(B) substantial participation from volunteer 
                leaders in the community involved (especially in 
                cooperation with individuals involved with youth such 
                as parents, teachers, coaches, youth workers, and 
                members of the clergy).
          ``(4) Mission and strategies.--The coalition shall, with 
        respect to the community involved--
                  ``(A) have as its principal mission the reduction of 
                illegal drug use, which, at a minimum, includes the use 
                of illegal drugs described in section 1037(6)(A), in a 
                comprehensive and long-term manner, with a primary 
                focus on youth in the community;
                  ``(B) describe and document the nature and extent of 
                the substance use and misuse problem, which, at a 
                minimum, includes the use and misuse of drugs described 
                in section 1037(6)(A), in the community;
                  ``(C)(i) provide a description of substance use and 
                misuse prevention and treatment programs and 
                activities, which, at a minimum, includes programs and 
                activities relating to the use and misuse of drugs 
                described in section 1037(6)(A), in existence at the 
                time of the grant application; and
                  ``(ii) identify substance use and misuse programs and 
                service gaps, which, at a minimum, includes programs 
                and gaps relating to the use and misuse of drugs 
                described in section 1037(6)(A), in the community;
                  ``(D) develop a strategic plan to reduce substance 
                use and misuse among youth, which, at a minimum, 
                includes the use and misuse of drugs described in 
                section 1037(6)(A), in a comprehensive and long-term 
                fashion; and
                  ``(E) work to develop a consensus regarding the 
                priorities of the community to combat substance use and 
                misuse among youth, which, at a minimum, includes the 
                use and misuse of drugs described in section 
                1037(6)(A).
          ``(5) Sustainability.--The coalition shall demonstrate that 
        the coalition is an ongoing concern by demonstrating that the 
        coalition--
                  ``(A) is--
                          ``(i)(I) a nonprofit organization; or
                          ``(II) an entity that the Administrator 
                        determines to be appropriate; or
                          ``(ii) part of, or is associated with, an 
                        established legal entity;
                  ``(B) receives financial support (including, in the 
                discretion of the Administrator, in-kind contributions) 
                from non-Federal sources; and
                  ``(C) has a strategy to solicit substantial financial 
                support from non-Federal sources to ensure that the 
                coalition and the programs operated by the coalition 
                are self-sustaining.
          ``(6) Accountability.--The coalition shall--
                  ``(A) establish a system to measure and report 
                outcomes--
                          ``(i) consistent with common indicators and 
                        evaluation protocols established by the 
                        Administrator; and
                          ``(ii) approved by the Administrator;
                  ``(B) conduct--
                          ``(i) for an initial grant under this 
                        subchapter, an initial benchmark survey of drug 
                        use among youth (or use local surveys or 
                        performance measures available or accessible in 
                        the community at the time of the grant 
                        application); and
                          ``(ii) biennial surveys (or incorporate local 
                        surveys in existence at the time of the 
                        evaluation) to measure the progress and 
                        effectiveness of the coalition; and
                  ``(C) provide assurances that the entity conducting 
                an evaluation under this paragraph, or from which the 
                coalition receives information, has experience--
                          ``(i) in gathering data related to substance 
                        use and misuse among youth; or
                          ``(ii) in evaluating the effectiveness of 
                        community anti-drug coalitions.
          ``(7) Additional criteria.--The Director shall not impose any 
        eligibility criteria on new applicants or renewal grantees not 
        provided in this chapter.
  ``(b) Grant Amounts.--
          ``(1) In general.--
                  ``(A) Grants.--
                          ``(i) In general.--Subject to clause (iv), 
                        for a fiscal year, the Administrator may grant 
                        to an eligible coalition under this paragraph, 
                        an amount not to exceed the amount of non-
                        Federal funds raised by the coalition, 
                        including in-kind contributions, for that 
                        fiscal year.
                          ``(ii) Suspension of grants.--If such grant 
                        recipient fails to continue to meet the 
                        criteria specified in subsection (a), the 
                        Administrator may suspend the grant, after 
                        providing written notice to the grant recipient 
                        and an opportunity to appeal.
                          ``(iii) Renewal grants.--Subject to clause 
                        (iv), the Administrator may award a renewal 
                        grant to a grant recipient under this 
                        subparagraph for each fiscal year following the 
                        fiscal year for which an initial grant is 
                        awarded, in an amount not to exceed the amount 
                        of non-Federal funds raised by the coalition, 
                        including in-kind contributions, for that 
                        fiscal year, during the 4-year period following 
                        the period of the initial grant.
                          ``(iv) Limitation.--The amount of a grant 
                        award under this subparagraph may not exceed 
                        $125,000 for a fiscal year.
                  ``(B) Coalition awards.--
                          ``(i) In general.--Except as provided in 
                        clause (ii), the Administrator may, with 
                        respect to a community, make a grant to 1 
                        eligible coalition that represents that 
                        community.
                          ``(ii) Exception.--The Administrator may make 
                        a grant to more than 1 eligible coalition that 
                        represents a community if--
                                  ``(I) the eligible coalitions 
                                demonstrate that the coalitions are 
                                collaborating with one another; and
                                  ``(II) each of the coalitions has 
                                independently met the requirements set 
                                forth in subsection (a).
          ``(2) Rural coalition grants.--
                  ``(A) In general.--
                          ``(i) In general.--In addition to awarding 
                        grants under paragraph (1), to stimulate the 
                        development of coalitions in sparsely populated 
                        and rural areas, the Administrator may award a 
                        grant in accordance with this section to a 
                        coalition that represents a county with a 
                        population that does not exceed 30,000 
                        individuals. In awarding a grant under this 
                        paragraph, the Administrator may waive any 
                        requirement under subsection (a) if the 
                        Administrator considers that waiver to be 
                        appropriate.
                          ``(ii) Matching requirement.--Subject to 
                        subparagraph (C), for a fiscal year, the 
                        Administrator may grant to an eligible 
                        coalition under this paragraph, an amount not 
                        to exceed the amount of non-Federal funds 
                        raised by the coalition, including in-kind 
                        contributions, for that fiscal year.
                          ``(iii) Suspension of grants.--If such grant 
                        recipient fails to continue to meet any 
                        criteria specified in subsection (a) that has 
                        not been waived by the Administrator pursuant 
                        to clause (i), the Administrator may suspend 
                        the grant, after providing written notice to 
                        the grant recipient and an opportunity to 
                        appeal.
                  ``(B) Renewal grants.--The Administrator may award a 
                renewal grant to an eligible coalition that is a grant 
                recipient under this paragraph for each fiscal year 
                following the fiscal year for which an initial grant is 
                awarded, in an amount not to exceed the amount of non-
                Federal funds raised by the coalition, including in-
                kind contributions, during the 4-year period following 
                the period of the initial grant.
                  ``(C) Limitations.--
                          ``(i) Amount.--The amount of a grant award 
                        under this paragraph shall not exceed $125,000 
                        for a fiscal year.
                          ``(ii) Awards.--With respect to a county 
                        referred to in subparagraph (A), the 
                        Administrator may award a grant under this 
                        section to not more than 1 eligible coalition 
                        that represents the county.
          ``(3) Additional grants.--
                  ``(A) In general.--Subject to subparagraph (F), the 
                Administrator may award an additional grant under this 
                paragraph to an eligible coalition awarded a grant 
                under paragraph (1) or (2) for any first fiscal year 
                after the end of the 4-year period following the period 
                of the initial grant under paragraph (1) or (2), as the 
                case may be.
                  ``(B) Scope of grants.--A coalition awarded a grant 
                under paragraph (1) or (2), including a renewal grant 
                under such paragraph, may not be awarded another grant 
                under such paragraph, and is eligible for an additional 
                grant under this section only under this paragraph.
                  ``(C) No priority for applications.--The 
                Administrator may not afford a higher priority in the 
                award of an additional grant under this paragraph than 
                the Administrator would afford the applicant for the 
                grant if the applicant were submitting an application 
                for an initial grant under paragraph (1) or (2) rather 
                than an application for a grant under this paragraph.
                  ``(D) Renewal grants.--Subject to subparagraph (F), 
                the Administrator may award a renewal grant to a grant 
                recipient under this paragraph for each of the fiscal 
                years of the 4-fiscal-year period following the fiscal 
                year for which the initial additional grant under 
                subparagraph (A) is awarded in an amount not to exceed 
                amounts as follows:
                          ``(i) For the first and second fiscal years 
                        of that 4-fiscal-year period, the amount equal 
                        to 80 percent of the non-Federal funds, 
                        including in-kind contributions, raised by the 
                        coalition for the applicable fiscal year.
                          ``(ii) For the third and fourth fiscal years 
                        of that 4-fiscal-year period, the amount equal 
                        to 67 percent of the non-Federal funds, 
                        including in-kind contributions, raised by the 
                        coalition for the applicable fiscal year.
                  ``(E) Suspension.--If a grant recipient under this 
                paragraph fails to continue to meet the criteria 
                specified in subsection (a), the Administrator may 
                suspend the grant, after providing written notice to 
                the grant recipient and an opportunity to appeal.
                  ``(F) Limitation.--The amount of a grant award under 
                this paragraph may not exceed $125,000 for a fiscal 
                year.
          ``(4) Process for suspension.--A grantee shall not be 
        suspended or terminated under paragraph (1)(A)(ii), 
        (2)(A)(iii), or (3)(C) unless that grantee is afforded a fair, 
        timely, and independent appeal prior to such suspension or 
        termination.
  ``(c) Treatment of Funds for Coalitions Representing Certain 
Organizations.--Funds appropriated for the substance use and misuse 
activities of a coalition that includes a representative of the Bureau 
of Indian Affairs, the Indian Health Service, or a tribal government 
agency with expertise in the field of substance use prevention may be 
counted as non-Federal funds raised by the coalition for purposes of 
this section.
  ``(d) Priority in Awarding Grants.--In awarding grants under 
subsection (b)(1)(A)(i), priority shall be given to a coalition serving 
economically disadvantaged areas.

``Sec. 1033. Information collection and dissemination with respect to 
                    grant recipients

  ``(a) Coalition Information.--
          ``(1) General auditing authority.--For the purpose of audit 
        and examination, the Administrator--
                  ``(A) shall have access to any books, documents, 
                papers, and records that are pertinent to any grant or 
                grant renewal request under this chapter; and
                  ``(B) may periodically request information from a 
                grant recipient to ensure that the grant recipient 
                meets the applicable criteria under section 1032(a).
          ``(2) Application process.--The Administrator shall issue a 
        request for proposal regarding, with respect to the grants 
        awarded under section 1032, the application process, grant 
        renewal, and suspension or withholding of renewal grants. Each 
        application under this paragraph shall be in writing and shall 
        be subject to review by the Administrator.
          ``(3) Reporting.--The Administrator shall, to the maximum 
        extent practicable and in a manner consistent with applicable 
        law, minimize reporting requirements by a grant recipient and 
        expedite any application for a renewal grant made under this 
        subchapter.
  ``(b) Data Collection and Dissemination.--
          ``(1) In general.--The Administrator may collect data from--
                  ``(A) national substance use and misuse organizations 
                that work with eligible coalitions, community anti-drug 
                coalitions, departments or agencies of the Federal 
                Government, or State or local governments and the 
                governing bodies of Indian tribes; and
                  ``(B) any other entity or organization that carries 
                out activities that relate to the purposes of the 
                Program.
          ``(2) Activities of administrator.--The Administrator may--
                  ``(A) evaluate the utility of specific initiatives 
                relating to the purposes of the Program;
                  ``(B) conduct an evaluation of the Program; and
                  ``(C) disseminate information described in this 
                subsection to--
                          ``(i) eligible coalitions and other substance 
                        use prevention organizations; and
                          ``(ii) the general public.
          ``(3) Consultation.--The Administrator shall carry out 
        activities under this subsection in consultation with the 
        National Community Antidrug Coalition Institute.
          ``(4) Limitation on use of certain funds for evaluation of 
        program.--Amounts for activities under paragraph (2)(B) may not 
        be derived from amounts under section 1038(a) except for 
        amounts that are available under section 1038(b) for 
        administrative costs.

``Sec. 1034. Technical assistance and training

  ``(a) In General.--
          ``(1) Technical assistance and agreements.--With respect to 
        any grant recipient or other organization, the Administrator 
        may--
                  ``(A) offer technical assistance and training; and
                  ``(B) enter into contracts and cooperative 
                agreements.
          ``(2) Coordination of programs.--The Administrator may 
        facilitate the coordination of programs between a grant 
        recipient and other organizations and entities.
  ``(b) Training.--The Administrator may provide training to any 
representative designated by a grant recipient in--
          ``(1) coalition building;
          ``(2) task force development;
          ``(3) mediation and facilitation, direct service, assessment 
        and evaluation; or
          ``(4) any other activity related to the purposes of the 
        Program.

``Sec. 1035. Supplemental grants for coalition mentoring activities

  ``(a) Authority to Make Grants.--As part of the program established 
under section 1031, the Director may award an initial grant under this 
subsection, and renewal grants under subsection (f), to any coalition 
awarded a grant under section 1032 that meets the criteria specified in 
subsection (d) in order to fund coalition mentoring activities by such 
coalition in support of the program.
  ``(b) Treatment With Other Grants.--
          ``(1) Supplement.--A grant awarded to a coalition under this 
        section is in addition to any grant awarded to the coalition 
        under section 1032.
          ``(2) Requirement for basic grant.--A coalition may not be 
        awarded a grant under this section for a fiscal year unless the 
        coalition was awarded a grant or renewal grant under section 
        1032(b) for that fiscal year.
  ``(c) Application.--A coalition seeking a grant under this section 
shall submit to the Administrator an application for the grant in such 
form and manner as the Administrator may require.
  ``(d) Criteria.--A coalition meets the criteria specified in this 
subsection if the coalition--
          ``(1) has been in existence for at least 5 years;
          ``(2) has achieved, by or through its own efforts, measurable 
        results in the prevention and treatment of substance use and 
        misuse among youth;
          ``(3) has staff or members willing to serve as mentors for 
        persons seeking to start or expand the activities of other 
        coalitions in the prevention and treatment of substance use and 
        misuse;
          ``(4) has demonstrable support from some members of the 
        community in which the coalition mentoring activities to be 
        supported by the grant under this section are to be carried 
        out; and
          ``(5) submits to the Administrator a detailed plan for the 
        coalition mentoring activities to be supported by the grant 
        under this section.
  ``(e) Use of Grant Funds.--A coalition awarded a grant under this 
section shall use the grant amount for mentoring activities to support 
and encourage the development of new, self-supporting community 
coalitions that are focused on the prevention and treatment of 
substance use and misuse in such new coalitions' communities. The 
mentoring coalition shall encourage such development in accordance with 
the plan submitted by the mentoring coalition under subsection (d)(5).
  ``(f) Renewal Grants.--The Administrator may make a renewal grant to 
any coalition awarded a grant under subsection (a), or a previous 
renewal grant under this subsection, if the coalition, at the time of 
application for such renewal grant--
          ``(1) continues to meet the criteria specified in subsection 
        (d); and
          ``(2) has made demonstrable progress in the development of 
        one or more new, self-supporting community coalitions that are 
        focused on the prevention and treatment of substance use and 
        misuse.
  ``(g) Grant Amounts.--
          ``(1) In general.--Subject to paragraphs (2) and (3), the 
        total amount of grants awarded to a coalition under this 
        section for a fiscal year may not exceed the amount of non-
        Federal funds raised by the coalition, including in-kind 
        contributions, for that fiscal year. Funds appropriated for the 
        substance use and misuse activities of a coalition that 
        includes a representative of the Bureau of Indian Affairs, the 
        Indian Health Service, or a tribal government agency with 
        expertise in the field of substance use prevention may be 
        counted as non-Federal funds raised by the coalition.
          ``(2) Initial grants.--The amount of the initial grant 
        awarded to a coalition under subsection (a) may not exceed 
        $75,000.
          ``(3) Renewal grants.--The total amount of renewal grants 
        awarded to a coalition under subsection (f) for any fiscal year 
        may not exceed $75,000.
  ``(h) Fiscal Year Limitation on Amount Available for Grants.--The 
total amount available for grants under this section, including renewal 
grants under subsection (f), in any fiscal year may not exceed the 
amount equal to five percent of the amount authorized to be 
appropriated by section 1038 for that fiscal year.
  ``(i) Priority in Awarding Initial Grants.--In awarding initial 
grants under this section, priority shall be given to a coalition that 
expressly proposes to provide mentorship to a coalition or aspiring 
coalition serving economically disadvantaged areas.

``Sec. 1036. Authorization for National Community Antidrug Coalition 
                    Institute

  ``(a) In General.--The Director shall, using amounts authorized to be 
appropriated by subsection (d), make a competitive grant to provide for 
the continuation of the National Community Anti-drug Coalition 
Institute.
  ``(b) Eligible Organizations.--An organization eligible for the grant 
under subsection (a) is any national nonprofit organization that 
represents, provides technical assistance and training to, and has 
special expertise and broad, national-level experience in community 
antidrug coalitions under this subchapter.
  ``(c) Use of Grant Amount.--The organization that receives the grant 
under subsection (a) shall continue a National Community Anti-Drug 
Coalition Institute to--
          ``(1) provide education, training, and technical assistance 
        for coalition leaders and community teams, with emphasis on the 
        development of coalitions serving economically disadvantaged 
        areas;
          ``(2) develop and disseminate evaluation tools, mechanisms, 
        and measures to better assess and document coalition 
        performance measures and outcomes; and
          ``(3) bridge the gap between research and practice by 
        translating knowledge from research into practical information.
  ``(d) Authorization of Appropriations.--The Director shall, using 
amounts authorized to be appropriated by section 1038, make a grant of 
$2,000,000 under subsection (a), for each of the fiscal years 2019 
through 2023.

``Sec. 1037. Definitions

  ``In this subchapter:
          ``(1) Administrator.--The term `Administrator' means the 
        Administrator appointed by the Director under section 1031(c).
          ``(2) Community.--The term `community' shall have the meaning 
        provided that term by the Administrator.
          ``(3) Eligible coalition.--The term `eligible coalition' 
        means a coalition that meets the applicable criteria under 
        section 1032(a).
          ``(4) Grant recipient.--The term `grant recipient' means the 
        recipient of a grant award under section 1032.
          ``(5) Program.--The term `Program' means the program 
        established under section 1031(a).
          ``(6) Substance use and misuse.--The term `substance use and 
        misuse' means--
                  ``(A) the illegal use or misuse of drugs, including 
                substances for which a listing is in effect under any 
                of schedules I through V under section 202 of the 
                Controlled Substances Act (21 U.S.C. 812);
                  ``(B) the misuse of inhalants or over the counter 
                drugs; or
                  ``(C) the use of alcohol, tobacco, or other related 
                product as such use is prohibited by State or local 
                law.
          ``(7) Youth.--The term `youth' shall have the meaning 
        provided that term by the Administrator.

``Sec. 1038. Drug-free communities reauthorization

  ``(a) Authorization of Appropriations.--There are authorized to be 
appropriated to the Office to carry out this subchapter $99,000,000 for 
each of fiscal years 2019 through 2023.
  ``(b) Administrative Costs.--Not more than 8 percent of the funds 
appropriated for this subchapter may be used by the Office or, in the 
discretion of the Director, an agency delegated to carry out the 
program under section 1031(d) to pay for administrative costs 
associated with carrying out the program.''.
  (d) Technical and Conforming Amendment.--The table of chapters for 
subtitle I of title 31, United States Code, is amended by adding at the 
end the following new item:

``10. Office of National Drug Control.......................    1001''.

SEC. 3. REPEALS.

  The following provisions are repealed:
          (1) Section 203 of the Office of National Drug Control Policy 
        Reauthorization Act of 2006 (Public Law 109-469; 21 U.S.C. 
        1708a).
          (2) Title VIII of the Office of National Drug Control Policy 
        Reauthorization Act of 2006 (Public Law 109-469).
          (3) Section 1105 of the Office of National Drug Control 
        Policy Reauthorization Act of 2006 (Public Law 109-469; 21 
        U.S.C. 1701 note).
          (4) Section 1110 of Office of National Drug Control Policy 
        Reauthorization Act of 2006 (Public Law 109-469; 21 U.S.C. 1705 
        note).
          (5) Section 1110A of the Office of National Drug Control 
        Policy Reauthorization Act of 2006 (Public Law 109-469; 21 
        U.S.C. 1705 note).
          (6) Section 4 of Public Law 107-82 (21 U.S.C. 1521 note).

SEC. 4. OPIOID CRISIS RESPONSE.

  (a) Emerging Threat Designation.--The Director shall designate 
opioids and opioid analogues as emerging threats, in accordance with 
section 1009 of title 31, United States Code, as added by section 2(b).
  (b) Opioid Response Plan.--
          (1) Issuance.--Not later than 60 days after the date of the 
        enactment of this Act, the Director shall publish, make 
        publicly available, and notify the President and the 
        appropriate congressional committees of, the plan required 
        under section 1009 of title 31, United States Code, as added by 
        section 2(b), to be designated as the ``National Opioid Crisis 
        Response Plan''.
          (2) Contents.--The Director shall ensure the plan establishes 
        measurable goals, including reducing fatal and non-fatal 
        overdoses, and includes the following:
                  (A) Initiatives to ensure the United States mail is 
                effectively screened to prevent illicit drugs from 
                entering the United States, including--
                          (i) designating the United States Postal 
                        Service as a National Drug Control Program 
                        Agency;
                          (ii) directing the United States Postal 
                        Service and any other related National Drug 
                        Control Program Agency to take any appropriate 
                        actions necessary to reduce the amount of 
                        illicit drugs entering the country; and
                          (iii) developing an international 
                        coordination plan, in accordance with section 
                        1010 of such title 31, United States Code, as 
                        added by section 2(b)), to include efforts to 
                        address international drug control initiatives 
                        and strengthen bilateral and multilateral 
                        strategies to reduce illicit drugs and 
                        precursor chemicals from entering the United 
                        States through international mail or across 
                        land borders or ports of entry.
                  (B) Support for universal adoption of evidence-based 
                prescribing guidelines, including--
                          (i) establishing a task force to supplement 
                        existing prescribing guidelines with evidence-
                        based standards and to facilitate, coordinate, 
                        and, as appropriate, conduct research to inform 
                        such guidelines;
                          (ii) encouraging the adoption of evidence-
                        based prescribing guidelines by each relevant 
                        agency, State and local governments, and 
                        private sector organizations;
                          (iii) issuing guidance to National Drug 
                        Control Program Agencies to, as appropriate, 
                        revise regulations to ensure professionals have 
                        effective continuing education requirements; 
                        and
                          (iv) disseminating and encouraging the 
                        adoption of best practices and evidence-based 
                        guidelines for effective prescribing practices.
                  (C) A program to monitor the prescription drug market 
                and illicit drug market for changes in trends relevant 
                to reducing the supply or demand of such drugs.
                  (D) An initiative to facilitate and coordinate 
                Federal, State and local government initiatives, 
                studies, and pilot or demonstration programs designed 
                to evaluate the benefits of drug courts and related 
                programs that reduce substance use prevalence.
                  (E) Programs, developed in coordination with the 
                private sector, to--
                          (i) facilitate the development of treatment 
                        and deterrent products, in accordance with 
                        section 1010(c) of title 31, United States 
                        Code, as added by section 2(b); and
                          (ii) encourage the expansion of medication 
                        disposal programs and technology.
                  (F) Initiatives to encourage the National Drug 
                Control Program Agencies and the program established 
                under section 1010(d) of title 31, United States Code, 
                as added by section 2(b)--
                          (i) to prioritize the development of 
                        sentencing standards or model codes for 
                        trafficking opioids and opioid analogues; and
                          (ii) to advise States on establishing laws 
                        and policies to address opioid issues based on 
                        the recommendations developed and set forth by 
                        the President's Commission on Combating Drug 
                        Addiction and the Opioid Crisis.
                  (G) Working groups, established in accordance with 
                section 1010 of title 31, United States Code, as added 
                by section 2(b), to develop standards, and encourage 
                the use of such standards, for the collection of data 
                necessary to understand and monitor the opioid crisis, 
                including--
                          (i) State medical examiner reports on deaths 
                        caused by overdoses and related statistical 
                        data; and
                          (ii) first responder opioid intoxication 
                        incidents.
                  (H) A program to identify successful college recovery 
                programs, including sober housing programs that provide 
                a shared living residence free of alcohol or illicit 
                drug use for individuals recovering from drug or 
                alcohol addiction and substance use disorders, on 
                college campuses and disseminate best practices to 
                Colleges and Universities to increase the number and 
                capacity of such programs.
                  (I) Convening working groups, consisting of the 
                appropriate National Drug Control Program Agencies, 
                State, local and Tribal governments, and other 
                appropriate stakeholders, established in accordance 
                with section 1010 of title 31, United States Code--
                          (i) to support Prescription Drug Monitoring 
                        Programs by--
                                  (I) facilitating the sharing of 
                                program data among States and Federal 
                                prescription drug monitoring programs 
                                to ensure interoperability of such 
                                programs;
                                  (II) assisting States in increasing 
                                utilization of such programs;
                                  (III) facilitating efforts to 
                                incorporate available overdose and 
                                naloxone deployment data into such 
                                programs;
                                  (IV) evaluating barriers to 
                                integrating program data with 
                                electronic health records; and
                                  (V) offering recommendations to 
                                address identified barriers; and
                          (ii) to develop standards, and encourage the 
                        use of such standards, for the collection of 
                        data necessary to understand and monitor the 
                        opioid crisis, including--
                                  (I) State medical examiner reports on 
                                deaths caused by overdoses and related 
                                statistical data; and
                                  (II) first responder opioid 
                                intoxication incidents.
                  (J) Research initiatives, to be initiated not later 
                than 30 days after the issuance of the plan, to 
                evaluate the uses and barriers to use of and the 
                effects of improving the following programs:
                          (i) Medication Assisted Treatment.
                          (ii) Data collection systems used to confirm 
                        opioid use by individuals who have been 
                        arrested or hospitalized.
                  (K) A requirement for an Advisory Committee on 
                Substance Use Disorder Treatment Standards, to be 
                established not later than 120 days after the issuance 
                of the plan, to promulgate model evidence-based 
                standards for substance use disorder treatment and 
                recovery facilities which--
                          (i) shall be chaired by the Director;
                          (ii) shall include as members of the advisory 
                        committee representatives of the relevant 
                        National Drug Control Program Agencies;
                          (iii) may include as members of the advisory 
                        committee government regulators, State 
                        representatives, consumer representatives, 
                        substance use disorder treatment providers, 
                        recovery residence owners and operators, and 
                        purchasers of substance use disorder 
                        treatments; and
                          (iv) shall ensure such model standards are 
                        promulgated no later than 2 years after the 
                        date of the issuance of the plan.
  (c) Recommendations.--Not later than 1 year after the date of the 
enactment of this Act, the Director shall submit to Congress a report 
on the results of the initiatives conducted under subsection (b)(2)(K) 
and recommendations based on such results.

SEC. 5. EXCEPTIONS AND RULES OF CONSTRUCTION.

  (a) Rules of Construction.--Nothing in this Act, or the amendments 
made by this act shall be construed as derogating the authorities and 
responsibilities of the Director of National Intelligence or the 
Director of the Central Intelligence Agency contained in the National 
Security Act of 1947 (50 U.S.C. 401 et seq.), the Central Intelligence 
Agency Act of 1949 (50 U.S.C. 403a et seq.), or any other law.
  (b) Inapplicability to Certain Programs.--This Act, and the 
amendments made by this Act, shall not apply to the National 
Intelligence Program and the Military Intelligence Program, unless such 
program or an element of such program is designated as a National Drug 
Control Program--
          (1) by the President; or
          (2) jointly by--
                  (A) in the case of the National Intelligence Program, 
                the Director and the Director of National Intelligence; 
                or
                  (B) in the case of the Military Intelligence Program, 
                the Director, the Director of National Intelligence, 
                and the Secretary of Defense.
  (c) Classified Information.--Any contents of any report required 
under this Act or the amendments made by this Act that involve 
information properly classified under criteria established by an 
Executive order shall be presented to Congress separately from the rest 
of such report.

SEC. 6. GAO STUDY AND REPORTS.

  (a) Reports.--
          (1) Initial.--Not later than 3 years after the date of the 
        enactment of this Act, the Comptroller General shall provide an 
        initial report to the appropriate Congressional Committees.
          (2) Final.--Not later than 6 years after the date of the 
        enactment of this Act, the Comptroller General shall provide a 
        final report to the appropriate Congressional Committees.
  (b) Contents of Report.--The reports described in subsection (a) 
shall include the following:
          (1) A review of the implementation of the education and 
        outreach campaign for emerging threats, including--
                  (A) whether the objectives of the campaign and the 
                media campaign have been met during the relevant 
                period; and
                  (B) whether the Office took steps to ensure that the 
                campaign operated in an efficient and effective manner 
                consistent with the overall strategy and focus of the 
                campaign.
          (2) A review of the adherence to policies and practices 
        implemented to ensure that Federal funds were used responsibly 
        to purchase advertising time and space and eliminate the 
        potential for waste, fraud and abuse.
          (3) An evaluation of the most recent, applicable National 
        Drug Control Strategy, including whether the National Drug 
        Control Strategy met the requirements of section 1005 of title 
        31, United States Code, as added by section 2(b).
          (4) An evaluation of whether the required annual assessments 
        prepared by the Office met the requirements of section 1006 of 
        title 31, United States Code, as added by section 2(b).
          (5) Such other matters as the Comptroller General determines 
        to be appropriate.

SEC. 7. DEFINITIONS.

  In this Act, the terms ``appropriate congressional committees'', 
``Director'', ``drug'', ``illicit drug use'', ``illicit drugs'', and 
``National Drug Control Program Agencies'' have the meaning given those 
terms in section 1001 of title 31, United States Code.

                   Summary and Purpose of Legislation

    H.R. 5925, the Coordinated Response through Interagency 
Strategy and Information Sharing Act, or the CRISIS Act, 
reauthorizes the Office of National Drug Control Policy (the 
Office) and changes the name of the Office to the Office of 
National Drug Control, to reflect the fact the Office's 
responsibilities extend beyond policymaking. The bill adds a 
new chapter 10 to title 31, United States Code. The new chapter 
10 establishes and details the Office's responsibilities and 
authorities, which are based on the previous authorizing 
statute. Chapter 10 also reauthorizes and codifies the High 
Intensity Drug Trafficking Areas Program and the Drug-Free 
Communities Support Program and directs the Office to issue an 
Opioid Response Plan not later than 60 days after enactment.

                  Background and Need for Legislation

    Thirty years ago, the Anti-drug Abuse Act of 1988 
established the Office to set the Nation's drug control policy 
and priorities and to coordinate and oversee government-wide 
implementation of the National Drug Control Program.\1\ The 
unified drug control policy and the Office's coordinating role 
are critical to ensure federal drug control efforts are 
effective and to prevent unnecessary duplication and waste. The 
National Drug Control Program includes nearly 40 designated 
executive departments, agencies, or components; elements of the 
Judicial branch; and at least 130 distinct programs.\2\ The 
President's fiscal year 2019 budget requests $29.9 billion for 
the drug control efforts of National Drug Control Program 
agencies.\3\
---------------------------------------------------------------------------
    \1\Pub. L. No. 100-690 (1988).
    \2\Exec. Office of the President, FY 2014 Budget and Performance 
Summary Report, https://www.whitehouse.gov/sites/whitehouse.gov/files/
ondcp/budget-performance/fy2014_budget_and_performance-summary.pdf.
    \3\Exec. Office of the President, National Drug Control Budget FY 
2019 Funding Highlights (on file with the Committee).
---------------------------------------------------------------------------
    The objectives of the National Drug Control Program 
generally focus on reducing the supply of, and demand for, 
illicit drugs, and cover a spectrum of activities, including 
prevention, treatment, interdiction, domestic law enforcement, 
and international coordination.

                    SUBSTANCE USE DISORDER EPIDEMIC

    In December 2017, the Centers for Disease Control and 
Prevention (CDC) reported life expectancy in the United States 
dropped for the second year in a row, primarily due to drug 
overdoses.\4\ The CDC also reported that in 2016, nearly 64,000 
Americans died from drug overdoses\5\--a figure that rivals the 
peak death figures from HIV/AIDS in the mid-1990s.\6\ The 
Department of Health and Human Services estimates more than 20 
million adults in the United States have substance use 
disorders.\7\ The availability of evidence-based treatment is 
critically important to addressing this epidemic, but a wide 
treatment gap exists. According to the President's Commission 
on Combating Drug Addiction and the Opioid Crisis (the 
President's Commission), ``[t]oday, only 10.6% of youth and 
adults who need treatment for a substance use disorder receive 
that treatment.''\8\
---------------------------------------------------------------------------
    \4\Kenneth D. Kochanek et al., Centers for Disease Control & 
Prevention, Mortality in the United States, 2016 (Dec. 2017), https://
www.cdc.gov/nchs/data/databriefs/db293.pdf.
    \5\Holly Hedegaard et al., Centers for Disease Control & 
Prevention, Drug Overdose Deaths in the United States, 1999-2016 (Dec. 
2017), https://www.cdc.gov/nchs/data/databriefs/db294.pdf.
    \6\Ctrs. for Disease Control & Prevention, HIV Surveillance 1981-
2008, 60(21) MMWR 689-96 (June 3, 2011), available at https://
www.cdc.gov/mmwr/preview/mmwrhtml/mm6021a2.htm.
    \7\Substance Abuse & Mental Health Services Administration, Mental 
and Substance Use Disorders, https://www.samhsa.gov/disorders (last 
updated June 20, 2017).
    \8\The President's Commission on Combating Drug Addiction and the 
Opioid Crisis, Final Report (2017) (hereinafter Commission Report).
---------------------------------------------------------------------------
    Opioids--prescription and illicit--are a leading 
contributor to the increase in drug overdose deaths in the 
United States. Opioids are a class of drugs that includes 
hydrocodone, oxycodone, heroin, and synthetic analogs such as 
fentanyl.\9\ Opioids are most often prescribed to relieve or 
manage pain. Opioids have also been heavily marketed by 
pharmaceutical companies and are highly addictive.\10\ A 
dramatic increase in the prescription rates for opioids in 
recent years has contributed to unprecedented levels of 
dependency and misuse.\11\ According to the President's 
Commission, ``sales of prescription opioids in the U.S. nearly 
quadrupled from 1999 to 2014.''\12\
---------------------------------------------------------------------------
    \9\Centers for Disease Control & Prevention: Opioid Data Analysis, 
https://www.cdc.gov/drugoverdose/data/analysis.html (last visited Apr. 
3, 2018).
    \10\Commission Report, supra note 8, at 20.
    \11\Nat'l Institute on Drug Abuse, Opioid Overdose Crisis, https://
www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis (last 
revised March 2018); Fentanyl: The Next Wave of the Opioid Crisis: 
Hearing before the H. Comm. on Energy & Commerce, 115th Cong. (Mar. 21, 
2017) (statement of Wilson M. Compton, Deputy Director, Nat'l Institute 
on Drug Abuse, Nat'l Institutes of Health, Dep't of Health & Human 
Serv.).
    \12\Commission Report, supra note 5.
---------------------------------------------------------------------------
    As the medical community has become more aware of the 
dangers of prescription opioids and has begun altering 
prescribing practices, there has been a dramatic increase in 
the use of non-prescription opioids, which are less expensive 
and easier to obtain.\13\ For example, since 2010, heroin-
related overdose deaths have increased fivefold.\14\ Synthetic 
opioids like fentanyl, which is 30 to 50 times more potent than 
heroin,\15\ accounted for more than 20,000 overdose deaths in 
2016.\16\
---------------------------------------------------------------------------
    \13\Nat'l Institute on Drug Abuse, Opioid Overdose Crisis, https://
www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis (last 
revised March 2018); Fentanyl: The Next Wave of the Opioid Crisis: 
Hearing before the H. Comm. on Energy & Commerce, 115th Cong. (Mar. 21, 
2017) (statement of Wilson M. Compton, Deputy Director, Nat'l Institute 
on Drug Abuse, Nat'l Institutes of Health, Dep't of Health & Human 
Serv.).
    \14\Centers for Disease Control & Prevention: Heroin Overdose Data, 
https://www.cdc.gov/drugoverdose/data/heroin.html (last visited Apr. 3, 
2018).
    \15\Drug Enf't Admin.: Fentanyl FAQs, https://www.dea.gov/druginfo/
fentanyl-faq.shtml (last visited June 5, 2018).
    \16\Nat'l Inst. on Drug Abuse: Overdose Death Rates, https://
www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates 
(last visited Apr. 3, 2018).
---------------------------------------------------------------------------
    The opioid crisis in the United States appears to be 
worsening. Every day, 175 Americans die from a drug overdose, 
115 of which are from opioids.\17\ In 2016, 2.1 million 
Americans had an opioid use disorder and 42,249 Americans died 
from overdosing on opioids.\18\ According to the CDC, from July 
2016 through September 2017, emergency room visits ``for 
suspected opioid overdoses'' increased 30 percent in the United 
States.\19\ During that period, emergency room visits due to 
opioid overdoses increased ``for men and women, all age groups, 
and all regions.''\20\ Dr. Anand Parekh, Chief Medical Advisor 
for the Bipartisan Policy Center, testified before the 
Committee, ``this crisis, 20 years in the making, will get 
worse before it gets better.''\21\
---------------------------------------------------------------------------
    \17\Nat'l Institute on Drug Abuse: Overdose Death Rates, https://
www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates 
(last visited June 5, 2018); Centers for Disease Control and 
Prevention, Understanding the Epidemic, https://www.cdc.gov/
drugoverdose/epidemic/index.html (last visited June 5, 2018).
    \18\A Sustainable Solution to the Evolving Opioid Crisis: 
Revitalizing the Office of National Drug Control Policy: Hearing Before 
the H. Comm. on Oversight & Gov't Reform, 115th Cong. (May 17, 2018) 
(statement of Dr. Anand Parekh, Chief Medical Advisor, Bipartisan 
Policy Center).
    \19\Press Release, Centers for Disease Control & Prevention, 
Emergency Department Data Show Rapid Increases in Opioid Overdoses 
(2018), available at https://www.cdc.gov/media/releases/2018/p0306-vs-
opioids-overdoses.html.
    \20\Id.
    \21\Hearing Before the H. Comm. on Oversight & Gov't Reform, supra 
note 18.
---------------------------------------------------------------------------

The Administration's Response: A Public Health Emergency and the 
        President's Commission on Combatting Drug Addiction and the 
        Opioid Crisis

    On October 26, 2017, the President directed the 
Administration to declare a public health emergency to address 
the growing opioid epidemic.\22\
---------------------------------------------------------------------------
    \22\Press Release, Dep't of Health & Human Serv., HHS Acting 
Secretary Declares Public Health Emergency to Address National Opioid 
Crisis (Oct. 26, 2017), https://www.hhs.gov/about/news/2017/10/26/hhs-
acting-secretary-declares-public-health-emergency-address-national-
opioid-crisis.html.
---------------------------------------------------------------------------
    On March 29, 2017, the President issued Executive Order 
13784, establishing the President's Commission on Combating 
Drug Addiction and the Opioid Crisis. The President charged the 
Commission with studying the scope and effectiveness of the 
federal response to drug addiction and the opioid crisis, and 
making recommendations to improve the federal response.\23\ The 
Office of National Drug Control Policy was responsible for 
facilitating the work of the Commission, providing 
administrative support, and ensuring compliance with the 
Federal Advisory Committee Act.\24\ Chaired by former New 
Jersey Governor Chris Christie, the Commission held multiple 
meetings and received testimony from numerous witnesses.\25\
---------------------------------------------------------------------------
    \23\Exec. Order No. 13784, 82 Fed. Reg. 16283 (Mar. 29, 2017).
    \24\Id.
    \25\2Office of Nat'l Drug Control Policy Meetings, https://
www.whitehouse.gov/ondcp/presidents-commission/meetings/ (last visited 
May 31, 2018).
---------------------------------------------------------------------------
    The Commission issued an interim report containing 9 
recommendations and a final report containing 56 
recommendations to address the opioid crisis.\26\ Governor 
Christie testified to the Committee on November 28, 2017, that 
the recommendations from both the draft and final reports 
``should be read together'' and constitute the full set of 
recommendations from the Commission.\27\ H.R. 5925 addresses 
findings and recommendations from the Commission's report by: 
(1) improving data access, collection, standardization, and 
requiring ONDCP to use this data to monitor, inform, evaluate, 
and address the crisis; (2) enhancing coordination efforts 
among and between states, federal agencies, private sector 
entities, and nonprofit organizations; and (3) strengthening 
capacity for oversight, tracking, and evidence-based decision 
making in the use of federal resources to combat the opioid 
epidemic.
---------------------------------------------------------------------------
    \26\Commission Report, supra note 8.
    \27\Combating the Opioid Crisis: Hearing Before the H. Comm. on 
Oversight & Gov't Reform, 115th Cong. (Nov. 28, 2017).
---------------------------------------------------------------------------

 THE OFFICE'S ROLE IN THE NATION'S DRUG CONTROL EFFORTS AND ACTIVITIES

    Over the last 30 years, the Office has operated under a 
number of authorizing and appropriating laws. Until 2010, the 
Director of the Office--often informally referred to as the 
nation's ``Drug Czar''--served on the President's cabinet. The 
Office's most recent authorization expired in 2010, and annual 
funding for the Office began to decline from more than $29.5 
million in fiscal year 2010 to $18.4 million in fiscal year 
2018.\28\
---------------------------------------------------------------------------
    \28\Pub. L. No. 111-117, div. C, title II, 123 Stat. 3170 (2009); 
Pub. L. No. 115-141 (2018).
---------------------------------------------------------------------------
    H.R. 5925 reaffirms the role of the Office by increasing 
its prominence and strengthening its coordinating roles and 
responsibilities. Prior authorizations, though well intended, 
have been layered one on top of the other in the statutes at 
large, creating ambiguity as to the state of current law.\29\ 
H.R. 5925 places the Office's authorizing law into the U.S. 
Code, creating a new chapter 10 in title 31. Putting the office 
in title 31 places the Office on level ground with the Office 
of Management and Budget (OMB).
---------------------------------------------------------------------------
    \29\According to the Office of Law Revision Counsel, ``A positive 
law title of the Code is itself a Federal statute. A non-positive law 
title of the Code is an editorial compilation of Federal statutes.'' 
Because of this distinction, non-positive law titles may not reflect 
the exact letter of the law. For example, section 103(f) of the 2006 
reauthorization, which created the role of the Interdiction Coordinator 
appears intended to replace the prior section 711 of the 1998 
reauthorization, which required an interdiction budget, but the 2006 
law directed the amendment of section 711 by ``by adding at the end'' a 
new section 711. Pub. L. 109-469, 120 Stat. 3507. The Office of Law 
Revision Counsel's editorial compilation reflects the likely intent of 
the law, which is to replace the 1998 section 711, but not the actual 
law, which is to add at the end of section 711. Positive Law 
Codification, OLC, http://uscode.house.gov/codification/
legislation.shtml (last visited June 1, 2018).
---------------------------------------------------------------------------

Office structure

    Prior authorizations established an Office led by a 
Director and four deputy directors, including a principal 
deputy director, a deputy director for demand reduction, a 
deputy director for supply reduction, and a deputy director for 
state, local, and tribal affairs. H.R. 5925 aims to respond to 
the nation's growing drug crisis by strengthening government-
wide coordination across agencies working on supply and demand 
reduction at the federal, state, local, and tribal levels. To 
that end, H.R. 5925 restructures the Office by reducing the 
number of deputy directors from four to one.
    H.R. 5925 also aims to decrease the potential for the 
emergence of ``silos'' within the Office, while ensuring 
necessary responsibility for, and attention to, the priority 
objectives of national drug control efforts. The bill creates 
four new coordinator positions, including: (1) a performance-
budget coordinator; (2) an emerging threats coordinator; (3) a 
state, local and tribal affairs coordinator; and (4) a 
treatment coordinator. The bill retains the interdiction 
coordinator position established in the 2006 reauthorization to 
coordinate interdiction activities under the National 
Interdiction Command and Control Plan.\30\ The bill creates a 
new treatment coordinator to coordinate efforts to expand the 
availability of evidence-based substance use disorder 
treatment. The shift from deputy directors to coordinators 
creates more flexibility in the Office's organizational 
structure while ensuring the Office's activities and resources 
are focused on key priorities.
---------------------------------------------------------------------------
    \30\Pub. L. No. 109-469.
---------------------------------------------------------------------------

National Drug Control Strategy

    The Office establishes national drug control policy 
primarily through the issuance of an annual National Drug 
Control Strategy (Strategy). The Strategy sets forth goals and 
performance measures for the National Drug Control Program 
agencies (NDCP agencies). The Strategy also communicates and 
reflects national drug control policy developed in coordination 
with state, local, and tribal governments.
    To ensure the Strategy remains current while reducing the 
sometimes unnecessary burden of annual reconsideration, H.R. 
5925 requires the Strategy to be promulgated quadrennially 
instead of annually. H.R. 5925 does not require the issuance of 
the Strategy until the second year of a new Presidential term, 
but requires the Office to issue a policy statement during the 
first year of a Presidential term. The policy statement is not 
required to provide the level of detail required of the 
Strategy. H.R. 5925 retains the requirement to update 
performance metrics annually, which will enable the Office to 
more precisely measure progress toward achieving the Strategy's 
goals and adjust performance targets and indicators 
appropriately.

National Drug Control Budget

    Since 1988, the Office has been responsible for reviewing 
the budget requests for each NDCP agency to ensure requested 
funding is adequate to achieve the goals of the Strategy.\31\ 
The annual cycle is as follows:
---------------------------------------------------------------------------
    \31\21 U.S.C. 1703(c).
---------------------------------------------------------------------------
          1. The Office submits suggested budget requests to 
        each NDCP agency by July 1 of each year;
          2. NDCP agencies submit proposed drug control budgets 
        to the Director prior to submission to OMB;
          3. The Director determines whether the proposed 
        budget request is adequate to meet the goals of the 
        Strategy and offers recommendations if such proposed 
        budget request is inadequate;
          4. NDCP agencies must revise any inadequate budget 
        requests prior to submitting them to OMB;
          5. NDCP agencies submit final budget requests to OMB 
        and the Director;
          6. The Director conducts a final review of each 
        request submitted to OMB and may decertify budgets that 
        are inadequate to achieve the goals of the Strategy; 
        and
          7. The Director submits a consolidated National Drug 
        Control Budget to the President and Congress.
    H.R. 5925 strengthens oversight of the budget resources of 
NDCP agencies by requiring the Office to provide an affirmative 
statement as to whether each agency's budgetary resources will 
be sufficient to enable it to meet the goals of the Strategy. 
The Office then must submit a consolidated budget that 
indicates the level of funding requested for each agency and a 
determination of whether the funding level is fully sufficient, 
partially sufficient, or insufficient to enable the agency to 
achieve the goals of the Strategy, with a proposal for any 
additional funding needed to fund the Strategy fully.

Education and Public Awareness Campaign

    The President's Commission recommended a national media 
campaign as an important initiative to address the opioid 
epidemic. The Commission recommended the Administration ``fund 
and collaborate with private sector and non-profit partners to 
design and implement a wide-reaching, national multi-platform 
media campaign addressing the hazards of substance use, the 
danger of opioids, and stigma.''\32\
---------------------------------------------------------------------------
    \32\Commission Report, supra note 8, at 12.
---------------------------------------------------------------------------
    H.R. 5925 requires the Office to establish and implement an 
education campaign focused on preventing substance misuse and 
raising public awareness of any drug designated as an emerging 
threat. H.R. 5925 designates opioids as an emerging threat, 
triggering the requirement for the Office to plan and implement 
a national evidence-based campaign to educate the public about 
the hazards of opioids and the availability of substance use 
disorder treatment. The education and public awareness campaign 
replaces the previously authorized media campaign--the 1998 
National Youth Anti-Drug Media Campaign--which focused on 
preventing drug use among youth.
    While the prior campaign was authorized for $210 million 
for fiscal years 2010 and 2011,\33\ H.R. 5925 authorizes $25 
million for carrying out the education and public awareness 
campaign to respond to emerging threats. The authorization 
covers the range of activities needed to support an effective 
campaign, including monitoring for emerging threats, developing 
and implementing the broader emerging threats plan, and 
ensuring sufficient data sharing and coordination to fulfill 
the functions of section 1009. The authorization is 
substantially lower than the previous authorization because the 
creation of new platforms, such as social media, has enabled 
information-sharing at a lower cost than traditional media.\34\
---------------------------------------------------------------------------
    \33\See 21 U.S.C. 1708(l).
    \34\See, e.g., Evaluating Communication Campaigns, Ctrs. for 
Disease Control, https://blogs.cdc.gov/publichealthmatters/2018/04/
evaluating-campaigns/ (last visited June 4, 2018).
---------------------------------------------------------------------------
    H.R. 5925 expressly requires the Director to ensure the 
media campaign is modeled on strategies proven to be effective. 
According to the President's Commission, ``Mass-media campaigns 
are one of the primary universal prevention strategies for 
delivering educational messages on health promotion to youth 
and adults.''\35\ However, the Commission's report also stated, 
``for a mass-media campaign to be effective, it is critical to 
develop coherent, credible, evidence based-messages that are 
grounded in behavioral science.''\36\ The report cites the 1998 
National Youth Anti-Drug Media Campaign as an example of an 
ineffective campaign.\37\ The media campaign authorized in 2006 
was more effective than the 1998 campaign, but it too was found 
not to have fully achieved its objectives.
---------------------------------------------------------------------------
    \35\Commission Report, supra note 8, at 44.
    \36\Id. at 45.
    \37\Id.; U.S. Gov't Accountability Off., GAO-06-818, ONDCP Media 
Campaign: Contractor's National Evaluation Did Not Find That the Youth 
Anti-Drug Media Campaign Was Effective in Reducing Youth Drug Use 
(2006).
---------------------------------------------------------------------------
    Given the lessons learned from prior campaigns and the 
urgent need for effective solutions in the face of the ongoing 
opioid epidemic, H.R. 5925 requires the Office to adopt an 
evidence-based approach at the onset of the Education and 
Public Awareness Campaign.

Opioid Plan

    H.R. 5925 requires the Office to issue a National Opioid 
Crisis Response Plan (Opioid Plan) within 60 days of the date 
of enactment to guide efforts to combat the opioid crisis. H.R. 
5925 requires the Director to ensure the Opioid Plan addresses 
several recommendations made by the President's Commission. For 
example, H.R. 5925 requires the Opioid Plan to provide for the 
creation of working groups consisting of appropriate 
stakeholders to support better use of Prescription Drug 
Monitoring Programs (PDMPs) by improving data sharing, 
increasing utilization of PDMPs, and supporting the 
incorporation of available overdose and naloxone deployment 
data.
    The Opioid Plan must include an evaluation of the benefits 
of drug courts and similar programs, such as pre-trial 
diversion and reentry programs that have shown promise at 
ending the cycle of addiction. The Opioid Plan must encourage 
NDCP agencies and states, through the Model Acts program, to 
develop sentencing standards or model codes on opioid analog 
trafficking and advise states on establishing policies based on 
the President's Commission recommendations.
    The Opioid Plan takes an important step to helping ensure 
that substance use disorder treatments are effective by 
requiring the establishment of an Advisory Committee on 
Substance Use Disorder Treatment Standards not later than 120 
days after the issuance of the Opioid Plan to promulgate 
voluntary model evidence-based standards for substance use 
disorder treatment and recovery facilities. The amendment 
leaves the Advisory Committee flexibility on which standards to 
address but such standards could include licensure of treatment 
programs, credentialing of treatment professionals, and the 
prevention of patient brokering and fee splitting arrangements 
between treatment and recovery residence programs, by the 
appropriate organizations or agencies and at the appropriate 
level of government.
    Nothing in H.R. 5925 prohibits or reduces access to 
behavior recovery treatment. Evidence-based behavioral recovery 
treatment, including faith-based programs and treatment, plays 
an important role in combating substance use disorder. While 
medication assisted treatment provides an important pathway to 
recovery, behavioral recovery treatment groups can be important 
components of long-term, sustained recovery.\38\ This includes 
Substance Abuse and Mental Health Services Administration 
(SAMHSA) list group programs such as Alcoholics Anonymous and 
other peer-support and faith-based, self-help, and group-based 
addiction recovery support solutions.\39\
---------------------------------------------------------------------------
    \38\R. Kathryn McHugh et al, Cognitive-Behavioral Therapy for 
Substance Use Disorders, 33 Psychiatric Clinics of N. Am. 511 (2010).
    \39\Substance Abuse & Mental Health Services Administration, 
Behavioral Health Treatment Services Locator, https://
findtreatment.samhsa.gov/locator/link-focSelfGP (last visited June 15, 
2018).
---------------------------------------------------------------------------

The Office's increased role in information sharing

    Many of the Commission's recommendations called for 
improving the collection, standardization, and dissemination of 
information. For example, the Commission recommended ``a 
federal effort to strengthen data collection activities 
enabling real-time surveillance of the opioid crisis at the 
national, state, local, and tribal levels.''\40\
---------------------------------------------------------------------------
    \40\Commission Report, supra note 5, at 14.
---------------------------------------------------------------------------
    The Government Accountability Office (GAO) also highlighted 
the need for the Office to strengthen information sharing 
initiatives in a report issued in March 2018.\41\ The report 
stated, ``embarking on a concerted effort to examine and 
address data related concerns, such as timeliness and accuracy, 
will allow law enforcement and public health agencies to better 
share information as they continue to understand and respond to 
the opioid epidemic.''\42\
---------------------------------------------------------------------------
    \41\U.S. Gov't Accountability Office, GAO-18-205, Combating 
Synthetic Opioids (2018).
    \42\Id.
---------------------------------------------------------------------------
    GAO recommended the Director, ``in collaboration with law 
enforcement and public health counterparts, lead a review on 
ways to improve the timeliness, accuracy, and accessibility of 
fatal and non-fatal overdose data from law enforcement and 
public health sources that provide critical information to 
understand and respond to the opioid epidemic.''\43\
---------------------------------------------------------------------------
    \43\Id.
---------------------------------------------------------------------------
    H.R. 5925 requires the Director to designate an agency to 
establish and operate a fusion center--which shall be a federal 
statistical agency--to work with NDCP agencies to facilitate 
the sharing of information on the use of illicit drugs, 
treatment for substance use disorders, and interdiction of 
illicit drugs.
    H.R. 5925 improves the availability of timely data on 
supply of and demand for illicit drugs by requiring the Office 
to create a ``data dashboard'' to provide basic data--updated 
at least quarterly--on the flows of illicit drugs and on drug 
use trends, including fatal and nonfatal overdoses. The Office 
is also required to develop a systematic plan to increase the 
collection of data to enable real-time tracking of drug trends.
    H.R. 5925 authorizes a toxicology screening program to 
obtain information on trends in the prevalence of drug use by 
collecting and analyzing urine and other samples that are not 
identifiable to the individual and otherwise would have been 
discarded by hospitals, correctional facilities, booking sites, 
probation programs, drug courts, and coroners and medical 
examiners. The Office must consider existing resources, 
expertise, and capabilities when designating an agency to house 
the fusion center, with an eye toward limiting additional costs 
and burdens associated with establishing and operating the 
center. The authorization for the fusion center includes 
important privacy protections regarding anonymization and use 
of data obtained through the toxicology screening program.
    H.R. 5925 requires the Director to establish a working 
group of federal agencies and state, local, and tribal 
government health and law enforcement agencies, data experts, 
and other stakeholders to develop interoperable data exchange 
standards to improve information sharing among states, federal 
agencies, and other relevant drug control data centers.

             GRANT PROGRAMS ADMINISTERED THROUGH THE OFFICE

    The Office currently administers two grant programs aimed 
at reducing illicit drug use and availability at the local 
level--the Drug Free Communities (DFC) program and the High 
Intensity Drug Trafficking Areas (HIDTA) program. The DFC 
program awards grants to community coalitions to prevent 
substance use among adolescents through community collaboration 
and organization.\44\ The HIDTA program coordinates federal, 
state, and local law enforcement efforts to identify and 
dismantle drug trafficking operations specific to each 
regionally-designated HIDTA area.\45\ Both programs allow 
grantees to tailor programs to meet the unique needs of their 
communities.
---------------------------------------------------------------------------
    \44\Office of Nat'l Drug Control Policy, Grants & Programs, https:/
/www.whitehouse.gov/ondcp/grants-programs/ (last visited Apr. 3, 2018).
    \45\Id.
---------------------------------------------------------------------------
    Congress has repeatedly expressed its intent for the Office 
to retain responsibility for administering the DFC and HIDTA 
programs. The Committee reaffirms this longstanding position by 
reauthorizing the programs with only minor--primarily 
technical--changes to previously enacted authorizing law. Each 
program is authorized to receive appropriated funding to carry 
out those programs at funding levels established in the FY 2018 
Consolidated Appropriations Act.\46\ The Office's role as a 
grant administrator is further clarified in new section 1002 as 
one of the seven principal responsibilities of the Office.
---------------------------------------------------------------------------
    \46\Pub. L. No. 115-141 (2018).
---------------------------------------------------------------------------

  Statement of Oversight Findings and Recommendations of the Committee

    In compliance with clause 3(c)(1) of rule XIII and clause 
(2)(b)(1) of rule X of the Rules of the House of 
Representatives, the Committee's oversight findings and 
recommendations are reflected in the previous section.

         Statement of General Performance Goals and Objectives

    In accordance with clause 3(c)(4) of rule XIII of the Rules 
of the House of Representatives, the Committee's performance 
goal or objective of this bill is to codify provisions relating 
to the Office of National Drug Control.

                          Legislative History

    H.R. 5925 is the product of a thorough examination during 
the 115th Congress by the Committee on Oversight and Government 
Reform, the Subcommittee on Government Operations, and the 
Subcommittee on Healthcare, Benefits, and Administrative Rules. 
The Committee held a series of hearings to examine 
reauthorizing the Office and to explore options for more 
effectively combatting the opioid epidemic.
    On July 26, 2017, the Committee held a hearing titled, 
``Office of National Drug Control Policy: Reauthorization in 
the 115th Congress.'' The hearing examined options for 
reauthorizing the Office and discussed the Office's effort to 
coordinate drug control policy and spending across the federal 
government.
    On November 28, 2017, the Committee held a field hearing 
titled, ``Combating the Opioid Crisis.'' The field hearing was 
at Johns Hopkins Hospital in Baltimore and discussed findings 
and recommendations from the President's Commission.
    On April 11, 2018, the Subcommittee on Healthcare, 
Benefits, and Administrative Rules held a hearing titled, 
``Local Responses and Resources to Curtail the Opioid 
Epidemic.'' The hearing examined how federal grant programs 
have assisted state and local communities and explored ways the 
federal government can effectively assist states in combating 
the opioid epidemic.
    On May 9, 2018, the Committee hosted a roundtable 
discussion with ONDCP officials to discuss options for 
empowering the Office to more effectively direct efforts to end 
the opioid crisis.
    On May 17, 2018, the Committee held a hearing titled, ``A 
Sustainable Solution to the Evolving Opioid Crisis: 
Revitalizing the Office of National Drug Control Policy.'' The 
hearing examined policy proposals for reauthorizing the Office 
and discussed how evidence-based policymaking and information 
sharing can be used to identify and respond to emerging drug 
trends.
    Committee staff also conducted field work to inform H.R. 
5925. In March 2018, Committee staff traveled to China to 
investigate the trafficking of illicit fentanyl through the 
U.S. Postal Service. Staff reviewed the roles of the Department 
of Homeland Security, the intelligence community, and the U.S. 
Postal Service to identify opportunities for better 
coordination and information sharing.
    On March 23, 2018, Committee staff conducted a site visit 
to a newly designated High Intensity Drug Trafficking Area 
initiative in Greenville, South Carolina within the Atlanta-
Carolinas HIDTA region and held a roundtable discussion. Staff 
met with federal and state law enforcement officials who 
highlighted the collaborative nature of the HIDTA program and 
discussed recent accomplishments in disrupting local drug 
trafficking organizations. For example, during one operation 
last year, HIDTA participants arrested 40 individuals, seized 
more than $1 million, and confiscated 44 kilograms of crystal 
methamphetamine, 2.6 kilograms of cocaine, and 370 grams of 
heroin.
    On May 23, 2018, Chairman Trey Gowdy (R-SC) introduced H.R. 
5925, the Coordinated Response through Interagency Strategy and 
Information Sharing (CRISIS) Act, with Ranking Member Elijah 
Cummings (D-MD), Subcommittee on Government Operations Chairman 
Mark Meadows (R-NC), and Subcommittee on Government Operations 
Ranking Member Gerald Connolly (D-VA). H.R. 5925 was referred 
to the Committee on Oversight and Government Reform, with 
additional referrals to the Committees on Energy and Commerce, 
Foreign Affairs, the Judiciary, Intelligence (Permanent 
Select), and Appropriations.

                        Committee Consideration

    On May 23, 2018, the Committee met in open session and, 
with a quorum being present, ordered the bill favorably 
reported, as amended, by voice vote.

                            Roll Call Votes

    There were no roll call votes requested or conducted during 
Committee consideration of H.R. 5925.

                       Explanation of Amendments

    During Committee consideration of the bill, Representative 
Elijah Cummings (D-MD), the Ranking Member of the Committee, 
offered an amendment to add the director of the fusion center 
to the membership of the emerging threats task force, clarify 
the emerging threats plan and information sharing requirements 
to include substance use disorder treatment, and clarify the 
treatment coordinator section of the bill. The amendment also 
introduces a new requirement to convene an advisory committee 
to promulgate standards for substance abuse disorder treatment 
and recovery facilities. The Cummings amendment was adopted by 
voice vote.
    Representative Stephen Lynch (D-MA) offered an amendment to 
require the President to notify Congress if the President has 
not issued the National Drug Control Strategy by the due date. 
The amendment also requires the President or a designee to 
appear before the Committee on Oversight and Government Reform 
of the House of Representatives and the Committee on the 
Judiciary of the Senate at a hearing not later than the first 
Monday in March following the failure of the President to 
submit the Strategy. Representative Gary Palmer (R-AL) offered 
an amendment to the amendment offered by Representative Lynch 
to strike the requirement for the President or a designee to 
appear at a hearing before the first Monday in March following 
the failure of the President to submit a Strategy, as this 
requirement is not necessary in order for either Committee to 
hold such a hearing. The Palmer amendment to the Lynch 
amendment was adopted by voice vote. The Lynch amendment, as 
amended, was adopted by voice vote.
    Representative Mark DeSaulnier (D-CA) offered an amendment 
to require the Government Accountability Office to conduct 
periodic audits on the Office's programs and operations. The 
DeSaulnier amendment was adopted by voice vote.
    Representative Paul Mitchell (R-MI) offered an amendment 
with the support of Representative Jamie Raskin (D-MD) to 
require the Director to establish a system to track federally 
funded initiatives and grant programs, establish performance 
metrics and goals for grant programs, develop a common 
application form for drug control related grant programs, and 
maintain a comprehensive list of all drug control program grant 
award opportunities. The amendment was adopted by voice vote.
    Pursuant to the unanimous consent agreement during the 
business meeting, a correction was made to the authorization of 
appropriations for the Office of National Drug Control's 
administration of the Drug Free Communities program in the 
reported text of section 1038 of Title 31, United States Code. 
The adopted version of the amendment in the nature of a 
substitute authorized ``$99,000,000 for fiscal year [sic] 2019 
through 2023.'' The corrected version in reported text 
authorizes that amount ``for each of fiscal years 2019 through 
2023.''

              Application of Law to the Legislative Branch

    Section 102(b)(3) of Public Law 104-1 requires a 
description of the application of this bill to the legislative 
branch where the bill relates to the terms and conditions of 
employment or access to public services and accommodations. 
This bill codifies provisions relating to the Office of 
National Drug Control, and for other purposes. As such, this 
bill does not relate to employment or access to public services 
and accommodations.

                    Duplication of Federal Programs

    In accordance with clause 2(c)(5) of rule XIII, H.R. 5925 
would reauthorize a program the Government Accountability 
Office (GAO) previously identified as having potential 
duplication in 2013. Both areas of potential duplication GAO 
subsequently reported as having been addressed. Specifically, 
GAO identified ``overlap and potential duplication across the 
fragmented 76 federal drug abuse prevention and treatment 
programs,'' recommending increased coordination.\47\ GAO 
reported this was fully addressed as of November 19, 2014.\48\ 
In addition, GAO identified potential inefficiencies from 
overlap in analytical and investigative support activities.\49\ 
GAO reported this was fully addressed as of March 21, 2018.\50\
---------------------------------------------------------------------------
    \47\Gov't Accountability Office, GAO-13-279SP, Actions Needed to 
Reduce Fragmentation, Overlap, and Duplication and Achieve Other 
Financial Benefit (2013).
    \48\Gov't Accountability Office, Duplication & Cost Savings GAO 
Action Tracker, Social Services: Drug Abuse Prevention and Treatment 
Programs, https://www.gao.gov/duplication/action_tracker/
Drug_Abuse_Prevention_and_Treatment_Programs/ (last updated Nov. 19, 
2014).
    \49\Gov't Accountability Office, supra note 47.
    \50\Gov't Accountability Office, Duplication & Cost Savings GAO 
Action Tracker, Homeland Security/Law Enforcement: Field-Based 
Information Sharing, https://www.gao.gov/duplication/action_tracker/
Field-Based_Information_Sharing/ (last updated Mar. 21, 2018).
---------------------------------------------------------------------------

                  Disclosure of Directed Rule Makings

    This bill directs the completion of specific rule makings 
within the meaning of section 551 of title 5, United States 
Code. Section 1021 of title 31, as added in section 2 of H.R. 
5925, codifies section 707 of the Office of National Drug 
Control Policy Reauthorization Act of 1998 as amended by the 
Office of National Drug Control Policy Reauthorization Act of 
2006, which requires the Director to establish and maintain 
regulations about the process to petition to be designated as a 
HIDTA. Section 4(b)(2)(B)(iii) requires the Director to issue 
guidance to agencies on appropriate revisions of regulations 
pertaining to prescribing guidelines and continuing education 
requirements.

                     Federal Advisory Committee Act

    H.R. 5925 establishes an advisory committee within the 
definition of Section 5(b) of the appendix to title 5, United 
States Code. Section 4(b)(2)(K) requires the Director of the 
Office to establish an advisory committee on substance use 
disorder treatment standards. There is not currently an 
existing advisory committee charged with developing evidence-
based standards for substance abuse disorder treatment and 
recovery facilities. The advisory committee must comply with 
the requirements in the Federal Advisory Committee Act (5 
U.S.C. App).

                      Unfunded Mandates Statement

    Pursuant to section 423 of the Congressional Budget and 
Impoundment Control Act (Pub. L. 113-67) the Committee has 
included a letter received from the Congressional Budget Office 
below.

                         Earmark Identification

    This bill does not include any congressional earmarks, 
limited tax benefits, or limited tariff benefits as defined in 
clause 9 of rule XXI of the House of Representatives.

                           Committee Estimate

    Pursuant to clause 3(d)(2)(B) of rule XIII of the Rules of 
the House of Representatives, the Committee includes below a 
cost estimate of the bill prepared by the Director of the 
Congressional Budget Office under section 402 of the 
Congressional Budget Act of 1974.

   New Budget Authority and Congressional Budget Office Cost Estimate

    Pursuant to clause 3(c)(3) of rule XIII of the House of 
Representatives, the cost estimate prepared by the 
Congressional Budget Office and submitted pursuant to section 
402 of the Congressional Budget Act of 1974 is as follows:

                                     U.S. Congress,
                               Congressional Budget Office,
                                      Washington, DC, June 8, 2018.
Hon. Trey Gowdy,
Chairman, Committee on Oversight and Government Reform,
House of Representatives, Washington, DC.
    Dear Mr. Chairman: The Congressional Budget Office has 
prepared the enclosed cost estimate for H.R. 5925, the CRISIS 
Act.
    If you wish further details on this estimate, we will be 
pleased to provide them. The CBO staff contact is Matthew 
Pickford.
            Sincerely,
                                             Mark P. Hadley
                                        (For Keith Hall, Director).
    Enclosure.

H.R. 5925--CRISIS Act

    Summary: H.R. 5925 would authorize appropriations for the 
operations of the Office of National Drug Control Policy 
(ONDCP) and change the office's name to the Office of National 
Drug Control (ONDC). The bill would authorize appropriations 
for programs administered by that office and for other federal 
anti-drug programs through 2023. Major programs administered by 
the office include the High-Intensity Drug Trafficking Areas 
program, the Drug-Free Communities program, and the Emerging 
Threats and Media Campaign.
    Assuming appropriation of the specified amounts, CBO 
estimates that implementing H.R. 5925 would cost about $1.5 
billion over the 2019-2023 period. Of that total, $1.1 billion 
would result from amounts specifically authorized for the High-
Intensity Drug Trafficking Areas program.
    Enacting the bill would affect direct spending because it 
would allow ONDC to accept and spend monetary gifts; therefore, 
pay-as-you-go procedures apply. However, CBO estimates that the 
net effect on direct spending would be negligible. Enacting 
H.R. 5925 would not affect revenues.
    CBO estimates that enacting H.R. 5925 would not 
significantly increase net direct spending or on-budget 
deficits in any of the four consecutive 10-year periods 
beginning in 2029.
    H.R. 5925 contains no intergovernmental or private-sector 
mandates as defined in the Unfunded Mandates Reform Act (UMRA).
    Estimated cost to the Federal Government: The estimated 
budgetary effect of H.R. 5925 is shown in the following table. 
The costs of the legislation fall within budget functions 750 
(administration of justice) and 800 (general government).

----------------------------------------------------------------------------------------------------------------
                                                            By fiscal year, in millions of dollars--
                                               -----------------------------------------------------------------
                                                   2019       2020       2021       2022       2023    2019-2023
----------------------------------------------------------------------------------------------------------------
                                 INCREASES IN SPENDING SUBJECT TO APPROPRIATION
 
High-Intensity Drug Trafficking Area:
    Authorization Level.......................        280        280        280        280        280      1,400
    Estimated Outlays.........................         70        238        266        280        280      1,134
Emerging Threats and Media Campaign:
    Authorization Level.......................         25         25         25         25         25        125
    Estimated Outlays.........................         23         25         25         25         25        123
Drug-Free Communities:
    Estimated Authorization Level.............         20         20         20         20         20         99
    Estimated Outlays.........................         18         20         20         20         20         98
Office of National Drug Control:
    Authorization Level.......................         18         18         18         18         18         92
    Estimated Outlays.........................         15         17         18         18         18         86
Other Provisions:
    Authorization Level.......................          3          3          3          3          3         16
    Estimated Outlays.........................          3          3          3          3          3         16
        Total Spending:
            Authorization Level a ............        346        346        346        346        346      1,732
            Estimated Outlays.................        129        303        332        346        346      1,457
----------------------------------------------------------------------------------------------------------------
Components may not sum to totals because of rounding.

    Basis of estimate: For this estimate, CBO assumes that the 
bill will be enacted near the end of 2018, that the authorized 
amounts will be provided each year, and that spending will 
follow historical patterns for ONDCP and its programs.
    The bill would reauthorize all the programs of ONDC through 
2023. Although the current authorization for ONDCP expired at 
the end of fiscal year 2011, the office and related programs 
received funding through 2018, including about $415 million in 
fiscal year 2018. The legislation would authorize the 
appropriation of specific amounts over the next five years for 
the following programs:
           High-Intensity Drug Trafficking Areas--$280 
        million each year for coordinating drug-control efforts 
        among local, state, and federal law enforcement 
        agencies, CBO estimates that implementing this 
        provision would cost $1.1 billion over the 2019-2023 
        period and about $0.3 billion after 2023;
           Emerging Threats and Media Campaign--$25 
        million each year for a media campaign about the 
        emerging threats and other anti-drug messages. CBO 
        estimates that implementing this provision would cost 
        $123 million over the 2019-2023 period;
           Drug-Free Communities--$99 million over the 
        2019-2023 period for the Drug Free Communities program, 
        which would make grants to community coalitions aimed 
        at reducing substance abuse by young people. Assuming 
        the $99 million is appropriated equally over the five 
        years, CBO estimates implementing this provision would 
        cost $98 million over the 2019-2023 period;
           Office of National Drug Control--$18.4 
        million each year for operation of the ONDC. CBO 
        estimates providing that appropriation would cost $86 
        million over the 2019-2023 period; and
           Other Provisions--$3.25 million each year 
        for the Model Act Program and the Drug Court Training 
        and Technical Assistance Program. CBO estimates 
        implementing those provisions would cost $16 million 
        over the 2019-2023 period.
    Pay-As-You-Go considerations: The Statutory Pay-As-You-Go 
Act of 2010 establishes budget-reporting and enforcement 
procedures for legislation affecting direct spending or 
revenues. H.R. 5925 would allow ONDC to accept and retain 
gifts; therefore, pay-as-you-go procedures apply. CBO 
estimates, however, that any net changes in direct spending 
would be negligible. Enacting the bill would not affect 
revenues.
    Increase in long-term direct spending and deficits: CBO 
estimates that enacting H.R. 5925 would not increase net direct 
spending or on-budget deficits in any of the four consecutive 
10-year periods beginning in 2029.
    Mandates: H.R. 5925 contains no intergovernmental or 
private-sector mandates as defined in UMRA.
    Estimate prepared by: Federal costs: Matthew Pickford; 
Mandates: Andrew Laughlin.
    Estimate reviewed by: Kim P. Cawley, Chief, Natural 
Resources Cost Estimate Unit; H. Samuel Papenfuss, Deputy 
Assistant Director for Budget Analysis.

                      Section-by-Section Analysis


Section 1. Short title

    Section 1 provides the short title of the bill, the 
``Coordinated Response through Interagency Strategy and 
Information Sharing Act'' or the ``CRISIS Act.''

Section 2. Office of National Drug Control

    This section renames the Office of National Drug Control 
Policy the Office of National Drug Control and creates a new 
chapter 10 in Title 31, United States Code, as follows:

                          SUBCHAPTER I--OFFICE

Section 1001. Definitions

    Section 1001 defines the terms used in chapter 10 
previously defined in the Office of National Drug Control 
Policy Reauthorization Act of 1998, as amended (Public Law 105-
277; 21 U.S.C. 1701 et seq.) (``prior law''), including 
amendments to the terms ``illicit drug use,'' ``illegal drug 
use,'' ``demand reduction,'' ``supply reduction,'' ``emerging 
threat,'' and ``substance use disorder treatment.''

Section 1002. Office of National Drug Control

    Section 1002 codifies 21 U.S.C. 1702(a), which established 
the Office, and expands the Office's responsibilities to 
include identifying and responding to illicit drug use emerging 
threats, administering and evaluating grant programs, and 
facilitating information sharing and data standardization among 
federal, state, and local entities.
    This section also codifies 21 U.S.C. 1702(b), 1703(a), 
(b)(1), and (b)(5) with changes to the structure of the office. 
Those changes include requiring the appointment of a director 
and deputy director, requiring the director to establish 
policies and objectives for the National Drug Control Program, 
and requiring the director to consult with state, local, and 
Tribal governments, and other relevant entities.

Section 1003. Administration of the office

    Section 1003 codifies prior law related to the 
administration of the office--21 U.S.C. 1702(c), 1703(a)(4)-
(5), (d)(1), (3)-(4), (6), (e)(1)-(2), and 1704(c)--and 
prohibits the use of funds authorized under the chapter for 
campaigns or ballot initiatives.

Section 1004. National Drug Control Program budget

    Section 1004 codifies prior law establishing the National 
Drug Control Program budget process--21 U.S.C. 1703(b)(8) and 
(c). In addition, Section 1004 requires a certification or 
decertification for each National Drug Control Program Agency 
budget request to Congress with a written justification and 
suggestion for alternative funding levels that may improve 
progress on achieving the Strategy for any budget request that 
does not fully fund the National Drug Control Programs of the 
agency. It requires the Office concurrently submit budget 
requests to the appropriate congressional committees when 
requests are submitted to the Office of Management and Budget 
or the President.

Section 1005. National Drug Control Strategy

    Section 1005 codifies prior law requiring the Director to 
promulgate a National Drug Control Strategy--21 U.S.C. 1705(a)-
(b). The section reduces the frequency from an annual 
requirement to a quadrennial requirement, and requires the 
release of a statement of drug priority policies in the first 
calendar year of a new administration and the release of annual 
performance plan supplement. A new provision requires the 
Strategy to be based on the best available evidence and to 
include a description of the current prevalence of illicit drug 
use and additional details for each Strategy goal. Additional 
details for each strategy goal must specify how each goal will 
be achieved, anticipated challenges, and the data necessary to 
evaluate performance.
    This section incorporates into the National Drug Control 
Strategy the Southwest Border Strategy (Office of National Drug 
Control Policy Reauthorization Act of 2006, Pub. L. No. 109-
469) and the Northern Border Strategy (Northern Border 
Counternarcotics Strategy Act of 2010, Pub. L. No. 111-356).
    This section also requires the President to notify the 
appropriate congressional committees if the President fails to 
submit a Strategy pursuant to the requirements of this section.

Section 1006. Development of an Annual National Drug Control Assessment

    Section 1006 codifies prior law requiring an annual 
assessment of National Drug Control Program Agencies (21 U.S.C. 
1703(b)(13)-(14)), with amendments to expand the contents of 
the assessment to include an accounting of funds distributed, 
an evaluation of the effectiveness of grant programs, an 
evaluation of emerging threat plans, and an accounting of funds 
obligated for the media campaign. This section codifies prior 
law by requiring a report on consultation (21 U.S.C. 
1703(b)(19)) and a performance measurement system (21 U.S.C. 
1705(c)-(d)), which are added as requirements for inclusion in 
the assessment.
    This section also requires the Director to designate or 
appoint a performance-budget coordinator to ensure the Director 
has sufficient information on each NDCP agency's performance, 
funding, and contributions to the achievement of the goals of 
the Strategy. The performance-budget coordinator is also 
required to advise the Director on agency budget and 
performance measures and to carry out other duties needed to 
assess agencies' budgets and performance.

Section 1007. Monitoring and evaluation of National Drug Control 
        Program

    Section 1007 codifies requirements for the Director to 
monitor the activities and funds expended by National Drug 
Control Program Agencies to ensure implementation of the 
Strategy--21 U.S.C. 1703(b)(4), (7), (d)(7), and 1704(d).
    This section also requires the Director to establish a 
coordinated tracking system of federally-funded initiatives and 
grant programs, to develop a plan to standardize the grant 
application process, to maintain a list of drug control grant 
award opportunities on the Office's website, and to report on 
progress under this section and the feasibility of block grants 
to states.

Section 1008. Coordination and oversight of the National Drug Control 
        Program

    Section 1008 codifies prior law requiring the Director to 
coordinate and oversee implementation by National Drug Control 
Program Agencies of the Strategy (21 U.S.C. 1703(b)(3)), 
requiring National Drug Control Program Agencies to notify the 
Director regarding any proposed policy changes related to a 
drug control program (21 U.S.C. 1703(d)(9) and (f)), requiring 
the Director to work in conjunction with the Assistant to the 
President for National Security Affairs (21 U.S.C. 1704(b)), 
and authorizing the Director to temporarily detail employees to 
other agencies (21 U.S.C. 1703(e)), to transfer funds between 
agencies (21 U.S.C. 1703(d)(8)), and to issue fund control 
notices to National Drug Control Program Agencies.
    This section also expands the authority of the Director to 
transfer funds for the purpose of implementing an emerging 
threats plan under section 1009 and specifies the purposes for 
which transferred funds may be used.

Section 1009. Emerging threats taskforce, plan, media campaign

    This section requires the Director to appoint an emerging 
and continuing threats coordinator (the Coordinator) to monitor 
emerging drug threats in the United States by convening a 
quarterly taskforce with relevant National Drug Control Program 
Agencies and state, local, and tribal governments to establish 
evidence-based criteria to identify emerging threats. This 
section also allows the Director to designate an emerging drug 
threat and requires a public written statement of any 
designation or termination of a designation of an emerging 
threat.
    This section requires the Director to publish an Emerging 
Threat Response Plan within 60 days of the designation of an 
emerging threat and to update the plan every 90 days until the 
plan's goals have been achieved. The plan is required to 
include a comprehensive assessment of the drug threat 
(including the need for and the availability of evidence-based 
substance use disorder treatment), goals to address the threat, 
and performance measures pertaining to the plan's goals. The 
Director is required to issue implementation guidance within 90 
days of the designation of an emerging threat. This section 
also allows the Director to award contracts or enter into 
interagency agreements in support of the identification of 
emerging threats in the plan.
    This section also requires the Coordinator to facilitate 
information sharing and coordination with relevant agencies and 
entities regarding the identification or status of emerging 
threats, monitor implementation of emerging threat response 
plans, and develop reporting systems to support adherence to 
performance measures. Agencies identified in an emerging threat 
response plan are required to submit a report to the 
Coordinator on implementation of the plan within 180 days of 
designation.
    This section revamps prior law (21 U.S.C. 1708)--which 
required a national youth anti-drug media campaign--by limiting 
the campaign to emerging drug threats, expanding the focus to 
education and public awareness, and requiring the campaign be 
developed in accordance with evidence of effective practices. 
The Director is required to establish and implement a national 
education and public awareness campaign to raise awareness of 
illicit drugs designated as emerging threats and to consult 
with appropriate National Drug Control Program Agencies, 
experts, state, local, and tribal governments, Congress, and 
the public to ensure evidence-based implementation of the 
campaign. The Director is authorized to accept gifts and 
donations to support the campaign and must issue an annual 
report to the appropriate congressional committees to identify 
the source(s) of any accepted gift or donation. Additionally, 
the Director is required to establish ethics guidelines to 
determine whether gifts or donations should be declined.
    This section also requires the Director to ensure the media 
campaign is evidence-based and accurate, meets accepted 
standards for public awareness campaigns, and utilizes 
effective strategies. The Director is required to use 
competitive procedures in selecting entities for the production 
and design of a campaign.
    This section codifies prior law requiring the Director to 
evaluate the performance of the campaign (21 U.S.C. 1708(h)) 
but clarifies reporting requirements and aligns the timing with 
the annual assessment under section 1006. The section also 
codifies prior law (21 U.S.C. 1708(b)(2)(C)), with the addition 
of a biennial evaluation of the campaign's effectiveness by an 
independent entity.
    This section codifies prior law establishing prohibitions 
on the use of funds authorized under this section (21 U.S.C. 
1708(e)).
    This section also reauthorizes funding for the campaign 
(Pub. L. No. 109-469) and related emerging threat activities. 
The section authorizes $25,000,000 for each fiscal year through 
2023, a reduction below the prior authorization of $195,000,000 
for fiscal years 2007 and 2008 and $210,000,000 for fiscal 
years 2009 through 2011.

Section 1010. National and international coordination

    This section requires the Director to ensure National Drug 
Control Program Agencies disseminate drug control research and 
information to state and local governments and other entities 
involved in demand reduction (21 U.S.C. 1703(b)(15)) and to 
coordinate with the private sector to promote research and 
development to treat addiction (21 U.S.C. 1703(b)(16)).
    This section also requires the Director to coordinate the 
development of evidence-based state standards by National Drug 
Control Program Agencies and other relevant entities for drug 
control policies, practices, and procedures. The Director is 
also required to encourage the adoption of state standards by 
facilitating the dissemination of standards through 
publications, training seminars, and other means to state and 
local governments.
    This section codifies section 1105 of the Office of 
National Drug Control Policy Reauthorization Act of 2006, which 
requires the Director to enter into an agreement with a 
nonprofit to advise states on establishing laws and policies to 
address illicit drug use issues. The section authorizes 
$1,250,000 for such agreement for each fiscal year through 
2023.
    This section authorizes, in accordance with Pub. L. No. 
115-141, the Director to make a grant to a nonprofit 
organization to provide training and technical assistance to 
drug courts and authorizes $2,000,000 for such grant for each 
fiscal year through 2023.
    This section requires the Director to appoint a state, 
local, and tribal affairs coordinator to coordinate drug 
control efforts between federal agencies and state, local, and 
tribal governments and perform other duties relevant to this 
section and section 1005.

Section 1011. Interdiction

    Section 1011 codifies prior law requiring the designation 
of an interdiction coordinator, establishment of an 
Interdiction Committee, and issuance of a Command and Control 
Plan (21 U.S.C. 1710).

Section 1012. Treatment coordinator

    Section 1012 requires the Director to designate or appoint 
a treatment coordinator to coordinate activities of the 
National Drug Control Program Agencies to expand the 
availability of evidence-based substance use disorder 
treatment, develop and issue a National Treatment Plan, assess 
the sufficiency of resources available for substance use 
disorder treatment, and encourage the adoption of treatment 
standards. The Treatment Coordinator is required to develop and 
issue an annual National Treatment Plan to identify the unmet 
need for treatment and the resources required to eliminate the 
unmet need for treatment.
    This section establishes a Treatment Committee to review 
the adequacy of evidence-based substance use disorder 
treatment, discuss the status of the National Treatment Plan, 
advise the Director concerning treatment initiatives, and 
submit an annual report to Congress on the results of the 
Committee's meetings and any significant findings.

Section 1013. Critical information coordination

    Section 1013 requires the Director to designate an agency 
to establish a National Drug Control Fusion Center as a 
statistical agency to work with National Drug Control Program 
Agencies to collect, compile, analyze, and facilitate the 
sharing of information on the use of illicit drugs, treatment 
for substance use disorders, and interdiction of illicit drugs. 
The Fusion Center Director is authorized to establish a 
toxicology screening program to conduct secondary analysis of 
urine samples that otherwise would be discarded at hospitals, 
correctional facilities, and similar institutions and to 
establish a program allowing state and local jurisdictions to 
submit up to 20 samples annually to analyze substances found in 
fatal overdose cases. This section prohibits the use of samples 
as evidence in any proceeding and requires the Fusion Center 
comply with the provisions of the Confidential Information 
Protection and Statistical Efficiency Act of 2002.
    This section also requires the Director to submit to 
Congress an annual plan, which must cover a four-year period 
and be updated annually, for increasing data collection to 
enable real-time surveillance of drug control threats, 
developing analysis and monitoring capabilities, and 
identifying and addressing relevant policy questions.
    This section codifies prior law, with amendments, 
prohibiting the use of federal funds by the Office on any study 
pertaining to legalization of schedule I substances (21 U.S.C. 
1703(b)(12)) and requiring any harm reduction program policies, 
including syringe exchange programs, to be evidence-based and 
developed in consultation with the National Institutes of 
Health and the National Academy of Sciences (21 U.S.C. 1702 
paragraph after subsection (a)).
    This section also requires the Director to establish and 
update at least quarterly a dashboard on the Office's website 
to show data visualizations of key data on illicit drug flows 
and seizures, fatal and non-fatal overdoses, and availability 
of substance use disorder treatment.
    This section codifies prior law requiring National Drug 
Control Program Agencies to provide the Director with data and 
information pertaining to drug control and funding for drug 
control policy (21 U.S.C. 1704(a)).
    This section requires the Director to establish a working 
group of federal agencies, state, local, and tribal government 
health and law enforcement agencies, and data governance 
experts to develop interoperable data exchange standards to 
improve information sharing among states, federal agencies, and 
other relevant drug control data centers. The section 
authorizes the Director, in consultation with the working 
group, relevant agencies, and state, local, and tribal 
governments, to designate data exchange standards for federal 
reporting and data exchange requirements for National Drug 
Control Programs.
    This section also codifies prior law requiring the 
reporting of specific data related to the status of drug 
control efforts (21 U.S.C. 1705(a)(2)).

Section 1014. Annual audit and investigation requirements

    Section 1014 codifies section 203(b) of the Office of 
National Drug Control Reauthorization of 2006 (Pub. L. No. 109-
469), requiring the Government Accountability Office to conduct 
an annual audit and investigation related to the Office.

Section 1015. Authorization of appropriations

    This section authorizes $18,400,000--the amount 
appropriated for fiscal year 2018 (Pub. L. No. 115-141)--for 
the Office for each fiscal year through 2023.

      SUBCHAPTER II--HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM

Section 1021. High Intensity Drug Trafficking Areas Program

    Section 1021 codifies prior law establishing the High 
Intensity Drug Trafficking Areas (HIDTA) Program (21 U.S.C. 
1706). The Section amends prior law to grant discretion to 
HIDTA Directors to use up to 5 percent of program funding for 
drug treatment programs, in addition to existing discretionary 
authority to use up to 5 percent of program funding for drug 
prevention programs. The Section also consolidates reporting 
requirements and clarifies at least 2.5 percent of program 
funding is used in areas with severe neighborhood safety and 
illegal drug distribution problems for safety and protection 
programs, including programs to prevent intimidation of 
potential witnesses. This section also authorizes 
$280,000,000--the amount appropriated for fiscal year 2018 
(Pub. L. No. 115-141)--for the Office to administer this 
subchapter for each fiscal year through 2023.

         SUBCHAPTER III--DRUG-FREE COMMUNITIES SUPPORT PROGRAM

    This subchapter codifies the Drug-Free Communities Act of 
1997, as amended, (Pub. L. No. 105-20, 21 U.S.C. 1531 seq.), 
updating the text and clarifying the Office's authority to use 
up to 8 percent of appropriated funds for administration of the 
program. This subchapter also authorizes $99,000,000--the 
amount appropriated for fiscal year 2018 (Pub. L. No. 115-
141)--for the Office to administer this subchapter for each 
fiscal year through 2023.

Section 3. Repeals

    Section 3 repeals prior laws--the contents of which are now 
incorporated into chapter 10 of title 31, as added by section 
2. This includes a repeal of the Office of National Drug 
Control Policy Reauthorization Act of 1998 (Public Law 105-277; 
21 U.S.C. 1701 et seq.) and chapter 2 of the National Narcotics 
Leadership Act of 1988 (Public Law 100-690; 21 U.S.C. 1501 et 
seq.). These repeals are included in H.R. 5925, notwithstanding 
prior repeals of both laws, to dispel any confusion and to 
ensure non-positive law titles of U.S. Code are updated by the 
Office of Law Revision Counsel to reflect the repeal of those 
statutes and accurately reflect current law.

Section 4. Opioid crisis response

    This section requires the Director to designate opioids and 
opioid analogues as an emerging threat in accordance with 
Emerging Threat provisions under section 1009 and to issue a 
``National Opioid Response Plan,'' which must include the 
following:
          1. Initiatives to increase the screening of mail to 
        prevent illicit drugs from entering the country and 
        designation of the United States Postal Service as a 
        National Drug Control Program Agency;
          2. Support for adoption of evidence-based prescribing 
        guidelines, including the establishment of a task force 
        to supplement existing prescribing guidelines, guidance 
        for federal continuing education requirements, and 
        dissemination of best practices;
          3. A program to monitor changes in prescription and 
        illicit drug markets;
          4. Studies to evaluate benefits of drug courts;
          5. Programs to coordinate with the private sector to 
        promote research and development of treatment and 
        deterrent products and expansion of disposal programs;
          6. Initiatives to encourage National Drug Control 
        Program Agencies and the Model Acts program to develop 
        sentencing standards or model codes for trafficking 
        opioids and opioid analogues and to advise states on 
        establishing policies based on the President's Opioid 
        Commission;
          7. Establishment of working groups to develop data 
        collection standards for medical examiner reports on 
        overdose data and first responder opioid intoxication 
        incidents;
          8. A program to identify successful college recovery 
        programs and to disseminate best practices;
          9. Working groups to support prescription drug 
        monitoring programs and other data collection programs;
          10. Initiation of research on Medication Assisted 
        Treatment and data collection to confirm opioid use by 
        individuals arrested or hospitalized; and
          11. Establishment of an Advisory Committee on 
        Substance Use Disorder Treatment Standards, no later 
        than 120 days after issuance of the plan, which will 
        promulgate evidence-based standards for substance abuse 
        disorder no later than 2 years after the issuance of 
        the plan.
    This section also requires the Director to submit a report 
to Congress on the findings and initiatives on Medication 
Assisted Treatment research.

Section 5. Exceptions and rules of construction

    This section codifies prior law relating to national 
intelligence (21 U.S.C. 1703(g)-(h)).

Section 6. GAO study and reports

    This section requires the Comptroller General to provide an 
initial report to Congress within three years of the date of 
enactment and a final report within six years on implementation 
of the Education and Public Awareness Campaign for Emerging 
Threat, the Strategy, and the annual assessment.

Section 7. Definitions

    This section defines terms for the Act as set forth in 
section 1001 of title 31, United States Code, as amended by 
section 2 of this bill.

         Changes in Existing Law Made by the Bill, as Reported

  In compliance with clause 3(e) of rule XIII of the Rules of 
the House of Representatives, changes in existing law made by 
the bill, as reported, are shown as follows (existing law 
proposed to be omitted is enclosed in black brackets, new 
matter is printed in italic, and existing law in which no 
change is proposed is shown in roman):

TITLE 31, UNITED STATES CODE

           *       *       *       *       *       *       *



                          SUBTITLE I--GENERAL

Chap.                                                               Sec.
      Definitions....................................................101
     * * * * * * *
1001Office of National Drug Control...................................

           *       *       *       *       *       *       *


              CHAPTER 10--OFFICE OF NATIONAL DRUG CONTROL

                          Subchapter I--Office

Sec.
1001. Definitions.
1002. Office of National Drug Control.
1003. Administration of the office.
1004. National drug control program budget.
1005. National drug control strategy.
1006. Development of an annual national drug control assessment.
1007. Monitoring and evaluation of national drug control program.
1008. Coordination and oversight of the national drug control program.
1009. Emerging threats taskforce, plan, media campaign.
1010. National and international coordination.
1011. Interdiction.
1012. Treatment coordinator.
1013. Critical information coordination.
1014. Annual audit and investigation requirements.
1015. Authorization of appropriations.

      Subchapter II--High Intensity Drug Trafficking Areas Program

1021. High intensity drug trafficking areas program.

          Subchapter III--Drug-Free Communities Support Program

1031. Establishment of drug-free communities support program.
1032. Program authorization.
1033. Information collection and dissemination with respect to grant 
          recipients.
1034. Technical assistance and training.
1035. Supplemental grants for coalition mentoring activities.
1036. Authorization for National Community Antidrug Coalition Institute.
1037. Definitions.
1038. Drug-free communities reauthorization.

                          SUBCHAPTER I--OFFICE

Sec. 1001. Definitions

  In this chapter:
          (1) Agency.--The term ``agency'' has the meaning 
        given the term ``executive agency'' in section 102.
          (2) Appropriate congressional committees.--The term 
        ``appropriate congressional committees'' means--
                  (A) the Committee on the Judiciary, the 
                Committee on Appropriations, and the Caucus on 
                International Narcotics Control of the Senate; 
                and
                  (B) the Committee on Oversight and Government 
                Reform, the Committee on the Judiciary, and the 
                Committee on Appropriations of the House of 
                Representatives.
          (3) Demand reduction.--The term ``demand reduction'' 
        means any activity conducted by a National Drug Control 
        Program Agency, other than an enforcement activity, 
        that is intended to reduce or prevent the use of drugs 
        or support or provide treatment and recovery efforts, 
        including--
                  (A) education about the dangers of illicit 
                drug use;
                  (B) services, programs, or strategies to 
                prevent substance use disorder, including 
                evidence-based education campaigns, community-
                based prevention programs, opioid diversion, 
                collection and disposal of unused prescription 
                drugs, and services to at-risk populations to 
                prevent or delay initial use of an illicit 
                substance;
                  (C) substance use disorder treatment;
                  (D) illicit drug use research;
                  (E) drug-free workplace programs;
                  (F) drug testing, including the testing of 
                employees;
                  (G) interventions for illicit drug use and 
                dependence;
                  (H) expanding availability of access to 
                health care services for the treatment of 
                substance use disorders;
                  (I) international drug control coordination 
                and cooperation with respect to activities 
                described in this paragraph;
                  (J) pre- and post-arrest criminal justice 
                interventions such as diversion programs, drug 
                courts, and the provision of evidence-based 
                treatment to individuals with substance use 
                disorders who are arrested or under some form 
                of criminal justice supervision, including 
                medication assisted treatment;
                  (K) other coordinated and joint initiatives 
                among Federal, State, local, and Tribal 
                agencies to promote comprehensive drug control 
                strategies designed to reduce the demand for, 
                and the availability of, illegal drugs;
                  (L) international illicit drug use education, 
                prevention, treatment, recovery, research, 
                rehabilitation activities, and interventions 
                for illicit drug use and dependence; and
                  (M) research related to any of the activities 
                described in this paragraph.
          (4) Director.--The term ``Director'' means the 
        Director of the Office of National Drug Control.
          (5) Drug.--The term ``drug'' has the meaning given 
        the term ``controlled substance'' in section 102(6) of 
        the Controlled Substances Act (21 U.S.C. 802(6)).
          (6) Drug control.--The term ``drug control'' means 
        any activity conducted by a National Drug Control 
        Program Agency involving supply reduction or demand 
        reduction.
          (7) Emerging threat.--The term ``emerging threat'' 
        means the occurrence of a new and growing trend in the 
        use of an illicit drug or class of drugs, including 
        rapid expansion in the supply of or demand for such 
        drug.
          (8) Illicit drug use; illicit drugs; illegal drugs.--
        The terms ``illicit drug use'', ``illicit drugs'', and 
        ``illegal drugs'' include the illegal or illicit use of 
        prescription drugs.
          (9) Law enforcement.--The term ``law enforcement'' or 
        ``drug law enforcement'' means all efforts by a 
        Federal, State, local, or Tribal government agency to 
        enforce the drug laws of the United States or any 
        State, including investigation, arrest, prosecution, 
        and incarceration or other punishments or penalties.
          (10) National drug control program.--The term 
        ``National Drug Control Program'' means programs, 
        policies, and activities undertaken by National Drug 
        Control Program Agencies pursuant to the 
        responsibilities of such agencies under the National 
        Drug Control Strategy, including any activities 
        involving supply reduction, demand reduction, or State, 
        local, and Tribal affairs.
          (11) National drug control program agency.--The term 
        ``National Drug Control Program Agency'' means any 
        agency (or bureau, office, independent agency, board, 
        division, commission, subdivision, unit, or other 
        component thereof) that is responsible for implementing 
        any aspect of the National Drug Control Strategy, 
        including any agency that receives Federal funds to 
        implement any aspect of the National Drug Control 
        Strategy, but does not include any agency that receives 
        funds for drug control activity solely under the 
        National Intelligence Program or the Military 
        Intelligence Program.
          (12) National drug control strategy; strategy.--The 
        term ``National Drug Control Strategy'' or ``Strategy'' 
        means the strategy developed and submitted to Congress 
        under section 1005.
          (13) Nonprofit organization.--The term ``nonprofit 
        organization'' means an organization that is described 
        in section 501(c)(3) of the Internal Revenue Code of 
        1986 and exempt from tax under section 501(a) of such 
        Code.
          (14) Office.--The term ``Office'' means the Office of 
        National Drug Control.
          (15) State, local, and tribal affairs.--The term 
        ``State, local, and Tribal affairs'' means domestic 
        activities conducted by a National Drug Control Program 
        Agency that are intended to reduce the availability and 
        use of illegal drugs, including--
                  (A) coordination and enhancement of Federal, 
                State, local, and Tribal law enforcement drug 
                control efforts;
                  (B) coordination and enhancement of efforts 
                among National Drug Control Program Agencies 
                and State, local, and Tribal demand reduction 
                and supply reduction agencies;
                  (C) coordination and enhancement of Federal, 
                State, local, and Tribal law enforcement 
                initiatives to gather, analyze, and disseminate 
                information and law enforcement intelligence 
                relating to drug control among domestic law 
                enforcement agencies; and
                  (D) other coordinated and joint initiatives 
                among Federal, State, local, and Tribal 
                agencies to promote comprehensive drug control 
                strategies designed to reduce the demand for, 
                and the availability of, illegal drugs.
          (16) Substance use disorder treatment.--The term 
        ``substance use disorder treatment'' means an evidence-
        based, professionally directed, deliberate, and planned 
        regimen including evaluation, observation, medical 
        monitoring, and rehabilitative services and 
        interventions such as pharmacotherapy, behavioral 
        therapy, and individual and group counseling, on an 
        inpatient or outpatient basis, to help patients with 
        substance use disorder reach recovery.
          (17) Supply reduction.--The term ``supply reduction'' 
        means any activity or program conducted by a National 
        Drug Control Program Agency that is intended to reduce 
        the availability or use of illegal drugs in the United 
        States or abroad, including--
                  (A) law enforcement outside the United 
                States;
                  (B) domestic law enforcement;
                  (C) source country programs, including 
                economic development programs primarily 
                intended to reduce the production or 
                trafficking of illicit drugs;
                  (D) activities to control international 
                trafficking in, and availability of, illegal 
                drugs, including--
                          (i) accurate assessment and 
                        monitoring of international drug 
                        production and interdiction programs 
                        and policies; and
                          (ii) coordination and promotion of 
                        compliance with international treaties 
                        relating to the production, 
                        transportation, or interdiction of 
                        illegal drugs;
                  (E) activities to conduct and promote 
                international law enforcement programs and 
                policies to reduce the supply of drugs;
                  (F) activities to facilitate and enhance the 
                sharing of domestic and foreign intelligence 
                information among National Drug Control Program 
                Agencies, relating to the production and 
                trafficking of drugs in the United States and 
                in foreign countries;
                  (G) activities to prevent the diversion of 
                drugs for their illicit use; and
                  (H) research related to any of the activities 
                described in this paragraph.

Sec. 1002. Office of National Drug Control

  (a) Establishment of Office.--There is established in the 
Executive Office of the President an Office of National Drug 
Control, which shall--
          (1) lead national drug control efforts, including 
        developing and assessing implementation of evidence-
        based drug control policy;
          (2) coordinate and oversee the implementation of the 
        national drug control policy, including the National 
        Drug Control Strategy;
          (3) assess and certify the adequacy of National Drug 
        Control Programs and the budget for those programs;
          (4) monitor and evaluate the effectiveness of 
        national drug control policy efforts, including the 
        National Drug Control Program Agencies' programs, by 
        developing and applying specific goals and performance 
        measurements and tracking program-level spending;
          (5) identify and respond to emerging threats related 
        to illicit drug use;
          (6) administer and evaluate grant programs in 
        furtherance of the National Drug Control Strategy; and
          (7) facilitate broad-scale information sharing and 
        data standardization among Federal, State, and local 
        entities to support the national drug control efforts.
  (b) Director of National Drug Control and Deputy Directors.--
          (1) Director.--
                  (A) In general.--There shall be at the head 
                of the Office a Director who shall hold the 
                same rank and status as the head of an 
                executive department listed in section 101 of 
                title 5, United States Code.
                  (B) Appointment.--The Director shall be 
                appointed by the President, by and with the 
                advice and consent of the Senate, and shall 
                serve at the pleasure of the President.
          (2) Deputy director.--
                  (A) In general.--There shall be a Deputy 
                Director who shall report directly to the 
                Director, be appointed by the President, and 
                serve at the pleasure of the President.
                  (B) Responsibilities.--The Deputy Director 
                shall--
                          (i) carry out the responsibilities 
                        delegated by the Director; and
                          (ii) be responsible for effectively 
                        coordinating with the Coordinators.
  (c) Responsibilities.--
          (1) Policies, goals, objectives, and priorities.--The 
        Director shall assist the President in directing 
        national drug control efforts, including establishing 
        policies, goals, objectives, and priorities for the 
        National Drug Control Program that are based on 
        evidence-based research.
          (2) Consultation.--To formulate the National Drug 
        Control policies, goals, objectives, and priorities, 
        the Director--
                  (A) shall consult with--
                          (i) State and local governments;
                          (ii) National Drug Control Program 
                        Agencies;
                          (iii) each committee, working group, 
                        council, or other entity established 
                        under this chapter, as appropriate;
                          (iv) the public;
                          (v) appropriate congressional 
                        committees; and
                          (vi) any other person in the 
                        discretion of the Director; and
                  (B) may--
                          (i) establish advisory councils;
                          (ii) acquire data from agencies; and
                          (iii) request data from any other 
                        entity.

Sec. 1003. Administration of the office

  (a) Employment.--
          (1) Authority of the director.--The Director may 
        select, appoint, employ, and fix compensation of such 
        officers and employees of the Office as may be 
        necessary to carry out the functions of the Office 
        under this chapter.
          (2) Prohibitions.--
                  (A) Generally.--No person shall serve as 
                Director or Deputy Director while serving in 
                any other position in the Federal Government.
                  (B) Prohibition on political campaigning.--
                Any officer or employee of the Office who is 
                appointed to that position by the President, by 
                and with the advice and consent of the Senate, 
                may not participate in Federal election 
                campaign activities, except that such official 
                is not prohibited by this paragraph from making 
                contributions to individual candidates.
  (b) Prohibition on the Use of Funds for Political Campaigns 
or Ballot Initiatives.--No funds authorized under this chapter 
may be obligated for the purpose of influencing any Federal, 
State, or local election or ballot initiative.
  (c) Personnel Detailed to Office.--
          (1) Evaluations.--Notwithstanding any provision of 
        chapter 43 of title 5, the Director shall perform the 
        evaluation of the performance of any employee detailed 
        to the Office for purposes of the applicable 
        performance appraisal system established under such 
        chapter for any rating period, or part thereof, that 
        such employee is detailed to such office.
          (2) Compensation.--
                  (A) Bonus payments.--Subject to the 
                availability of appropriations, the Director 
                may provide periodic bonus payments to any 
                employee detailed to the Office.
                  (B) Restrictions.--An amount paid under this 
                paragraph to an employee for any period--
                          (i) shall not be greater than 20 
                        percent of the basic pay paid or 
                        payable to such employee for such 
                        period; and
                          (ii) shall be in addition to the 
                        basic pay of such employee.
                  (C) Aggregate amount.--The aggregate amount 
                paid during any fiscal year to an employee 
                detailed to the Office as basic pay, awards, 
                bonuses, and other compensation shall not 
                exceed the annual rate payable at the end of 
                such fiscal year for positions at level III of 
                the Executive Schedule.
  (d) Congressional Access to Information.--The location of the 
Office in the Executive Office of the President shall not be 
construed as affecting access by Congress, or any committee of 
the House of Representatives or the Senate, to any--
          (1) information, document, or study in the possession 
        of, or conducted by or at the direction of the 
        Director; or
          (2) personnel of the Office.
  (e) Other Authorities of the Director.--In carrying out this 
chapter, the Director may--
          (1) use for administrative purposes, on a 
        reimbursable basis, the available services, equipment, 
        personnel, and facilities of Federal, State, and local 
        agencies;
          (2) procure the services of experts and consultants 
        in accordance with section 3109 of title 5 relating to 
        appointments in the Federal Service, at rates of 
        compensation for individuals not to exceed the daily 
        equivalent of the rate of pay payable under level IV of 
        the Executive Schedule under section 5311 of such 
        title; and
          (3) use the mails in the same manner as any other 
        agency.
  (f) General Services Administration.--The Administrator of 
General Services shall provide to the Director, on a 
reimbursable basis, such administrative support services as the 
Director may request.

Sec. 1004. National drug control program budget

  (a) Budget Recommendations.--Not later than July 1 of each 
year, the Director shall provide to the head of each National 
Drug Control Program Agency budget recommendations, including 
requests for specific initiatives that are consistent with the 
priorities of the President under the National Drug Control 
Strategy, which shall--
          (1) apply to the budget for the next fiscal year 
        scheduled for formulation under chapter 11, and each of 
        the 4 subsequent fiscal years; and
          (2) address funding priorities developed in the 
        National Drug Control Strategy.
  (b) Responsibilities of National Drug Control Program 
Agencies.--
          (1) In general.--For each fiscal year, the head of 
        each National Drug Control Program Agency shall 
        transmit to the Director a copy of the proposed drug 
        control budget request of such agency at the same time 
        as that budget request is submitted to their superiors 
        (and before submission to the Office of Management and 
        Budget) in the preparation of the budget of the 
        President submitted to Congress under section 1105(a).
          (2) Submission of drug control budget requests.--The 
        head of each National Drug Control Program Agency shall 
        ensure timely development and submission to the 
        Director of each proposed drug control budget request 
        transmitted pursuant to this subsection, in such format 
        as may be designated by the Director with the 
        concurrence of the Director of the Office of Management 
        and Budget.
          (3) Content of drug control budget requests.--A drug 
        control budget request submitted by the head of a 
        National Drug Control Program Agency under this 
        subsection shall include all requests for funds for any 
        drug control activity undertaken by such agency, 
        including demand reduction, supply reduction, and 
        State, local, and Tribal affairs, including any drug 
        law enforcement activities. If an activity has both 
        drug control and nondrug control purposes or 
        applications, such agency shall estimate by a 
        documented calculation the total funds requested for 
        that activity that would be used for drug control, and 
        shall set forth in its request the basis and method for 
        making the estimate.
  (c) Review and Certification of Budget Requests and Budget 
Submissions of National Drug Control Program Agencies.--
          (1) In general.--The Director shall review each drug 
        control budget request submitted to the Director under 
        subsection (b).
          (2) Review of budget requests.--
                  (A) Inadequate requests.--If the Director 
                concludes that a budget request submitted under 
                subsection (b) is inadequate, in whole or in 
                part, to implement the objectives of the 
                National Drug Control Strategy with respect to 
                the agency or program at issue for the year for 
                which the request is submitted, the Director 
                shall submit to the head of the applicable 
                National Drug Control Program Agency a written 
                description identifying the funding levels and 
                specific initiatives that would, in the 
                determination of the Director, make the request 
                adequate to implement those objectives.
                  (B) Adequate requests.--If the Director 
                concludes that a budget request submitted under 
                subsection (b) is adequate to implement the 
                objectives of the National Drug Control 
                Strategy with respect to the agency or program 
                at issue for the year for which the request is 
                submitted, the Director shall submit to the 
                head of the applicable National Drug Control 
                Program Agency a written statement confirming 
                the adequacy of the request.
                  (C) Record.--The Director shall maintain a 
                record of each description submitted under 
                subparagraph (A) and each statement submitted 
                under subparagraph (B).
          (3) Specific requests.--The Director shall not 
        confirm the adequacy of any budget request that 
        requests a level of funding that will not enable 
        achievement of the goals of the National Drug Control 
        Strategy, including--
                  (A) requests funding for Federal law 
                enforcement activities that do not adequately 
                compensate for transfers of drug enforcement 
                resources and personnel to law enforcement and 
                investigation activities;
                  (B) requests funding for law enforcement 
                activities on the borders of the United States 
                that do not adequately direct resources to drug 
                interdiction and enforcement;
                  (C) requests funding for drug treatment 
                activities that do not provide adequate results 
                and accountability measures;
                  (D) requests funding for drug treatment 
                activities that do not adequately support and 
                enhance Federal drug treatment programs and 
                capacity; and
                  (E) requests funding for the operations and 
                management of the Department of Homeland 
                Security that does not include a specific 
                request for funds for the Office of 
                Counternarcotics Enforcement to carry out its 
                responsibilities under section 878 of the 
                Homeland Security Act of 2002 (6 U.S.C. 458).
          (4) Agency response.--
                  (A) In general.--The head of a National Drug 
                Control Program Agency that receives a 
                description under paragraph (2)(A) shall 
                include the funding levels and initiatives 
                described by the Director in the budget 
                submission for that agency to the Office of 
                Management and Budget.
                  (B) Impact statement.--The head of a National 
                Drug Control Program Agency that has altered 
                its budget submission under this paragraph 
                shall include as an appendix to the budget 
                submission for that agency to the Office of 
                Management and Budget an impact statement that 
                summarizes--
                          (i) the changes made to the budget 
                        under this paragraph; and
                          (ii) the impact of those changes on 
                        the ability of that agency to perform 
                        its other responsibilities, including 
                        any impact on specific missions or 
                        programs of the agency.
                  (C) Congressional notification.--The head of 
                a National Drug Control Program Agency shall 
                submit a copy of any impact statement under 
                subparagraph (B) to the Senate, the House of 
                Representatives, and the appropriate 
                congressional committees, at the time the 
                budget for that agency is submitted to Congress 
                under section 1105(a).
          (5) Certification of budget submissions.--
                  (A) In general.--At the time a National Drug 
                Control Program Agency submits its budget 
                request to the Office of Management and Budget, 
                the head of the National Drug Control Program 
                Agency shall submit a copy of the budget 
                request to the Director.
                  (B) Review and certification of 
                submissions.--The Director shall review each 
                budget submission submitted under subparagraph 
                (A) and submit to the appropriate congressional 
                committees one of the following:
                          (i) A written certification of the 
                        budget request for the agency 
                        indicating such request fully funds the 
                        National Drug Control Programs as 
                        necessary to achieve the goals of the 
                        National Drug Control Strategy, 
                        including a written statement 
                        explaining the basis for the 
                        determination that the budget provides 
                        sufficient resources for the agency to 
                        achieve the goals of the Strategy.
                          (ii) A written certification of the 
                        budget request for the agency 
                        indicating such request partially funds 
                        the National Drug Control Programs as 
                        necessary to achieve the goals of the 
                        Strategy, including a written statement 
                        explaining the basis for the 
                        determination and identifying the level 
                        of funding sufficient to achieve the 
                        goals of the Strategy.
                          (iii) A written decertification of 
                        the budget request for the agency 
                        indicating the Director is unable to 
                        determine whether such budget request 
                        for the agency fully funds or partially 
                        funds the National Drug Control 
                        Programs as necessary to achieve the 
                        goals of the National Drug Control 
                        Strategy, including a written statement 
                        identifying the additional information 
                        necessary for the Director to make a 
                        determination on such budget and the 
                        level of funding sufficient to achieve 
                        the goals of the Strategy.
                          (iv) A written decertification of the 
                        budget request for the agency 
                        indicating that such budget is 
                        insufficient to fund the National Drug 
                        Control Programs as necessary to 
                        achieve the goals of the Strategy, 
                        including a written statement 
                        explaining the basis for the 
                        determination that the budget is 
                        insufficient and identifying the level 
                        of funding sufficient to achieve the 
                        goals of the Strategy.
  (d) National Drug Control Program Budget Proposal.--For each 
fiscal year, following the transmission of proposed drug 
control budget requests to the Director under subsection (b), 
the Director shall, in consultation with the head of each 
National Drug Control Program Agency and the head of each major 
national organization that represents law enforcement officers, 
agencies, or associations--
          (1) develop a consolidated National Drug Control 
        Program budget proposal designed to implement the 
        National Drug Control Strategy and to inform Congress 
        and the public about the total amount proposed to be 
        spent on all supply reduction, demand reduction, State, 
        local, and Tribal affairs, including any drug law 
        enforcement, and other drug control activities by the 
        Federal Government, which shall conform to the content 
        requirements set forth in subsection (b)(3) and 
        include--
                  (A) for each National Drug Control Program 
                Agency, a list of whether the funding level is 
                full, partial, or insufficient to achieve the 
                goals of the National Drug Control Strategy or 
                whether the Director is unable to determine 
                whether the budget request for the agency fully 
                funds or partially funds the agency's 
                activities and contributions as necessary to 
                achieve the goals of National Drug Control 
                Strategy;
                  (B) a statement describing the extent to 
                which any budget of a National Drug Control 
                Program Agency with less than full funding 
                hinders progress on achieving the goals of the 
                National Drug Control Strategy; and
                  (C) alternative funding structures that could 
                improve progress on achieving the goals of the 
                National Drug Control Strategy; and
          (2) submit the consolidated budget proposal to the 
        President and Congress.
  (e) Budget Estimate or Request Submission to Congress.--
Whenever the Director submits any budget estimate or request to 
the President or the Office of Management and Budget, the 
Director shall concurrently transmit copies of that estimate or 
request to the appropriate congressional committees.
  (f) Reprogramming and Transfer Requests.--
          (1) In general.--No National Drug Control Program 
        Agency shall submit to Congress a reprogramming or 
        transfer request with respect to any amount of 
        appropriated funds in an amount exceeding $1,000,000 
        that is included in the National Drug Control Program 
        budget unless the request has been approved by the 
        Director. If the Director has not responded to a 
        request for reprogramming subject to this paragraph 
        within 30 days after receiving notice of the request 
        having been made, the request shall be deemed approved 
        by the Director under this paragraph and forwarded to 
        Congress.
          (2) Appeal.--The head of any National Drug Control 
        Program Agency may appeal to the President any 
        disapproval by the Director of a reprogramming or 
        transfer request under this subsection.

Sec. 1005. National drug control strategy

  (a) In General.--
          (1) Statement of drug policy priorities.--The 
        Director shall release a statement of drug policy 
        priorities in the calendar year of a Presidential 
        inauguration following the inauguration but not later 
        than April 1.
          (2) National drug control strategy submitted by the 
        president.--Not later than the first Monday in February 
        following the year in which the term of the President 
        commences, the President shall submit to Congress a 
        National Drug Control Strategy.
  (b) Development of the National Drug Control Strategy.--
          (1) Promulgation.--The Director shall promulgate the 
        National Drug Control Strategy, which shall set forth a 
        comprehensive plan to reduce illicit drug use and the 
        consequences of such illicit drug use in the United 
        States by limiting the availability of and reducing the 
        demand for illegal drugs and promoting prevention, 
        early intervention, treatment, and recovery support for 
        individuals with substance use disorders.
          (2) State and local commitment.--The Director shall 
        seek the support and commitment of State, local, and 
        Tribal officials in the formulation and implementation 
        of the National Drug Control Strategy.
          (3) Strategy based on evidence.--The Director shall 
        ensure the National Drug Control Strategy is based on 
        the best available medical and scientific evidence 
        regarding the policies that are most effective in 
        reducing the demand for and supply of illegal drugs.
          (4) Process for development and submission of 
        national drug control strategy.--In developing and 
        effectively implementing the National Drug Control 
        Strategy, the Director--
                  (A) shall consult with--
                          (i) the heads of the National Drug 
                        Control Program Agencies;
                          (ii) the United States Interdiction 
                        Coordinator;
                          (iii) the Interdiction Committee;
                          (iv) the appropriate congressional 
                        committees and any other committee of 
                        jurisdiction;
                          (v) State, local, and Tribal 
                        officials;
                          (vi) private citizens and 
                        organizations, including community and 
                        faith-based organizations, with 
                        experience and expertise in demand 
                        reduction;
                          (vii) private citizens and 
                        organizations with experience and 
                        expertise in supply reduction; and
                          (viii) appropriate representatives of 
                        foreign governments; and
                  (B) in satisfying the requirements of 
                subparagraph (A), shall ensure, to the maximum 
                extent possible, that State, local, and Tribal 
                officials and relevant private organizations 
                commit to support and take steps to achieve the 
                goals and objectives of the National Drug 
                Control Strategy.
  (c) Contents of the National Drug Control Strategy.--
          (1) In general.--The National Drug Control Strategy 
        submitted under subsection (a)(2) shall include the 
        following:
                  (A) A description of the current prevalence 
                of illicit drug use in the United States, 
                including both the availability of illicit 
                drugs and the prevalence of substance use 
                disorders, which shall include the following:
                          (i) Such description for the previous 
                        three years for any drug identified as 
                        an emerging threat under section 1009 
                        and any other illicit drug identified 
                        by the Director as having a significant 
                        impact on the prevalence of illicit 
                        drug use.
                          (ii) A summary of the data and trends 
                        presented in the Drug Control Data 
                        Dashboard required under section 1013.
                  (B) A mission statement detailing the major 
                functions of the National Drug Control Program.
                  (C) A list of comprehensive, research-based, 
                long-range, quantifiable goals for reducing 
                illicit drug use, including--
                          (i) the percentage of the total flow 
                        of illicit drugs to be interdicted 
                        during the time period covered by the 
                        Strategy; and
                          (ii) the number of individuals to 
                        receive treatment for substance use 
                        disorders.
                  (D) A description of how each goal listed in 
                the National Drug Control Strategy will be 
                achieved, including--
                          (i) a list of relevant National Drug 
                        Control Program Agencies and each such 
                        agency's related programs, activities, 
                        and available assets and the role of 
                        each such program, activity, and asset 
                        in achieving the goal;
                          (ii) a list of relevant stakeholders 
                        and each such stakeholder's role in 
                        achieving the goal;
                          (iii) an estimate of Federal funding 
                        and other resources needed to achieve 
                        each goal;
                          (iv) an identification of existing or 
                        new coordinating mechanisms needed to 
                        achieve the goal; and
                          (v) a description of the Office's 
                        role in facilitating the achievement of 
                        such goal.
                  (E) For each year covered by the Strategy, a 
                performance evaluation plan for each goal 
                listed in the National Drug Control Strategy 
                for each National Drug Control Program Agency, 
                including--
                          (i) specific performance measures for 
                        each National Drug Control Program 
                        Agency and each such agency's related 
                        programs and activities;
                          (ii) annual and quarterly objectives 
                        and targets for each performance 
                        measure; and
                          (iii) an estimate of Federal funding 
                        and other resources needed to achieve 
                        each performance measure.
                  (F) A list identifying existing data sources 
                or a description of data collection needed to 
                evaluate performance, including a description 
                of how the Director will obtain such data.
                  (G) A list of anticipated challenges to 
                achieving the National Drug Control Strategy 
                goals and planned actions to address such 
                challenges;
                  (H) A description of how each goal was 
                determined, including--
                          (i) a description of each required 
                        consultation and how such consultation 
                        was incorporated;
                          (ii) data, research, or other 
                        information used to inform the 
                        decision; and
                          (iii) a statement of whether the goal 
                        established in subparagraph (C)(i) will 
                        be adequate to disrupt drug trafficking 
                        organizations that supply the majority 
                        of foreign-sourced illicit drugs 
                        trafficked into the United States.
                  (I) A 5-year projection for program and 
                budget priorities.
                  (J) A review of international, State, local, 
                and private sector drug control activities to 
                ensure that the United States pursues 
                coordinated and effective drug control at all 
                levels of government.
                  (K) Such statistical data and information as 
                the Director considers appropriate to 
                demonstrate and assess trends relating to 
                illicit drug use, the effects and consequences 
                of illicit drug use (including the effects on 
                children), supply reduction, demand reduction, 
                drug-related law enforcement, and the 
                implementation of the National Drug Control 
                Strategy.
          (2) Additional strategies.--
                  (A) In general.--The Director shall include 
                in the National Drug Control Strategy the 
                additional strategies required under this 
                paragraph and shall comply with the following:
                          (i) Provide a copy of the additional 
                        strategies to the appropriate 
                        congressional committees and to the 
                        Committee on Armed Services and the 
                        Committee on Homeland Security of the 
                        House of Representatives, and the 
                        Committee on Homeland Security and 
                        Governmental Affairs and the Committee 
                        on Armed Services of the Senate.
                          (ii) Issue the additional strategies 
                        in consultation with the head of each 
                        relevant National Drug Control Program 
                        Agency and any relevant official of a 
                        State, local or Tribal government, and 
                        the government of other countries.
                          (iii) Not change any existing agency 
                        authority or construe any strategy 
                        described under this paragraph to amend 
                        or modify any law governing interagency 
                        relationship but may include 
                        recommendations about changes to such 
                        authority or law.
                          (iv) Present separately from the rest 
                        of any strategy described under this 
                        paragraph any information classified 
                        under criteria established by an 
                        Executive order, or whose public 
                        disclosure, as determined by the 
                        Director or the head of any relevant 
                        National Drug Control Program Agency, 
                        would be detrimental to the law 
                        enforcement or national security 
                        activities of any Federal, State, 
                        local, or Tribal agency.
                  (B) Requirement for southwest border 
                counternarcotics.--
                          (i) Purposes.--The Southwest Border 
                        Counternarcotics Strategy shall--
                                  (I) set forth the 
                                Government's strategy for 
                                preventing the illegal 
                                trafficking of drugs across the 
                                international border between 
                                the United States and Mexico, 
                                including through ports of 
                                entry and between ports of 
                                entry on that border;
                                  (II) state the specific roles 
                                and responsibilities of the 
                                relevant National Drug Control 
                                Program Agencies for 
                                implementing that strategy; and
                                  (III) identify the specific 
                                resources required to enable 
                                the relevant National Drug 
                                Control Program Agencies to 
                                implement that strategy.
                          (ii) Specific content related to drug 
                        tunnels between the united states and 
                        mexico.--The Southwest Border 
                        Counternarcotics Strategy shall 
                        include--
                                  (I) a strategy to end the 
                                construction and use of tunnels 
                                and subterranean passages that 
                                cross the international border 
                                between the United States and 
                                Mexico for the purpose of 
                                illegal trafficking of drugs 
                                across such border; and
                                  (II) recommendations for 
                                criminal penalties for persons 
                                who construct or use such a 
                                tunnel or subterranean passage 
                                for such a purpose.
                  (C) Requirement for northern border 
                counternarcotics strategy.--
                          (i) Purposes.--The Northern Border 
                        Counternarcotics Strategy shall--
                                  (I) set forth the strategy of 
                                the Federal Government for 
                                preventing the illegal 
                                trafficking of drugs across the 
                                international border between 
                                the United States and Canada, 
                                including through ports of 
                                entry and between ports of 
                                entry on the border;
                                  (II) state the specific roles 
                                and responsibilities of each 
                                relevant National Drug Control 
                                Program Agency for implementing 
                                the strategy;
                                  (III) identify the specific 
                                resources required to enable 
                                the relevant National Drug 
                                Control Program Agencies to 
                                implement the strategy;
                                  (IV) be designed to promote, 
                                and not hinder, legitimate 
                                trade and travel; and
                                  (V) reflect the unique nature 
                                of small communities along the 
                                international border between 
                                the United States and Canada, 
                                ongoing cooperation and 
                                coordination with Canadian law, 
                                enforcement authorities, and 
                                variations in the volumes of 
                                vehicles and pedestrians 
                                crossing through ports of entry 
                                along the international border 
                                between the United States and 
                                Canada.
                          (ii) Specific content related to 
                        cross-border indian reservations.--The 
                        Northern Border Counternarcotics 
                        Strategy shall include--
                                  (I) a strategy to end the 
                                illegal trafficking of drugs to 
                                or through Indian reservations 
                                on or near the international 
                                border between the United 
                                States and Canada; and
                                  (II) recommendations for 
                                additional assistance, if any, 
                                needed by Tribal law 
                                enforcement agencies relating 
                                to the strategy, including an 
                                evaluation of Federal technical 
                                and financial assistance, 
                                infrastructure capacity 
                                building, and interoperability 
                                deficiencies.
          (3) Classified information.--Any contents of the 
        National Drug Control Strategy that involve information 
        properly classified under criteria established by an 
        Executive order shall be presented to Congress 
        separately from the rest of the National Drug Control 
        Strategy.
          (4) Selection of data and information.--In selecting 
        data and information for inclusion under paragraph (1), 
        the Director shall ensure--
                  (A) the inclusion of data and information 
                that will permit analysis of current trends 
                against previously compiled data and 
                information where the Director believes such 
                analysis enhances long-term assessment of the 
                National Drug Control Strategy; and
                  (B) the inclusion of data and information to 
                permit a standardized and uniform assessment of 
                the effectiveness of drug treatment programs in 
                the United States.
  (d) Annual Performance Supplement.--Not later than the first 
Monday in February of each year following the year in which the 
National Drug Control Strategy is submitted pursuant to 
subsection (a)(2), the Director shall submit to the appropriate 
congressional committees a supplement to the Strategy that 
shall include--
          (1) annual and quarterly quantifiable and measurable 
        objectives and specific targets to accomplish long-term 
        quantifiable goals specified in the Strategy; and
          (2) for each year covered by the Strategy, a 
        performance evaluation plan for each goal listed in the 
        Strategy for each National Drug Control Program Agency, 
        including--
                  (A) specific performance measures for each 
                National Drug Control Program Agency and each 
                such agency's related programs and activities;
                  (B) annual and quarterly objectives and 
                targets for each performance measure; and
                  (C) an estimate of Federal funding and other 
                resources needed to achieve each performance 
                measure.
  (e) Submission of Revised Strategy.--The President may submit 
to Congress a revised National Drug Control Strategy that meets 
the requirements of this section--
          (1) at any time, upon a determination of the 
        President, in consultation with the Director, that the 
        National Drug Control Strategy in effect is not 
        sufficiently effective; or
          (2) if a new President or Director takes office.
  (f) Failure of President to Submit National Drug Control 
Strategy.--If the President does not submit a National Drug 
Control Strategy to Congress in accordance with subsection 
(a)(2), not later than five days after the first Monday in 
February following the year in which the term of the President 
commences, the President shall send a notification to the 
appropriate congressional committees--
          (1) explaining why the Strategy was not submitted; 
        and
          (2) specifying the date by which the Strategy will be 
        submitted.

Sec. 1006. Development of an annual national drug control assessment

  (a) Timing.--Not later than the first Monday in February of 
each year, the Director shall submit to the President, 
Congress, and the appropriate congressional committees, a 
report assessing the progress of each National Drug Control 
Program Agency toward achieving the annual goals, objectives, 
and targets contained in the National Drug Control Strategy 
applicable to the prior fiscal year.
  (b) Process for Development of the Annual Assessment.--Not 
later than November 1 of each year, the head of each National 
Drug Control Program Agency shall submit, in accordance with 
guidance issued by the Director, to the Director an evaluation 
of progress by the agency with respect to drug control program 
goals using the performance measures for the agency developed 
under this section, including progress with respect to--
          (1) success in achieving the goals of the National 
        Drug Control Strategy;
          (2) success in reducing domestic and foreign sources 
        of illegal drugs;
          (3) success in expanding access to and increasing the 
        effectiveness of substance use disorder treatment;
          (4) success in protecting the borders of the United 
        States (and in particular the Southwestern border of 
        the United States) from penetration by illegal 
        narcotics;
          (5) success in reducing crime associated with drug 
        use in the United States;
          (6) success in reducing the negative health and 
        social consequences of drug use in the United States; 
        and
          (7) implementation of drug treatment and prevention 
        programs in the United States and improvements in the 
        adequacy and effectiveness of such programs.
  (c) Contents of the Annual Assessment.--The Director shall 
include in the annual assessment required under subsection 
(a)--
          (1) a summary of each evaluation received by the 
        Director under subsection (b);
          (2) a summary of the progress of each National Drug 
        Control Program Agency toward the drug control program 
        goals of the agency using the performance measures for 
        the agency developed under this section;
          (3) an assessment of the effectiveness of each Drug 
        Control Program agency and program in achieving the 
        National Drug Control Strategy for the previous year, 
        including a specific evaluation of whether the 
        applicable goals, measures, objectives, and targets for 
        the previous year were met;
          (4) for National Drug Control Program Agencies that 
        administer grant programs, an evaluation of the 
        effectiveness of each grant program, including an 
        accounting of the funds disbursed by the program in the 
        prior year and a summary of how those funds were used 
        by the grantees and sub-grantees during that period;
          (5) a detailed accounting of the amount of funds 
        obligated by each National Drug Control Program Agency 
        in carrying out the responsibilities of that agency 
        under the Strategy, including the information submitted 
        to the Director under section 1007(b);
          (6) an assessment of the effectiveness of any 
        Emerging Threat Response Plan in effect for the 
        previous year, including a specific evaluation of 
        whether the objectives and targets were met and reasons 
        for the success or failure of the previous year's plan;
          (7) a detailed accounting of the amount of funds 
        obligated during the previous fiscal year for carrying 
        out the media campaign under section 1009(d), including 
        each recipient of funds, the purpose of each 
        expenditure, the amount of each expenditure, any 
        available outcome information, and any other 
        information necessary to provide a complete accounting 
        of the funds expended; and
          (8) the assessments required under this subsection 
        shall be based on the Performance Measurement System 
        describe in subsection (d).
  (d) Performance Measurement System.--The Director shall 
include in the annual assessment required under subsection (a) 
a national drug control performance measurement system, that--
          (1) develops annual, 2-year, and 5-year performance 
        measures, objectives, and targets for each National 
        Drug Control Strategy goal and objective established 
        for reducing drug use, availability, and the 
        consequences of drug use;
          (2) describes the sources of information and data 
        that will be used for each performance measure 
        incorporated into the performance measurement system;
          (3) identifies major programs and activities of the 
        National Drug Control Program Agencies that support the 
        goals and annual objectives of the National Drug 
        Control Strategy;
          (4) evaluates the contribution of demand reduction 
        and supply reduction activities implemented by each 
        National Drug Control Program Agency in support of the 
        National Drug Control Strategy;
          (5) monitors consistency between the drug-related 
        goals, measures, targets, and objectives of the 
        National Drug Control Program Agencies and ensures that 
        each agency's goals and budgets support, and are fully 
        consistent with, the National Drug Control Strategy; 
        and
          (6) coordinates the development and implementation of 
        national drug control data collection and reporting 
        systems to support policy formulation and performance 
        measurement, including an assessment of--
                  (A) the quality of current drug use 
                measurement instruments and techniques to 
                measure supply reduction and demand reduction 
                activities;
                  (B) the adequacy of the coverage of existing 
                national drug use measurement instruments and 
                techniques to measure the illicit drug user 
                population, and groups that are at risk for 
                illicit drug use;
                  (C) the adequacy of the coverage of existing 
                national treatment outcome monitoring systems 
                to measure the effectiveness of substance use 
                disorder treatment in reducing illicit drug use 
                and criminal behavior during and after the 
                completion of substance use disorder treatment; 
                and
                  (D) the actions the Director shall take to 
                correct any deficiencies and limitations 
                identified pursuant to subparagraphs (A), (B), 
                and (C).
  (e) Modifications.--A description of any modifications made 
during the preceding year to the national drug performance 
measurement system described in subsection (d) shall be 
included in each report submitted under subsection (a).
  (f) Annual Report on Consultation.--The Director shall 
include in the annual assessment required under subsection 
(a)--
          (1) a detailed description of how the Office has 
        consulted with and assisted State, local, and Tribal 
        governments with respect to the formulation and 
        implementation of the National Drug Control Strategy 
        and other relevant issues; and
          (2) a general review of the status of, and trends in, 
        demand reduction activities by private sector entities 
        and community-based organizations, including faith-
        based organizations, to determine their effectiveness 
        and the extent of cooperation, coordination, and mutual 
        support between such entities and organizations and 
        Federal, State, local, and Tribal government agencies.
  (g) Performance-budget Coordinator.--
          (1) Designation.--The Director shall designate or 
        appoint a United States Performance-Budget Coordinator 
        to--
                  (A) ensure the Director has sufficient 
                information about the performance of each 
                National Drug Control Program Agency, the 
                impact Federal funding has had on the goals in 
                the Strategy, and the likely contributions to 
                the goals of the Strategy based on funding 
                levels of each National Drug Control Program 
                Agency, to make an independent assessment of 
                the budget request of each agency under section 
                1004;
                  (B) advise the Director on agency budgets, 
                performance measures and targets, and 
                additional data and research needed to make 
                informed policy decisions in the National Drug 
                Control Budget and Strategy; and
                  (C) other duties as may be determined by the 
                Director with respect to measuring or assessing 
                performance or agency budgets.
          (2) Determination of position.--The Director shall 
        determine whether the coordinator position is a career 
        or noncareer position in the Senior Executive Service.

Sec. 1007. Monitoring and evaluation of national drug control program

  (a) In General.--The Director shall monitor implementation of 
the National Drug Control Program and the activities of the 
National Drug Control Program Agencies in carrying out the 
goals and objectives of the National Drug Control Strategy 
including--
          (1) conducting program and performance audits and 
        evaluations; and
          (2) requesting assistance from the Inspector General 
        of the relevant agency in such audits and evaluations.
  (b) Accounting of Funds Expended.--Not later than December 1 
of each year and in accordance with guidance issued by the 
Director, the head of each National Drug Control Program Agency 
shall submit to the Director a detailed accounting of all funds 
expended by the agency for National Drug Control Program 
activities during the previous fiscal year and shall ensure 
such detailed accounting is authenticated by the Inspector 
General for such agency prior to submission to the Director.
  (c) Notification.--The Director shall notify any National 
Drug Control Program Agency if its activities are not in 
compliance with the responsibilities of the agency under the 
National Drug Control Strategy, transmit a copy of each such 
notification to the President and the appropriate congressional 
committees, and maintain a copy of each such notification.
  (d) Recommendations.--The Director shall make such 
recommendations to the President and the appropriate 
congressional committees as the Director determines are 
appropriate regarding changes in the organization, management, 
and budgets of the National Drug Control Program Agencies, and 
changes in the allocation of personnel to and within those 
agencies, to implement the policies, goals, priorities, and 
objectives established under section 1002(c)(1) and the 
National Drug Control Strategy.
  (e) Authorization, Development, and Implementation of a 
Coordinated Tracking System.--
          (1) Establishment.--The Director, shall establish a 
        coordinated tracking system of federally-funded 
        initiatives and grant programs which shall--
                  (A) be the central repository of all relevant 
                grants;
                  (B) identify duplication, overlap, or gaps in 
                funding to provide increased accountability of 
                federally-funded grants for substance abuse 
                treatment, prevention, and enforcement;
                  (C) identify impediments that applicants 
                currently have in the grant application process 
                with applicable agencies; and
                  (D) be developed and maintained by the Office 
                with the support of designated National Drug 
                Control Program Agencies, and any other agency 
                determined by the Director.
          (2) Performance metrics.--The Director shall identify 
        metrics and achievable goals for grant recipients in 
        furtherance of the Strategy. Such metrics should be 
        used to measure how effective each federally funded 
        initiative is in achieving the objectives of the 
        Strategy and to enable comparisons of federally funded 
        initiatives to identify those that are the most cost 
        effective.
          (3) Grant application standardization.--The Director, 
        in consultation with the head of each National Drug 
        Control Program Agency, shall develop a plan for 
        coordinating and standardizing drug control grant 
        application processes and develop a joint application 
        to be used by all National Drug Control Program 
        Agencies to reduce the administrative burden and 
        improve oversight of Federal funds.
          (4) Central portal.--The Director shall maintain on 
        the public, electronic portal of the Office a list all 
        drug control grant award opportunities available in a 
        central location. The head of each National Drug 
        Control Program Agency shall provide a complete list of 
        all drug control program grant award opportunities to 
        the Director and annually update such list.
          (5) Report to congress.--The Director shall include 
        in the assessment submitted to Congress under section 
        1006 an assessment on progress under this section and 
        the feasibility of block grants of Federal funding to 
        States.

Sec. 1008. Coordination and oversight of the national drug control 
                    program

  (a) In General.--The Director shall coordinate and oversee 
the implementation by the National Drug Control Program 
Agencies of the policies, goals, objectives, and priorities 
established under section 1002(c)(1) and the fulfillment of the 
responsibilities of such agencies under the National Drug 
Control Strategy and make recommendations to National Drug 
Control Program Agency heads with respect to implementation of 
National Drug Control Programs.
  (b) Detailing Employees to Other Agencies.--
          (1) Request.--The Director may request the head of an 
        agency or program of the Federal Government to place 
        agency personnel who are engaged in drug control 
        activities on temporary detail to another agency in 
        order to implement the National Drug Control Strategy.
          (2) Agency compliance.--The head of the agency shall 
        comply with such a request.
          (3) Maximum number of detailees.--The maximum number 
        of personnel who may be detailed to another agency 
        (including the Office) under this subsection during any 
        fiscal year is--
                  (A) for the Department of Defense, 50; and
                  (B) for any other agency, 10.
  (c) Directing Federal Funding.--The Director may transfer 
funds made available to a National Drug Control Program Agency 
for National Drug Control Strategy programs and activities to 
another account within such agency or to another National Drug 
Control Program Agency for National Drug Control Strategy 
programs and activities, except that--
          (1) the authority under this subsection may be 
        limited in an annual appropriations Act or other 
        provision of Federal law;
          (2) the Director may exercise the authority under 
        this subsection only with the concurrence of the head 
        of each affected agency;
          (3) in the case of an interagency transfer, the total 
        amount of transfers under this subsection may not 
        exceed 3 percent of the total amount of funds made 
        available for National Drug Control Strategy programs 
        and activities to the agency from which those funds are 
        to be transferred;
          (4) funds transferred to an agency under this 
        subsection may only be used to increase the funding for 
        programs or activities authorized by law;
          (5) the Director shall--
                  (A) submit to the appropriate congressional 
                committees and any other applicable committees 
                of jurisdiction, a reprogramming or transfer 
                request in advance of any transfer under this 
                subsection in accordance with the regulations 
                of the affected agency or agencies; and
                  (B) annually submit to the appropriate 
                congressional committees a report describing 
                the effect of all transfers of funds made 
                pursuant to this subsection or section 1004(f) 
                during the 12-month period preceding the date 
                on which the report is submitted; and
          (6) funds may only be used for--
                  (A) expansion of demand reduction activities;
                  (B) interdiction of illicit drugs on the high 
                seas, in United States territorial waters, and 
                at United States ports of entry by officers and 
                employees of Drug Control Program Agencies and 
                domestic and foreign law enforcement officers;
                  (C) accurate assessment and monitoring of 
                international drug production and interdiction 
                programs and policies;
                  (D) activities to facilitate and enhance the 
                sharing of domestic and foreign intelligence 
                information among Drug Control Program Agencies 
                related to the production and trafficking of 
                drugs in the United States and foreign 
                countries; and
                  (E) activities to prevent the diversion of 
                prescription drugs for illicit use and research 
                related to any of these activities.
  (d) Directing Federal Funding to Respond to Emerging 
Threats.--
          (1) In general.--The Director may transfer funds made 
        available to a National Drug Control Program Agency for 
        National Drug Control Strategy programs and activities 
        to another account within such agency or to another 
        National Drug Control Program Agency for National Drug 
        Control Strategy programs and activities to implement 
        the provisions of a plan developed under section 1009, 
        except that--
                  (A) the authority under this subsection may 
                be limited in an annual appropriations Act or 
                other provision of Federal law;
                  (B) in the case of an interagency transfer, 
                the total amount of transfers under this 
                subsection may not exceed 10 percent of the 
                total amount of funds made available for 
                National Drug Control Strategy programs and 
                activities to the agency from which those funds 
                are to be transferred;
                  (C) funds transferred to an agency under this 
                subsection may only be used to increase the 
                funding for programs or activities authorized 
                by law;
                  (D) no transfer of funds under this 
                subsection may result in a reduction in total 
                Federal expenditures for substance use disorder 
                treatment;
                  (E) the Director shall--
                          (i) submit to the appropriate 
                        congressional committees and any other 
                        applicable committees of jurisdiction, 
                        a reprogramming or transfer request in 
                        advance of any transfer under this 
                        subsection in accordance with the 
                        regulations of each affected agency; 
                        and
                          (ii) annually submit to the 
                        appropriate congressional committees a 
                        report describing the effect of all 
                        transfers of funds made pursuant to 
                        this subsection or section 1004(f) 
                        during the 12-month period preceding 
                        the date on which the report is 
                        submitted; and
                  (F) funds may only be used for--
                          (i) expansion of demand reduction 
                        activities;
                          (ii) interdiction of illicit drugs on 
                        the high seas, in United States 
                        territorial waters, and at United 
                        States ports of entry by officers and 
                        employees of Drug Control Program 
                        agencies and domestic and foreign law 
                        enforcement officers;
                          (iii) accurate assessment and 
                        monitoring of international drug 
                        production and interdiction programs 
                        and policies;
                          (iv) activities to facilitate and 
                        enhance the sharing of domestic and 
                        foreign intelligence information among 
                        Drug Control Program Agencies related 
                        to the production and trafficking of 
                        drugs in the United States and foreign 
                        countries; and
                          (v) activities to prevent the 
                        diversion of prescription drugs for 
                        illicit use and research related to any 
                        of these activities.
          (2) Inadequacy of transfer.--In the event the 
        authority under this subsection is inadequate to 
        implement the provisions of a plan developed under 
        section 1009, the Director shall submit a request for 
        funding to Congress as soon as the Director becomes 
        aware of the need for additional funding.
  (e) Fund Control Notices.--
          (1) In general.--The Director may issue to the head 
        of a National Drug Control Program Agency a fund 
        control notice to ensure compliance with the National 
        Drug Control Program Strategy. A fund control notice 
        may direct that all or part of an amount appropriated 
        to the National Drug Control Program Agency account be 
        obligated by--
                  (A) months, fiscal year quarters, or other 
                time periods; and
                  (B) activities, functions, projects, or 
                object classes.
          (2) Unauthorized obligation or expenditure 
        prohibited.--An officer or employee of a National Drug 
        Control Program Agency shall not make or authorize an 
        expenditure or obligation contrary to a fund control 
        notice issued by the Director.
          (3) Disciplinary action for violation.--In the case 
        of a violation of paragraph (2) by an officer or 
        employee of a National Drug Control Program Agency, the 
        head of the agency, upon the request of and in 
        consultation with the Director, may subject the officer 
        or employee to appropriate administrative discipline, 
        including, when circumstances warrant, suspension from 
        duty without pay or removal from office.
          (4) Congressional notice.--Not later than 5 days 
        after issuance of a fund control notice, the Director 
        shall submit a copy of such fund control notice to the 
        appropriate congressional committees and make such 
        notice publicly available.
          (5) Restrictions.--The Director shall not issue a 
        fund control notice to direct that all or part of an 
        amount appropriated to the National Drug Control 
        Program Agency account be obligated, modified, or 
        altered in any manner contrary, in whole or in part, to 
        a specific appropriation or statute.
  (f) Exclusions.--The authorities described under subsections 
(c), (d), and (e) do not apply to any program under subchapter 
II or III.
  (g) Foreign Assistance Act Participation.--The Director may 
participate in the drug certification process pursuant to 
section 490 of the Foreign Assistance Act of 1961 (22 U.S.C. 
2291j) and section 706 of the Department of State Authorization 
Act for Fiscal Year 2003 (22 U.S.C. 229j-l).
  (h) Certifications of Policy Changes to Director.--
          (1) In general.--Subject to paragraph (2), the head 
        of a National Drug Control Program Agency shall, unless 
        exigent circumstances require otherwise, notify the 
        Director in writing regarding any proposed change in 
        policies relating to the activities of that agency 
        under the National Drug Control Program prior to 
        implementation of such change. The Director shall 
        promptly review such proposed change and certify to the 
        head of that agency in writing whether such change is 
        consistent with the National Drug Control Strategy.
          (2) Exception.--If prior notice of a proposed change 
        under paragraph (1) is not practicable--
                  (A) the head of the National Drug Control 
                Program Agency shall notify the Director of the 
                proposed change as soon as practicable; and
                  (B) upon such notification, the Director 
                shall review the change and certify to the head 
                of that agency in writing whether the change is 
                consistent with the National Drug Control 
                Strategy.
  (i) Work in Conjunction With Assistant for National Security 
Affairs.--The Director shall, in any matter affecting national 
security interests, work in conjunction with the Assistant to 
the President for National Security Affairs.

Sec. 1009. Emerging threats taskforce, plan, media campaign

  (a) Emerging Threats Task Force.--
          (1) Emerging and continuing threats coordinator.--The 
        Director shall designate or appoint a United States 
        Emerging and Continuing Threats Coordinator to perform 
        the duties of that position described in this section 
        and such other duties as may be determined by the 
        Director. The Director shall determine whether the 
        coordinator position is a career or noncareer position 
        in the Senior Executive Service.
          (2) Establishment and monitoring.--The Emerging and 
        Continuing Threats Coordinator (referred to in this 
        section as the ``Coordinator'') shall monitor evolving 
        and emerging drug threats in the United States and 
        shall serve as Chair of an Emerging Threats Task Force 
        (in this section, referred to as the ``task force''). 
        The Director shall appoint other members of the Task 
        force, which shall include representatives from--
                  (A) National Drug Control Program Agencies or 
                other agencies;
                  (B) State, local, and Tribal governments;
                  (C) the Director of the Fusion Center 
                established in section 1013; and
                  (D) other entities as determined to be 
                necessary by the Director.
          (3) Information review and sharing.--
                  (A) In general.--The task force shall 
                disseminate and facilitate the sharing with 
                Federal, State, local, and Tribal officials and 
                other entities as determined by the Director of 
                pertinent information and data relating to the 
                following:
                          (i) Recent trends in drug supply and 
                        demand.
                          (ii) Fatal and nonfatal overdoses.
                          (iii) Demand for and availability of 
                        evidence-based substance use disorder 
                        treatment, including the extent of the 
                        unmet treatment need, and treatment 
                        admission trends.
                          (iv) Recent trends in drug 
                        interdiction, supply, and demand from 
                        State, local, and Tribal law 
                        enforcement agencies.
                          (v) Other subject matter as 
                        determined necessary by the Director.
                  (B) Contract, agreement, and other 
                authority.--The Director may award contracts, 
                enter into interagency agreements, manage 
                individual projects, and conduct other 
                operational activities in support of the 
                identification of emerging threats and in 
                support of the development, implementation, and 
                assessment of Emerging Threat Response Plans.
                  (C) Data analysis activities.--In support of 
                the task force, the National Drug Control 
                Fusion Center is authorized to conduct and 
                provide to the task force the results of data 
                analysis activities that the task force 
                requests to aid in their review of recent 
                trends in the data disseminated under 
                subparagraph (A).
          (4) Criteria to identify emerging drug threats.--Not 
        later than 60 days after the date on which a task force 
        first meets, the task force shall develop and recommend 
        to the Director criteria to be used to identify an 
        emerging drug threat or the termination of an emerging 
        drug threat designation based on information gathered 
        by the task force in paragraph (2), statistical data, 
        and other evidence.
          (5) Meetings.--The task force shall meet in person 
        not less frequently than quarterly and at additional 
        meetings if determined to be necessary by and at the 
        call of the Chair to--
                  (A) identify and discuss evolving and 
                emerging drug trends in the United States using 
                the criteria established in paragraph (3);
                  (B) formulate the plan described in 
                subsection (c);
                  (C) oversee implementation of the plan 
                described in subsection (c); and
                  (D) provide such other advice to the 
                Coordinator and Director concerning strategy 
                and policies for emerging drug threats and 
                trends as the task force determines to be 
                appropriate.
  (b) Designation.--
          (1) In general.--The Director, in consultation with 
        the Coordinator, the task force, and the head of each 
        National Drug Control Program Agency, may designate an 
        emerging drug threat in the United States.
          (2) Standards for designation.--The Director, in 
        consultation with the Coordinator, shall promulgate and 
        make publicly available standards by which a 
        designation under paragraph (1) and the termination of 
        such designation may be made. In developing such 
        standards, the Director shall consider the 
        recommendations of the task force and other criteria 
        the Director considers to be appropriate.
          (3) Public statement required.--The Director shall 
        publish a public written statement on the portal of the 
        Office explaining the designation of an emerging drug 
        threat or the termination of such designation and shall 
        notify the appropriate congressional committees of the 
        availability of such statement when a designation or 
        termination of such designation has been made.
  (c) Plan.--
          (1) Public availability of plan.--Not later than 60 
        days after making a designation under subsection (b), 
        the Director shall publish and make publicly available 
        an Emerging Threat Response Plan and notify the 
        President and the appropriate congressional committees 
        of such plan's availability.
          (2) Timing.--Not less frequently than every 90 days 
        after the date on which the plan is published under 
        paragraph (1), the Director shall update the plan and 
        report on implementation of the plan, until the 
        Director issues the public statement required under 
        subsection (b)(3) to terminate the emerging threat 
        designation.
          (3) Contents of an emerging threat response plan.--
        The Director shall include in the plan--
                  (A) a comprehensive strategic assessment of 
                the emerging drug threat, including the current 
                availability of, demand for, and effectiveness 
                of evidence-based prevention, treatment, and 
                enforcement programs and efforts to respond to 
                the emerging drug threat;
                  (B) comprehensive, research-based, long-
                range, quantifiable goals for addressing the 
                emerging drug threat, including for reducing 
                the supply of the emerging drug threat and for 
                expanding the availability and effectiveness of 
                evidence-based substance use disorder treatment 
                and prevention programs to reduce the demand 
                for the emerging drug threat;
                  (C) performance measures pertaining to the 
                plan's goals, including quantifiable and 
                measurable objectives and specific targets;
                  (D) the level of funding needed to implement 
                the plan, including whether funding is 
                available to be reprogrammed or transferred to 
                support implementation of the plan or whether 
                additional appropriations are necessary to 
                implement the plan;
                  (E) an implementation strategy for the 
                education and public awareness campaign under 
                subsection (d), including goals as described 
                under subparagraph (B) and performance 
                measures, objectives, and targets, as described 
                under subparagraph (C); and
                  (F) any other information necessary to inform 
                the public of the status, progress, or response 
                of an emerging drug threat.
          (4) Implementation.--
                  (A) In general.--Not later than 90 days after 
                the date on which a designation is made under 
                subsection (b), the Director, in consultation 
                with the President, the appropriate 
                congressional committees, and the head of each 
                National Drug Control Program Agency, shall 
                issue guidance on implementation of the plan 
                described in subsection (c) to the National 
                Drug Control Program Agencies and any other 
                relevant agency determined to be necessary by 
                the Director.
                  (B) Coordinator's responsibilities.--The 
                Coordinator shall--
                          (i) direct the implementation of the 
                        plan among the agencies identified in 
                        the plan, State, local, and Tribal 
                        governments, and other relevant 
                        entities;
                          (ii) facilitate information-sharing 
                        between agencies identified in the 
                        plan, State, local, and Tribal 
                        governments, and other relevant 
                        entities; and
                          (iii) monitor implementation of the 
                        plan by coordinating the development 
                        and implementation of collection and 
                        reporting systems to support 
                        performance measurement and adherence 
                        to the plan by agencies identified in 
                        plan, where appropriate.
                  (C) Reporting.--Not later than 180 days after 
                designation under subsection (b) and in 
                accordance with paragraph (2)(C), the head of 
                each agency identified in the plan shall submit 
                to the Coordinator a report on implementation 
                of the plan.
  (d) Education and Public Awareness Campaign for Emerging Drug 
Threats.--
          (1) In general.--Not later than 90 days after a 
        designation under subsection (b), the Director shall 
        establish and implement an evidence-based substance use 
        prevention education and public awareness campaign to 
        inform the public about the dangers of any drug 
        designated as an emerging drug threat. Such campaign 
        shall--
                  (A) educate the public about the dangers of 
                such drug, including patient and family 
                education about the characteristics and hazards 
                of such drugs and methods to safeguard against 
                such dangers, including the safe disposal of 
                such drugs;
                  (B) support evidence-based prevention 
                programs targeting audiences' attitudes, 
                perceptions, and beliefs concerning substance 
                use and intentions to initiate or continue such 
                use;
                  (C) increase awareness of the negative 
                consequences of drug use;
                  (D) encourage individuals affected by 
                substance use disorders to seek treatment and 
                provide such individuals with information on 
                how to recognize addiction issues, what forms 
                of evidence-based treatment options are 
                available, and how to access such treatment; 
                and
                  (E) combat the stigma of addiction and 
                substance use disorders, including the stigma 
                of treating such disorders with medication-
                assisted treatment therapies.
          (2) Consultation.--For the planning of the campaign 
        under paragraph (1), the Secretary shall consult with--
                  (A) the head of any appropriate National Drug 
                Control Program Agency to obtain advice on 
                evidence-based scientific information for 
                policy, program development, and evaluation;
                  (B) experts in evidence-based media 
                campaigns, education, evaluation, and 
                communication;
                  (C) experts on the designated drug;
                  (D) State, local, and Tribal government 
                officials and relevant agencies;
                  (E) the public;
                  (F) appropriate congressional committees; and
                  (G) any other affected person.
          (3) Gifts and donations.--
                  (A) In general.--The Director may accept 
                gifts and donations (in cash or in kind, 
                including voluntary and uncompensated services 
                or property), which shall be available until 
                expended, for the purpose of supporting the 
                education and outreach campaign authorized in 
                this section, including the media campaign.
                  (B) Ethics guidelines.--The Director shall 
                establish written guidelines setting forth the 
                criteria to be used in determining whether a 
                gift or donation should be declined under this 
                section because the acceptance of the gift or 
                donation would--
                          (i) reflect unfavorably upon the 
                        ability of the Director or the Office, 
                        or any employee of the Office, to carry 
                        out responsibilities or official duties 
                        under this chapter in a fair and 
                        objective manner; or
                          (ii) compromise the integrity or the 
                        appearance of integrity of programs or 
                        services provided under this chapter or 
                        of any official involved in those 
                        programs or services.
                  (C) Annual report required.--Not later than 
                the first Monday in the February of each year, 
                the Director shall submit to the appropriate 
                congressional committees an annual report that 
                identifies the sources of any gift or donation 
                accepted by the Office or any contractor acting 
                on behalf of the Office, under this subsection, 
                including the value of each gift and donation 
                provided by each source of the gift.
          (4) Implementation.--
                  (A) In general.--For any campaign established 
                under this subsection, the Director shall 
                ensure the following:
                          (i) Implementation is evidence-based, 
                        meets accepted standards for public 
                        awareness campaigns, and uses available 
                        resources in a manner to make the most 
                        progress toward achieving the goals 
                        identified in the emerging threats plan 
                        and paragraph (1).
                          (ii) Information disseminated through 
                        the campaign is accurate.
                          (iii) The Director approves the 
                        strategy of the campaign, all material 
                        distributed through the campaign, and 
                        the use of any Federal funds used for 
                        the campaign.
                          (iv) The campaign is designed using 
                        strategies found to be most effective 
                        at achieving such goals, which may 
                        include--
                                  (I) a media campaign, as 
                                described in subparagraph (B);
                                  (II) local, regional, or 
                                population specific messaging;
                                  (III) establishing 
                                partnerships and promoting 
                                coordination among community 
                                stakeholders, including public, 
                                nonprofit organizations, and 
                                for profit entities;
                                  (IV) providing support, 
                                training, and technical 
                                assistance to establish and 
                                expand school and community 
                                prevention programs;
                                  (V) creating websites to 
                                publicize and disseminate 
                                information;
                                  (VI) conducting outreach and 
                                providing educational resources 
                                for parents;
                                  (VII) establishing State or 
                                regional advisory councils to 
                                provide input and 
                                recommendations to raise 
                                awareness regarding the drug 
                                designated as an emerging drug 
                                threat;
                                  (VIII) collaborating with law 
                                enforcement; and
                                  (IX) support for school-based 
                                public health education classes 
                                to improve teen knowledge about 
                                the effects of such designated 
                                drug.
                  (B) Media campaign.--Any campaign implemented 
                under this subsection may include a media 
                component, which--
                          (i) shall be designed to prevent the 
                        use of the drug designated as an 
                        emerging drug threat and to achieve the 
                        goals of paragraph (1);
                          (ii) shall be carried out through 
                        competitively awarded contracts to 
                        entities providing for the professional 
                        production and design of such campaign; 
                        and
                          (iii) may include the use of 
                        television, radio, Internet, social 
                        media, and other commercial marketing 
                        venues and may be targeted to specific 
                        age groups based on peer-reviewed 
                        social research.
                  (C) Required notice for communication from 
                the office.--Any communication, including an 
                advertisement, paid for or otherwise 
                disseminated by the Office directly or through 
                a contract awarded by the Office shall include 
                a prominent notice informing the audience that 
                the communication was a paid for by of the 
                Office.
          (5) Evaluation.--
                  (A) Performance evaluation.--The Director 
                shall include an evaluation of the campaign in 
                the annual assessment under section 1006, which 
                shall include the following:
                          (i) A performance evaluation of the 
                        campaign, including progress toward 
                        meeting the goals, objectives, 
                        measures, and targets identified in the 
                        emerging threats plan.
                          (ii) A description of all policies 
                        and practices to eliminate the 
                        potential for waste, fraud, abuse, and 
                        to ensure Federal funds are used 
                        responsibly.
                          (iii) A list of all contracts or 
                        other agreements entered into to 
                        implement the campaign.
                          (iv) The results of any financial 
                        audit of the campaign.
                          (v) A description of any evidence 
                        used to develop the campaign.
                  (B) Independent evaluation.--Not later than 
                180 days after establishing a campaign under 
                paragraph (1) and not less than frequently than 
                every two years thereafter, the Director 
                shall--
                          (i) designate an independent entity 
                        to evaluate the effectiveness of the 
                        campaign with meeting the goals 
                        established in the emerging threat plan 
                        and paragraph (1); and
                          (ii) submit the results of the 
                        independent evaluation to the 
                        appropriate congressional committees.
          (6) Funding prohibitions.--None of the amounts made 
        available under this subsection may be obligated for 
        any of the following:
                  (A) To supplant current anti-drug community-
                based coalitions.
                  (B) To supplant pro bono public service time 
                donated by national and local broadcasting 
                network for other public services campaigns.
                  (C) For partisan political purposes, or 
                express advocacy in support of or to defeat any 
                clearly identified candidate, clearly 
                identified ballot initiative, or clearly 
                identified legislative or regulatory proposal.
                  (D) For any advocacy in support of any 
                particular company, industry association, or 
                advocacy group or the explicit policy positions 
                held by such groups.
                  (E) To direct any individuals to a specific 
                type of substance use disorder treatment, 
                treatment facility, medical provider, or form 
                of medication assisted treatment.
                  (F) To fund any advertising that features any 
                elected officials, persons seeking elected 
                office, cabinet level officials, or other 
                Federal officials employed pursuant to section 
                213 of Schedule C of title 5, Code of Federal 
                Regulations.
  (e) Authorization of Appropriations.--There is authorized to 
be appropriated to the Office to carry out this section, 
$25,000,000 for each of fiscal years 2019 through 2023.

Sec. 1010. National and international coordination

  (a) Dissemination of Research and Information to States.--The 
Director shall ensure that drug control research and 
information is effectively disseminated by National Drug 
Control Program Agencies to State and local governments and 
nongovernmental entities involved in demand reduction by--
          (1) encouraging formal consultation between any such 
        agency that conducts or sponsors research, and any such 
        agency that disseminates information in developing 
        research and information product development agendas;
          (2) encouraging such agencies (as appropriate) to 
        develop and implement dissemination plans that 
        specifically target State and local governments and 
        nongovernmental entities involved in demand reduction; 
        and
          (3) supporting the substance abuse information 
        clearinghouse administered by the Administrator of the 
        Substance Abuse and Mental Health Services 
        Administration and established in section 501(d)(16) of 
        the Public Health Service Act by--
                  (A) encouraging all National Drug Control 
                Program Agencies to provide all appropriate and 
                relevant information; and
                  (B) supporting the dissemination of 
                information to all interested entities.
  (b) Standards.--
          (1) Development.--The Director shall coordinate the 
        development of evidence-based standards developed by 
        National Drug Control Program Agencies and other 
        relevant agencies and non-Federal entities to State, 
        local, and Tribal governments and nongovernmental 
        entities related to drug control policies, practices, 
        and procedures, such as the investigation of drug-
        related deaths, by--
                  (A) encouraging appropriate agencies and 
                State, local, and Tribal governments to develop 
                data standards for drug control practices and 
                procedures and related statistical data;
                  (B) encouraging information sharing between 
                appropriate agencies and State, local, and 
                Tribal governments of relevant drug control 
                information and data;
                  (C) establishing a working group of agencies, 
                State, local, and Tribal governments, and other 
                relevant stakeholders to discuss and develop 
                such standards; and
                  (D) facilitating collaboration among 
                agencies, non-Federal entities, States, local, 
                and Tribal governments, and nongovernmental 
                agencies.
          (2) Implementation.--The Director shall promote the 
        implementation of the standards described in paragraph 
        (1) by--
                  (A) encouraging adoption by providing the 
                standards to State and local governments 
                through the internet, annual publications or 
                periodicals, and other widely-disseminated 
                means; and
                  (B) facilitating the use and dissemination of 
                such standards among State and local 
                governments by--
                          (i) providing technical assistance to 
                        State, local, and Tribal governments 
                        seeking to adopt or implement such 
                        standards; and
                          (ii) coordinating seminars and 
                        training sessions for State, local, and 
                        Tribal governments seeking to adopt or 
                        implement such standards.
  (c) Private Sector.--
          (1) In general.--The Director or the head of a 
        National Drug Control Program (as designated by the 
        Director) shall coordinate with the private sector to 
        promote private research and development of medications 
        to treat or prevent addiction, including research and 
        development for non-addictive pain management 
        medication, abuse deterrent formulations, medication-
        assisted treatment, and other addiction research 
        determined to be necessary by the Director by--
                  (A) encouraging the sharing of information 
                regarding evidence-based treatment addiction 
                findings and related data between agencies and 
                the private sector, as appropriate;
                  (B) encouraging collaboration between 
                appropriate agencies and the private sector; 
                and
                  (C) providing private sector entities with 
                relevant statistical data and information to 
                enhance research as permissible.
          (2) Working group.--The Director may establish a 
        working group of National Drug Control Program 
        Agencies, State, local, and Tribal governments, and the 
        private sector stakeholders to discuss and disseminate 
        best practices, research and development, and other 
        related issues, as appropriate.
  (d) Model Acts Program.--
          (1) In general.--The Director shall provide for or 
        shall enter into an agreement with a nonprofit 
        organization to--
                  (A) advise States on establishing laws and 
                policies to address illicit drug use issues; 
                and
                  (B) revise such model State drug laws and 
                draft supplementary model State laws to take 
                into consideration changes in illicit drug use 
                issues in the State involved.
          (2) Authorization of appropriations.--There is 
        authorized to be appropriated to carry out this 
        subsection $1,250,000 for each of fiscal years 2019 
        through 2023.
  (e) Drug Court Training and Technical Assistance Program.--
          (1) Grants authorized.--The Director may make a grant 
        to a nonprofit organization for the purpose of 
        providing training and technical assistance to drug 
        courts.
          (2) Authorization of appropriations.--There is 
        authorized to be appropriated to carry out this 
        subsection $2,000,000 for each of fiscal years 2019 
        through 2023.
  (f) International Coordination.--The Director shall 
facilitate international drug control coordination efforts.
  (g) State, Local, and Tribal Affairs Coordinator.--The 
Director shall designate or appoint a United States State, 
Local, and Tribal Affairs Coordinator to perform the duties of 
the Office outlined in this section and section 1005 and such 
other duties as may be determined by the Director with respect 
to coordination of drug control efforts between agencies and 
State, local, and Tribal governments. The Director shall 
determine whether the coordinator position is a career or 
noncareer position in the Senior Executive Service.

Sec. 1011. Interdiction

  (a) United States Interdiction Coordinator.--
          (1) In general.--The Director shall designate or 
        appoint a United States Interdiction Coordinator to 
        perform the duties of that position described in 
        paragraph (2) and such other duties as may be 
        determined by the Director with respect to coordination 
        of efforts to interdict illicit drugs from entering the 
        United States.
          (2) Responsibilities.--The United States Interdiction 
        Coordinator shall be responsible to the Director for--
                  (A) coordinating the interdiction activities 
                of the National Drug Control Program Agencies 
                to ensure consistency with the National Drug 
                Control Strategy;
                  (B) on behalf of the Director, developing and 
                issuing, on or before March 1 of each year and 
                in accordance with paragraph (4), a National 
                Interdiction Command and Control Plan to ensure 
                the coordination and consistency described in 
                subparagraph (A);
                  (C) assessing the sufficiency of assets 
                committed to illicit drug interdiction by the 
                relevant National Drug Control Program 
                Agencies; and
                  (D) advising the Director on the efforts of 
                each National Drug Control Program Agency to 
                implement the National Interdiction Command and 
                Control Plan.
          (3) Staff.--The Director shall assign such permanent 
        staff of the Office as he considers appropriate to 
        assist the United States Interdiction Coordinator to 
        carry out the responsibilities described in paragraph 
        (2), and may request that appropriate National Drug 
        Control Program Agencies detail or assign staff to 
        assist in carrying out such activities.
          (4) National interdiction command and control plan.--
                  (A) Purposes.--The National Interdiction 
                Command and Control Plan--
                          (i) shall set forth the Government's 
                        strategy for drug interdiction;
                          (ii) shall state the specific roles 
                        and responsibilities of the relevant 
                        National Drug Control Program Agencies 
                        for implementing that strategy;
                          (iii) shall identify the specific 
                        resources required to enable the 
                        relevant National Drug Control Program 
                        Agencies to implement that strategy; 
                        and
                          (iv) may include recommendations 
                        about changes to existing agency 
                        authorities or laws governing 
                        interagency relationships.
                  (B) Consultation with other agencies.--Before 
                the submission of the National Drug Control 
                Strategy or annual supplement required under 
                section 1005(d), as applicable, the United 
                States Interdiction Coordinator shall issue the 
                National Interdiction Command and Control Plan, 
                in consultation with the other members of the 
                Interdiction Committee described in subsection 
                (c).
                  (C) Report to congress.--On or before March 1 
                of each year, the Director, through the United 
                States Interdiction Coordinator, shall provide 
                to the appropriate congressional committees, to 
                the Committee on Armed Services and the 
                Committee on Homeland Security of the House of 
                Representatives, and to the Committee on 
                Homeland Security and Governmental Affairs and 
                the Committee on Armed Services of the Senate, 
                a report that includes--
                          (i) a copy of that year's National 
                        Interdiction Command and Control Plan;
                          (ii) information for the previous 10 
                        years regarding the number and type of 
                        seizures of drugs by each National Drug 
                        Control Program Agency conducting drug 
                        interdiction activities and statistical 
                        information on the geographic areas of 
                        such seizures; and
                          (iii) information for the previous 10 
                        years regarding the number of air and 
                        maritime patrol hours undertaken by 
                        each National Drug Control Program 
                        Agency conducting drug interdiction 
                        activities and statistical information 
                        on the geographic areas in which such 
                        patrol hours took place.
                  (D) Classified annex.--The report submitted 
                pursuant to subparagraph (C) may include a 
                classified annex.
  (b) Interdiction Committee.--
          (1) In general.--The Interdiction Committee shall 
        meet to--
                  (A) discuss and resolve issues related to the 
                coordination, oversight, and integration of 
                international, border, and domestic drug 
                interdiction efforts in support of the National 
                Drug Control Strategy;
                  (B) review the annual National Interdiction 
                Command and Control Plan, and provide advice to 
                the Director and the United States Interdiction 
                Coordinator concerning that plan; and
                  (C) provide such other advice to the Director 
                concerning drug interdiction strategy and 
                policies as the committee determines is 
                appropriate.
          (2) Chair.--The Director shall designate one of the 
        members of the Interdiction Committee to serve as 
        chair.
          (3) Meetings.--The members of the Interdiction 
        Committee shall meet, in person and not through any 
        delegate or representative, at least once per calendar 
        year, before March 1. At the call of the Director or 
        the chair, the Interdiction Committee may hold 
        additional meetings, which shall be attended by the 
        members in person, or through such delegates or 
        representatives as the members may choose.
          (4) Report.--Not later than September 30 of each 
        year, the chair of the Interdiction Committee shall 
        submit to the Director and to the appropriate 
        congressional committees a report describing the 
        results of the meetings and any significant findings of 
        the committee during the previous 12 months. Such 
        report may include a classified annex.

Sec. 1012. Treatment coordinator

  (a) United States Treatment Coordinator.--
          (1) In general.--The Director shall designate or 
        appoint a United States Treatment Coordinator to 
        perform the responsibilities of that position described 
        in paragraph (2) and such other duties as may be 
        determined by the Director with respect to coordination 
        of efforts to expand the availability of substance use 
        disorder treatment with the goal of eliminating the 
        unmet treatment need.
          (2) Responsibilities.--The United States Treatment 
        Coordinator shall be responsible to the Director for--
                  (A) coordinating the activities of the 
                National Drug Control Program Agencies 
                undertaken to expand the availability of 
                evidence-based substance use disorder treatment 
                to ensure consistency with the National Drug 
                Control Strategy;
                  (B) on behalf of the Director, developing and 
                issuing, on or before March 1 of each year and 
                in accordance with paragraph (4), a National 
                Treatment Plan to ensure the coordination and 
                consistency described in subparagraph (A);
                  (C) assessing the sufficiency of Federal 
                resources directed to substance use disorder 
                treatment by the relevant National Drug Control 
                Program Agencies;
                  (D) encouraging the adoption by all substance 
                use disorder treatment providers of evidence-
                based standards to guide all aspects of 
                treatment provided; and
                  (E) advising the Director on the efforts of 
                each National Drug Control Program Agency to 
                implement the National Treatment Plan.
          (3) Staff.--The Director shall assign such permanent 
        staff of the Office of the United States Treatment 
        Coordinator as the Director determines to be 
        appropriate to assist the United States Treatment 
        Coordinator to carry out the responsibilities described 
        in paragraph (2), and may request that appropriate 
        National Drug Control Program Agencies detail or assign 
        staff to assist in carrying out such responsibilities.
          (4) National treatment plan.--
                  (A) Purposes.--The National Treatment Plan--
                          (i) shall identify the unmet need for 
                        treatment for evidence-based substance 
                        use disorders including opioid use 
                        disorders, and set forth the 
                        Government's strategy for closing the 
                        gap between available and needed 
                        treatment through all sources;
                          (ii) shall describe the specific 
                        roles and responsibilities of the 
                        relevant National Drug Control Program 
                        Agencies for implementing that 
                        strategy;
                          (iii) shall identify the specific 
                        resources required to enable the 
                        relevant National Drug Control Program 
                        Agencies to implement that strategy;
                          (iv) shall identify the resources, 
                        including private sources, required to 
                        eliminate the unmet need for evidence-
                        based substance use disorder treatment; 
                        and
                          (v) may include recommendations about 
                        changes to existing agency authorities 
                        or laws governing interagency 
                        relationships.
                  (B) Consultation with other agencies.--Before 
                the submission of the National Treatment 
                Strategy or annual supplement required under 
                section 1005(d), as applicable, the United 
                States Treatment Coordinator shall issue the 
                National Treatment Plan, in consultation with 
                the other members of the Interdiction Committee 
                described in subsection (b).
                  (C) Report to congress.--On or before March 1 
                of each year, the Director, through the United 
                States Treatment Coordinator, shall provide to 
                the appropriate congressional committees a 
                report that includes a copy of that year's 
                National Treatment Plan;
  (b) Treatment Committee.--
          (1) In general.--The Treatment Committee shall meet 
        to--
                  (A) review and discuss the adequacy of 
                evidence-based substance use disorder treatment 
                as well as the unmet need for treatment;
                  (B) review and discuss the status of the 
                implementation of the National Treatment Plan; 
                and
                  (C) provide such other advice to the Director 
                concerning substance use disorder treatment 
                initiatives as the committee determines is 
                appropriate.
          (2) Chair.--The Director shall designate one of the 
        members of the Treatment Committee to serve as chair.
          (3) Meetings.--The members of the Treatment Committee 
        shall meet, in person and not through any delegate or 
        representative, at least once per calendar year, before 
        March 1. At the call of the Director or the chair, the 
        Treatment Committee may hold additional meetings, which 
        shall be attended by the members in person, or through 
        such delegates or representatives as the members may 
        choose.
          (4) Report.--Not later than September 30 of each 
        year, the chair of the Treatment Committee shall submit 
        to the Director and to the appropriate congressional 
        committees a report describing the results of the 
        meetings and any significant findings of the committee 
        during the previous 12 months. Such report may include 
        a classified annex.

Sec. 1013. Critical information coordination

  (a) National Drug Control Fusion Center.--
          (1) Establishment.--The Director shall, in 
        consultation with the head of each National Drug 
        Control Program Agency, designate an agency to 
        establish a National Drug Control Fusion Center 
        (referred to in this section as the ``Center''). The 
        Center shall operate under the authority of the 
        Director and shall work with the National Drug Control 
        Program Agencies to collect, compile, analyze, and 
        facilitate the sharing of data on the use of illicit 
        drugs, treatment for substance use disorder, and 
        interdiction of illicit drugs. The Center shall be 
        considered a ``statistical agency or unit'', as that 
        term is defined in section 502 of the Confidential 
        Information Protection and Statistical Efficiency Act 
        of 2002 (44 U.S.C. 3501 note) and shall have the 
        necessary independence to ensure any data or 
        information acquired by an agency under a pledge of 
        confidentiality and for exclusively statistical 
        purposes is used exclusively for statistical purposes.
          (2) Center director.--There shall be at the head of 
        the Center a Center Director who shall be appointed by 
        the Director from among individuals qualified and 
        distinguished in data governance and statistical 
        analysis.
          (3) Data compilation.--The Director, acting through 
        the Center Director, shall do the following:
                  (A) Coordinate data collection activities 
                among the National Drug Control Program 
                Agencies.
                  (B) Collect information not otherwise 
                collected by National Drug Control Program 
                Agencies as necessary to inform the National 
                Drug Control Strategy.
                  (C) Compile and analyze any data required to 
                be collected under this chapter.
                  (D) Disseminate technology, as appropriate, 
                to States and local jurisdictions to enable or 
                improve the collection of data on drug use, 
                including the recordation of the occurrence of 
                fatal and non-fatal drug overdoses.
                  (E) Compile information collected by National 
                Drug Control Program Agencies on grants issued 
                through any National Drug Control Program, 
                including for any grant the following:
                          (i) The recipient.
                          (ii) The amount.
                          (iii) The intended purpose.
                          (iv) Any evidence of the efficacy of 
                        the outcomes achieved by the program 
                        funded through the grant.
                          (v) Any assessments of how the grant 
                        met its intended purpose.
          (4) Toxicology screening.--
                  (A) Establishment.--The Center Director may 
                establish a toxicology screening program that 
                engages in--
                          (i) secondary analysis of urine 
                        samples that would otherwise be 
                        discarded by--
                                  (I) hospitals and drug 
                                treatment programs;
                                  (II) correctional facilities, 
                                booking sites, probation 
                                programs, drug courts, and 
                                related facilities; and
                                  (III) coroners and medical 
                                examiners; and
                          (ii) analysis of other physical 
                        samples, as determined by the Center 
                        Director to be valuable for 
                        understanding the prevalence of any 
                        illicit drug.
                  (B) De-identification of information.--The 
                Center Director shall ensure that no samples 
                have any personally identifiable information 
                prior to collection.
                  (C) Limitation on use.--No data obtained from 
                analysis conducted under this paragraph may be 
                used as evidence in any proceeding.
                  (D) State program.--The Center Director may 
                establish a program that enables States and 
                local jurisdictions to submit up to 20 urine 
                samples per year for toxicology analysis for 
                the purposes of identifying substances present 
                in individuals who have suffered fatal drug 
                overdoses.
          (5) Authority to contract.--The Director may award 
        contracts, enter into interagency agreements, manage 
        individual projects, and conduct other operational 
        activities under this subsection.
  (b) Critical Drug Control Information and Evidence Plan.--
          (1) In general.--Not later than the first Monday in 
        February of each year, the Director shall submit to 
        Congress a systematic plan for increasing data 
        collection to enable real-time surveillance of drug 
        control threats, developing analysis and monitoring 
        capabilities, and identifying and addressing policy 
        questions relevant to the National Drug Control Policy, 
        Strategy, and Program. Such plan shall be made 
        available on the public online portal of the Office, 
        shall cover at least a 4-year period beginning with the 
        first fiscal year following the fiscal year in which 
        the plan is submitted and published, and contain the 
        following:
                  (A) A list of policy-relevant questions for 
                which the Director and each National Drug 
                Control Program Agency intends to develop 
                evidence to support the National Drug Control 
                Program and Strategy.
                  (B) A list of data the Director and each 
                National Drug Control Program Agency intends to 
                collect, use, or acquire to facilitate the use 
                of evidence in drug control policymaking and 
                monitoring.
                  (C) A list of methods and analytical 
                approaches that may be used to develop evidence 
                to support the National Drug Control Program 
                and Strategy and related policy.
                  (D) A list of any challenges to developing 
                evidence to support policymaking, including any 
                barriers to accessing, collecting, or using 
                relevant data.
                  (E) A description of the steps the Director 
                and the head of each National Drug Control 
                Program Agency will take to effectuate the 
                plan.
                  (F) Any other relevant information as 
                determined by the Director.
          (2) Consultation.--In developing the plan required 
        under paragraph (1), the Director shall consult with 
        the following:
                  (A) The public.
                  (B) Any evaluation or analysis units and 
                personnel of the Office.
                  (C) Office officials responsible for 
                implementing privacy policy.
                  (D) Office officials responsible for data 
                governance.
                  (E) The appropriate congressional committees.
                  (F) Any other individual or entity as 
                determined by the Director.
  (c) Evidence-based Policy.--
          (1) Harm reduction programs.--When developing the 
        national drug control policy, any policy of the 
        Director, including policies relating to syringe 
        exchange programs for intravenous drug users, shall be 
        based on the best available medical and scientific 
        evidence regarding the effectiveness of such policy in 
        promoting individual health, preventing the spread of 
        infectious disease and the impact of such policy on 
        drug addiction and use. In making any policy relating 
        to harm reduction programs, the Director shall consult 
        with the National Institutes of Health and the National 
        Academy of Sciences.
          (2) Fund restriction for the legalization of 
        controlled substances.--The Director shall ensure that 
        no Federal funds appropriated to the Office shall be 
        expended for any study or contract relating to the 
        legalization (for a medical use or any other use) for 
        which a listing in schedule I is in effect under 
        section 202 of the Controlled Substances Act (21 U.S.C. 
        812).
  (d) Drug Control Data Dashboard.--
          (1) Establishment.--The Director, in consultation 
        with the Center Director, shall establish and maintain 
        a data dashboard on the online portal of the Office to 
        be known as the ``Drug Control Data Dashboard''. The 
        Director shall ensure the user interface of the 
        dashboard is constructed with modern design standards. 
        To the extent practicable, the data made available on 
        the dashboard shall be publicly available in a machine-
        readable format and searchable by year, agency, drug, 
        and location.
          (2) Data.--The data included in the Drug Control Data 
        Dashboard shall be updated not less frequently than 
        quarterly and shall include, at a minimum, the 
        following:
                  (A) For each substance identified under 
                section 1005(c)(1)(A)(i)--
                          (i) the total amount seized and 
                        disrupted in the calendar year and each 
                        of the previous 3 calendar years;
                          (ii) the known and estimated flows 
                        into the United States from all sources 
                        in the calendar year and each of the 
                        previous 3 calendar years;
                          (iii) the total amount of known flows 
                        that could not be interdicted or 
                        disrupted in the calendar year and each 
                        of the previous 3 calendar years;
                          (iv) the known and estimated levels 
                        of domestic production in the calendar 
                        year and each of the previous three 
                        calendar years, including the levels of 
                        domestic production if the drug is a 
                        prescription drug, as determined under 
                        the Federal Food, Drug, and Cosmetic 
                        Act, for which a listing is in effect 
                        under section 202 of the Controlled 
                        Substances Act (21 U.S.C. 812); and
                          (v) the average street price for the 
                        calendar year and the highest known 
                        street price during the preceding 10-
                        year period.
                  (B) For the calendar year and each of the 
                previous three years data sufficient to show, 
                disaggregated by State and, to the extent 
                feasible, by region within a State, county, or 
                city, the following:
                          (i) The number of fatal and non-fatal 
                        overdoses caused by each drug 
                        identified under subparagraph (A)(i).
                          (ii) The prevalence of substance use 
                        disorders.
                          (iii) The number of individuals who 
                        have received substance use disorder 
                        treatment, including medication 
                        assisted treatment, for a substance use 
                        disorder, including treatment provided 
                        through publicly-financed health care 
                        programs.
                          (iv) The extent of the unmet need for 
                        substance use disorder treatment, 
                        including the unmet need for 
                        medication-assisted treatment.
                  (C) Data sufficient to show the extent of 
                prescription drug diversion, trafficking, and 
                misuse in the calendar year and each of the 
                previous 3 calendar years.
                  (D) Any quantifiable measures the Director 
                determines to be appropriate to detail progress 
                toward the achievement of the goals of the 
                National Drug Control Strategy.
  (e) Access to Information.--
          (1) In general.--Upon the request of the Director, 
        the head of any National Drug Control Program Agency 
        shall cooperate with and provide to the Director any 
        statistics, studies, reports, and other information 
        prepared or collected by the agency concerning the 
        responsibilities of the agency under the National Drug 
        Control Strategy that relate to--
                  (A) drug control; or
                  (B) the manner in which amounts made 
                available to that agency for drug control are 
                being used by that agency.
          (2) Protection of intelligence information.--
                  (A) In general.--The authorities conferred on 
                the Office and the Director by this chapter 
                shall be exercised in a manner consistent with 
                provisions of the National Security Act of 1947 
                (50 U.S.C. 401 et seq.). The Director of 
                National Intelligence shall prescribe such 
                regulations as may be necessary to protect 
                information provided pursuant to this chapter 
                regarding intelligence sources and methods.
                  (B) Duties of director.--The Director of 
                National Intelligence and the Director of the 
                Central Intelligence Agency shall, to the 
                maximum extent practicable in accordance with 
                subparagraph (A), render full assistance and 
                support to the Office and the Director.
          (3) Required reports from national drug control 
        agencies.--The head of each National Drug Control 
        Program Agency shall submit to the Director such 
        information and reports as requested from such National 
        Drug Control Program Agency by the Director, which 
        shall include from the appropriate National Drug 
        Control Program Agencies:
                  (A) Not later than July 1 of each year, the 
                head of a designated National Drug Control 
                Program Agency shall submit to the Director and 
                the appropriate congressional committees an 
                assessment of the quantity of illegal drug 
                cultivation and manufacturing in the United 
                States on lands owned or under the jurisdiction 
                of their respective agencies that was seized or 
                eradicated by their personnel during the 
                preceding calendar year.
                  (B) Not later than July 1 of each year, the 
                head of a designated National Drug Control 
                Program Agency shall submit to the Director and 
                the appropriate congressional committees 
                information for the preceding year regarding--
                          (i) the number and type of seizures 
                        of drugs by each component of the 
                        agency seizing drugs, as well as 
                        statistical information on the 
                        geographic areas of such seizures; and
                          (ii) the number of air and maritime 
                        patrol hours primarily dedicated to 
                        drug supply reduction missions 
                        undertaken by each component of the 
                        agency.
                  (C) Not later than July 1 of each year, the 
                head of a designated National Drug Control 
                Program Agency shall submit to the Director and 
                the appropriate congressional committees 
                information for the preceding year regarding 
                the number of air and maritime patrol hours 
                primarily dedicated to drug supply reduction 
                missions undertaken by each component of the 
                agency.
                  (D) Not later than July 1 of each year, the 
                head of a designated National Drug Control 
                Program Agency shall submit to the Director and 
                the appropriate congressional committees 
                information for the preceding year regarding 
                the number and type of--
                          (i) arrests for drug violations;
                          (ii) prosecutions for drug violations 
                        by United States Attorneys; and
                          (iii) seizures of drugs by each 
                        component of the Department of Justice 
                        seizing drugs, as well as statistical 
                        information on the geographic areas of 
                        such seizures.
  (f) Data Exchange Standards for Improved Interoperability.--
          (1) Interagency and intergovernmental designation and 
        use of data exchange standards working group.--The 
        Director shall establish a working group of National 
        Drug Control Program Agencies, State, local and Tribal 
        government health and law enforcement agencies, and 
        data governance experts to develop consensus data 
        exchange standards for necessary categories of 
        information that allow effective electronic exchange of 
        information between States, between State agencies, 
        between States and National Drug Control Program 
        Agencies, and any other drug control relevant data 
        exchange.
          (2) Data exchange standards must be nonproprietary 
        and interoperable.--The data exchange standards 
        designated under paragraph (1) shall, to the extent 
        practicable, be nonproprietary and interoperable.
          (3) Other requirements.--In designating data exchange 
        standards under this subsection, the working group 
        shall, to the extent practicable, incorporate--
                  (A) interoperable standards developed and 
                maintained by an international voluntary 
                consensus standards body, as defined by the 
                Office of Management and Budget;
                  (B) interoperable standards developed and 
                maintained by intergovernmental partnerships; 
                and
                  (C) interoperable standards developed and 
                maintained by Federal entities with authority 
                over contracting and financial assistance.
          (4) Data exchange standards for federal reporting.--
                  (A) Designation.--The Director may, in 
                consultation with the working group established 
                under this section, National Drug Control 
                Program Agencies, and State, local, and Tribal 
                governments, designate data exchange standards 
                to govern Federal reporting and exchange 
                requirements for National Drug Control 
                Programs, as appropriate.
                  (B) Requirements.--The data exchange 
                reporting standards required by subparagraph 
                (A) shall, to the extent practicable--
                          (i) incorporate a widely accepted, 
                        nonproprietary, searchable, machine-
                        readable format;
                          (ii) be consistent with and implement 
                        applicable accounting principles;
                          (iii) be implemented in a manner that 
                        is cost-effective and improves program 
                        efficiency and effectiveness; and
                          (iv) be capable of being continually 
                        upgraded as necessary.
                  (C) Incorporation of nonproprietary 
                standards.--In designating data exchange 
                standards under this paragraph, the Director 
                shall, to the extent practicable, incorporate 
                existing nonproprietary standards.
                  (D) Rule of construction.--Nothing in this 
                paragraph shall be construed to require a 
                change to existing data exchange standards for 
                Federal reporting about a program referred to 
                in this section, if the head of the agency 
                responsible for administering the program finds 
                the standards to be effective and efficient.
          (5) Termination.--The working group established under 
        paragraph (1) shall terminate not earlier than 60 days 
        after the public notification of termination by the 
        Director.
  (g) Annual Data Collection and Dissemination Requirements.--
          (1) In general.--The Director shall collect and 
        disseminate, as appropriate, such information as the 
        Director determines is appropriate, but not less than 
        the information described in this subsection. To the 
        extent practicable, the data shall be publicly 
        available in a machine-readable format on the Drug 
        Control Data Dashboard, be searchable by year, agency, 
        drug, and location, and cover not less than the 
        previous 10-year period.
          (2) Preparation and dissemination of information.--
        The Director shall prepare and disseminate the 
        following:
                  (A) An assessment of current illicit drug use 
                (including inhalants and steroids) and 
                availability, impact of illicit drug use, and 
                treatment availability, which assessment shall 
                include--
                          (i) estimates of drug prevalence and 
                        frequency of use as measured by 
                        national, State, and local surveys of 
                        illicit drug use and by other special 
                        studies of nondependent and dependent 
                        illicit drug use;
                          (ii) illicit drug use in the 
                        workplace and the productivity lost by 
                        such use; and
                          (iii) illicit drug use by arrestees, 
                        probationers, and parolees.
                  (B) An assessment of the reduction of illicit 
                drug availability, for each drug identified 
                under section 1005(c)(1)(A)(i), as measured 
                by--
                          (i) the quantities of such drug 
                        available for consumption in the United 
                        States;
                          (ii) the amount of such drug entering 
                        the United States;
                          (iii) the number of illicit drug 
                        manufacturing laboratories seized and 
                        destroyed of each relevant drug and the 
                        number of hectares cultivated and 
                        destroyed domestically and in other 
                        countries of each relevant drug;
                          (iv) the number of metric tons of 
                        such drug seized; and
                          (v) changes in the price and purity 
                        of such drug.
                  (C) An assessment of the reduction of the 
                consequences of illicit drug use and 
                availability, which shall include--
                          (i) the cost of treating substance 
                        use disorder in the United States, such 
                        as the quantity of illicit drug-related 
                        services provided;
                          (ii) the annual national health care 
                        cost of illicit drug use; and
                          (iii) the extent of illicit drug-
                        related crime and criminal activity.
                  (D) A determination of the status of drug 
                treatment in the United States, by assessing--
                          (i) public and private treatment 
                        utilization; and
                          (ii) the number of illicit drug users 
                        the Director estimates meet diagnostic 
                        criteria for treatment.
                  (E) A summary of the efforts made to 
                coordinate with private sector entities to 
                conduct private research and development of 
                medications to treat addiction by--
                          (i) screening chemicals for potential 
                        therapeutic value;
                          (ii) developing promising compounds;
                          (iii) conducting clinical trials;
                          (iv) seeking Food and Drug 
                        Administration approval for drugs to 
                        treat addiction;
                          (v) marketing the drug for the 
                        treatment of addiction;
                          (vi) urging physicians to use the 
                        drug in the treatment of addiction; and
                          (vii) encouraging insurance companies 
                        to reimburse the cost of the drug for 
                        the treatment of addiction.

Sec. 1014. Annual audit and investigation requirements

  (a) Periodic Government Accountability Office Audits of 
Programs and Operations.--Not later than December 31, 2019, and 
every 3 years thereafter, the Comptroller General shall--
          (1) conduct and supervise an audit and investigation 
        relating to the programs and operations of--
                  (A) the Office; or
                  (B) certain programs within the Office, 
                including--
                          (i) the High Intensity Drug 
                        Trafficking Areas Program; and
                          (iii) the media campaign under 
                        section 1009(d); and
          (2) submit to the Director and the appropriate 
        congressional committees a report containing an 
        evaluation of and recommendations on the--
                  (A) policies and activities of the programs 
                and operations subject to the audit and 
                investigation;
                  (B) economy, efficiency, and effectiveness in 
                the administration of the reviewed programs and 
                operations; and
                  (C) policy or management changes needed to 
                prevent and detect fraud and abuse in such 
                programs and operations.

Sec. 1015. Authorization of appropriations

  There are authorized to be appropriated to carry out this 
chapter, except as otherwise specified, to remain available 
until expended, $18,400,000 for each of fiscal years 2019 
through 2023.

      SUBCHAPTER II--HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM

Sec. 1021. High intensity drug trafficking areas program

  (a) Establishment.--
          (1) In general.--There is established in the Office a 
        program to be known as the High Intensity Drug 
        Trafficking Areas Program (in this section referred to 
        as the ``Program'').
          (2) Purpose.--The purpose of the Program is to reduce 
        drug trafficking and drug production in the United 
        States by--
                  (A) facilitating cooperation among Federal, 
                State, local, and Tribal law enforcement 
                agencies to share information and implement 
                coordinated enforcement activities;
                  (B) enhancing law enforcement intelligence 
                sharing among Federal, State, local, and Tribal 
                law enforcement agencies;
                  (C) providing reliable law enforcement 
                intelligence to law enforcement agencies needed 
                to design effective enforcement strategies and 
                operations; and
                  (D) supporting coordinated law enforcement 
                strategies which maximize use of available 
                resources to reduce the supply of illegal drugs 
                in designated areas and in the United States as 
                a whole.
  (b) Designation.--
          (1) In general.--The Director, in consultation with 
        the Attorney General, the Secretary of the Treasury, 
        the Secretary of Homeland Security, heads of the 
        National Drug Control Program Agencies, and the 
        Governor of each applicable State, may designate any 
        specified area of the United States as a high intensity 
        drug trafficking area.
          (2) Activities.--After making a designation under 
        paragraph (1) and in order to provide Federal 
        assistance to the area so designated, the Director 
        may--
                  (A) obligate such sums as are appropriated 
                for the Program;
                  (B) direct the temporary reassignment of 
                Federal personnel to such area, subject to the 
                approval of the head of the agency that employs 
                such personnel;
                  (C) take any other action authorized under 
                this chapter to provide increased Federal 
                assistance to those areas; and
                  (D) coordinate activities under this section 
                (specifically administrative, recordkeeping, 
                and funds management activities) with State, 
                local, and Tribal officials.
  (c) Petitions for Designation.--The Director shall establish 
and maintain regulations under which a coalition of interested 
law enforcement agencies from an area may petition for 
designation as a high intensity drug trafficking area (in this 
section referred to as the ``HIDTA''). Such regulations shall 
provide for a regular review by the Director of the petition, 
including a recommendation regarding the merit of the petition 
to the Director by a panel of qualified, independent experts.
  (d) Factors for Consideration.--In considering whether to 
designate an area under this section as a high intensity drug 
trafficking area, the Director shall consider, in addition to 
such other criteria as the Director considers to be 
appropriate, the extent to which--
          (1) the area is a significant center of illegal drug 
        production, manufacturing, importation, or 
        distribution;
          (2) State, local, and Tribal law enforcement agencies 
        have committed resources to respond to the drug 
        trafficking problem in the area, thereby indicating a 
        determination to respond aggressively to the problem;
          (3) drug-related activities in the area are having a 
        significant harmful impact in the area, and in other 
        areas of the country; and
          (4) a significant increase in allocation of Federal 
        resources is necessary to respond adequately to drug-
        related activities in the area.
  (e) Organization of High Intensity Drug Trafficking Areas.--
          (1) Executive board and officers.--To be eligible for 
        funds appropriated under this section, each high 
        intensity drug trafficking area shall be governed by an 
        Executive Board. The Executive Board shall designate a 
        chairman, vice chairman, and any other officers to the 
        Executive Board that it determines are necessary.
          (2) Responsibilities.--The Executive Board of a high 
        intensity drug trafficking area shall be responsible 
        for--
                  (A) providing direction and oversight in 
                establishing and achieving the goals of the 
                high intensity drug trafficking area;
                  (B) managing the funds of the high intensity 
                drug trafficking area;
                  (C) reviewing and approving all funding 
                proposals consistent with the overall objective 
                of the high intensity drug trafficking area; 
                and
                  (D) reviewing and approving all reports to 
                the Director on the activities of the high 
                intensity drug trafficking area.
          (3) Board representation.--None of the funds 
        appropriated under this section may be expended for any 
        high intensity drug trafficking area, or for a 
        partnership or region of a high intensity drug 
        trafficking area, if the Executive Board for such area, 
        region, or partnership, does not apportion an equal 
        number of votes between representatives of 
        participating agencies and representatives of 
        participating State, local, and Tribal agencies. Where 
        it is impractical for an equal number of 
        representatives of agencies and State, local, and 
        Tribal agencies to attend a meeting of an Executive 
        Board in person, the Executive Board may use a system 
        of proxy votes or weighted votes to achieve the voting 
        balance required by this paragraph.
          (4) No agency relationship.--The eligibility 
        requirements of this section are intended to ensure the 
        responsible use of Federal funds. Nothing in this 
        section is intended to create an agency relationship 
        between individual high intensity drug trafficking 
        areas and the Federal Government.
  (f) Use of Funds.--The Director shall ensure that not more 
than 5 percent of Federal funds appropriated for the Program 
are expended for drug treatment programs and not more than 5 
percent of the Federal funds appropriated for the Program are 
expended for drug prevention programs.
  (g) Counterterrorism Activities.--
          (1) Assistance authorized.--The Director may 
        authorize use of resources available for the Program to 
        assist Federal, State, local, and Tribal law 
        enforcement agencies in investigations and activities 
        related to terrorism and prevention of terrorism, 
        especially but not exclusively with respect to such 
        investigations and activities that are also related to 
        drug trafficking.
          (2) Limitation.--The Director shall ensure--
                  (A) that assistance provided under paragraph 
                (1) remains incidental to the purpose of the 
                Program to reduce drug availability and carry 
                out drug-related law enforcement activities; 
                and
                  (B) that significant resources of the Program 
                are not redirected to activities exclusively 
                related to terrorism, except on a temporary 
                basis under extraordinary circumstances, as 
                determined by the Director.
  (h) Role of Drug Enforcement Administration.--The Director, 
in consultation with the Attorney General, shall ensure that a 
representative of the Drug Enforcement Administration is 
included in the Intelligence Support Center for each high 
intensity drug trafficking area.
  (i) Emerging Threat Response Fund.--
          (1) In general.--Subject to the availability of 
        appropriations, the Director may expend up to 10 
        percent of the amounts appropriated under this section 
        on a discretionary basis, in accordance with the 
        criteria established under paragraph (2)--
                  (A) to respond to any emerging drug 
                trafficking threat in an existing high 
                intensity drug trafficking area;
                  (B) to establish a new high intensity drug 
                trafficking area; or
                  (C) to expand an existing high intensity drug 
                trafficking area.
          (2) Consideration of impact.--In allocating funds 
        under this subsection, the Director shall consider--
                  (A) the impact of activities funded on 
                reducing overall drug traffic in the United 
                States, or minimizing the probability that an 
                emerging drug trafficking threat will spread to 
                other areas of the United States; and
                  (B) such other criteria as the Director 
                considers appropriate.
  (j) Annual Hidta Program Budget Submissions.--As part of the 
documentation that supports the President's annual budget 
request for the Office, the Director shall submit to Congress a 
budget justification that includes--
          (1) the amount proposed for each HIDTA, conditional 
        upon a review by the Office of the request submitted by 
        such HIDTA and the performance of such HIDTA, with 
        supporting narrative descriptions and rationale for 
        each request;
          (2) a detailed justification that explains--
                  (A) the reasons for the proposed funding 
                level and how such funding level was determined 
                based on a current assessment of the drug 
                trafficking threat in each high intensity drug 
                trafficking area;
                  (B) how such funding will ensure that the 
                goals and objectives of each such area will be 
                achieved; and
                  (C) how such funding supports the National 
                Drug Control Strategy; and
          (3) the amount of HIDTA funds used to investigate and 
        prosecute organizations and individuals trafficking in 
        each major illicit drug, as identified by the Director, 
        in the prior calendar year, and a description of how 
        those funds were used.
  (k) Hidta Annual Evaluation Report.--As part of each National 
Drug Control Evaluation assessment under section 1006, the 
Director shall include, for each designated high intensity drug 
trafficking area, a report that--
          (1) describes--
                  (A) the specific purposes for the high 
                intensity drug trafficking area; and
                  (B) the specific long-term and short-term 
                goals and objectives for the high intensity 
                drug trafficking area;
          (2) includes an evaluation of the performance of the 
        high intensity drug trafficking area in accomplishing 
        the specific long-term and short-term goals and 
        objectives identified under subparagraph (1)(B);
          (3) assesses the number and operation of all 
        federally funded drug enforcement task forces within 
        such high intensity drug trafficking area;
          (4) describes--
                  (A) each Federal, State, local, and Tribal 
                drug enforcement task force operating in such 
                high intensity drug trafficking area;
                  (B) how such task forces coordinate with each 
                other, with any high intensity drug trafficking 
                area task force, and with investigations 
                receiving funds from the Organized Crime and 
                Drug Enforcement Task Force;
                  (C) what steps, if any, each such task force 
                takes to share information regarding drug 
                trafficking and drug production with other 
                federally funded drug enforcement task forces 
                in the high intensity drug trafficking area;
                  (D) the role of the high intensity drug 
                trafficking area in coordinating the sharing of 
                such information among task forces;
                  (E) the nature and extent of cooperation by 
                each Federal, State, local, and Tribal 
                participant in ensuring that such information 
                is shared among law enforcement agencies and 
                with the high intensity drug trafficking area;
                  (F) the nature and extent to which 
                information sharing and enforcement activities 
                are coordinated with joint terrorism task 
                forces in the high intensity drug trafficking 
                area; and
                  (G) any recommendations for measures needed 
                to ensure that task force resources are 
                utilized efficiently and effectively to reduce 
                the availability of illegal drugs in the high 
                intensity drug trafficking areas; and
          (5) in consultation with the Director of National 
        Intelligence--
                  (A) evaluates existing and planned law 
                enforcement intelligence systems supported by 
                such high intensity drug trafficking area, or 
                utilized by task forces receiving any funding 
                under the Program, including the extent to 
                which such systems ensure access and 
                availability of law enforcement intelligence to 
                Federal, State, local, and Tribal law 
                enforcement agencies within the high intensity 
                drug trafficking area and outside of such area;
                  (B) evaluates the extent to which Federal, 
                State, local, and Tribal law enforcement 
                agencies participating in each high intensity 
                drug trafficking area are sharing law 
                enforcement intelligence information to assess 
                current drug trafficking threats and design 
                appropriate enforcement strategies; and
                  (C) identifies the measures needed to improve 
                effective sharing of information and law 
                enforcement intelligence regarding drug 
                trafficking and drug production among Federal, 
                State, local, and Tribal law enforcement 
                participating in a high intensity drug 
                trafficking area, and between such agencies and 
                similar agencies outside the high intensity 
                drug trafficking area.
  (l) Coordination of Law Enforcement Intelligence Sharing With 
Organized Crime Drug Enforcement Task Force Program.--
          (1) Drug enforcement intelligence sharing.--The 
        Director, in consultation with the Attorney General, 
        shall ensure that any drug enforcement intelligence 
        obtained by the Intelligence Support Center for each 
        high intensity drug trafficking area is shared, on a 
        timely basis, with the drug intelligence fusion center 
        operated by the Organized Crime Drug Enforcement Task 
        Force of the Department of Justice.
          (2) Certification.--Before the Director awards any 
        funds to a high intensity drug trafficking area, the 
        Director shall certify that the law enforcement 
        entities participating in that HIDTA are providing 
        laboratory seizure data to the national clandestine 
        laboratory database at the El Paso Intelligence Center.
  (m) Authorization of Appropriations.--There is authorized to 
be appropriated to the Office to carry out this section 
$280,000,000 for each fiscal years 2019 through 2023.
  (n) Specific Purposes.--
          (1) In general.--The Director shall ensure that, of 
        the amounts appropriated for a fiscal year for the 
        Program, at least 2.5 percent is used in high intensity 
        drug trafficking areas with severe neighborhood safety 
        and illegal drug distribution problems.
          (2) Required uses.--The funds used under paragraph 
        (1) shall be used to ensure the safety of neighborhoods 
        and the protection of communities, including the 
        prevention of the intimidation of witnesses of illegal 
        drug distribution and related activities and the 
        establishment of or support for programs that provide 
        protection or assistance to witnesses in court 
        proceedings.
          (3) Best practice models.--The Director shall work 
        with the HIDTAs to develop and maintain best practice 
        models to assist State, local, and Tribal governments 
        in addressing witness safety, relocation, financial and 
        housing assistance, or any other services related to 
        witness protection or assistance in cases of illegal 
        drug distribution and related activities. The Director 
        shall ensure dissemination of the best practice models 
        to each HIDTA.

         SUBCHAPTER III--DRUG-FREE COMMUNITIES SUPPORT PROGRAM

Sec. 1031. Establishment of drug-free communities support program

  (a) Establishment.--The Director shall establish a program to 
support communities in the development and implementation of 
comprehensive, long-term plans and programs to prevent and 
treat substance use and misuse among youth.
  (b) Program.--In carrying out the Program, the Director 
shall--
          (1) make and track grants to grant recipients;
          (2) provide for technical assistance and training, 
        data collection, and dissemination of information on 
        state-of-the-art practices that the Director determines 
        to be effective in reducing substance use; and
          (3) provide for the general administration of the 
        Program.
  (c) Administration.--The Director shall appoint an 
Administrator to carry out the Program.
  (d) Contracting.--The Director may employ any necessary staff 
and may enter into contracts or agreements with national drug 
control agencies, including interagency agreements, to delegate 
authority for the execution of grants and for such other 
activities necessary to carry out this chapter.

Sec. 1032. Program authorization

  (a) Grant Eligibility.--To be eligible to receive an initial 
grant or a renewal grant under this subchapter, a coalition 
shall meet each of the following criteria:
          (1) Application.--The coalition shall submit an 
        application to the Administrator in accordance with 
        section 1033(a)(2).
          (2) Major sector involvement.--
                  (A) In general.--The coalition shall consist 
                of 1 or more representatives of each of the 
                following categories:
                          (i) Youth.
                          (ii) Parents.
                          (iii) Businesses.
                          (iv) The media.
                          (v) Schools.
                          (vi) Organizations serving youth.
                          (vii) Law enforcement.
                          (viii) Religious or fraternal 
                        organizations.
                          (ix) Civic and volunteer groups.
                          (x) Health care professionals.
                          (xi) State, local, or tribal 
                        governmental agencies with expertise in 
                        the field of substance use prevention 
                        or substance use disorders (including, 
                        if applicable, the State authority with 
                        primary authority for substance use and 
                        misuse).
                          (xii) Other organizations involved in 
                        reducing the prevalence of substance 
                        use and misuse or substance use 
                        disorders.
                  (B) Elected officials.--If feasible, in 
                addition to representatives from the categories 
                listed in subparagraph (A), the coalition shall 
                have an elected official (or a representative 
                of an elected official) from--
                          (i) the Federal Government; and
                          (ii) the government of the 
                        appropriate State and political 
                        subdivision thereof or the governing 
                        body or an Indian tribe (as that term 
                        is defined in section 4(e) of the 
                        Indian Self-Determination Act (25 
                        U.S.C. 450b(e))).
                  (C) Representation.--An individual who is a 
                member of the coalition may serve on the 
                coalition as a representative of not more than 
                1 category listed under subparagraph (A).
          (3) Commitment.--The coalition shall demonstrate, to 
        the satisfaction of the Administrator--
                  (A) that the representatives of the coalition 
                have worked together on substance use and 
                misuse reduction initiatives, which, at a 
                minimum, includes initiatives that target drugs 
                described in section 1037(6)(A), for a period 
                of not less than 6 months, acting through 
                entities such as task forces, subcommittees, or 
                community boards; and
                  (B) substantial participation from volunteer 
                leaders in the community involved (especially 
                in cooperation with individuals involved with 
                youth such as parents, teachers, coaches, youth 
                workers, and members of the clergy).
          (4) Mission and strategies.--The coalition shall, 
        with respect to the community involved--
                  (A) have as its principal mission the 
                reduction of illegal drug use, which, at a 
                minimum, includes the use of illegal drugs 
                described in section 1037(6)(A), in a 
                comprehensive and long-term manner, with a 
                primary focus on youth in the community;
                  (B) describe and document the nature and 
                extent of the substance use and misuse problem, 
                which, at a minimum, includes the use and 
                misuse of drugs described in section 
                1037(6)(A), in the community;
                  (C)(i) provide a description of substance use 
                and misuse prevention and treatment programs 
                and activities, which, at a minimum, includes 
                programs and activities relating to the use and 
                misuse of drugs described in section 
                1037(6)(A), in existence at the time of the 
                grant application; and
                  (ii) identify substance use and misuse 
                programs and service gaps, which, at a minimum, 
                includes programs and gaps relating to the use 
                and misuse of drugs described in section 
                1037(6)(A), in the community;
                  (D) develop a strategic plan to reduce 
                substance use and misuse among youth, which, at 
                a minimum, includes the use and misuse of drugs 
                described in section 1037(6)(A), in a 
                comprehensive and long-term fashion; and
                  (E) work to develop a consensus regarding the 
                priorities of the community to combat substance 
                use and misuse among youth, which, at a 
                minimum, includes the use and misuse of drugs 
                described in section 1037(6)(A).
          (5) Sustainability.--The coalition shall demonstrate 
        that the coalition is an ongoing concern by 
        demonstrating that the coalition--
                  (A) is--
                          (i)(I) a nonprofit organization; or
                          (II) an entity that the Administrator 
                        determines to be appropriate; or
                          (ii) part of, or is associated with, 
                        an established legal entity;
                  (B) receives financial support (including, in 
                the discretion of the Administrator, in-kind 
                contributions) from non-Federal sources; and
                  (C) has a strategy to solicit substantial 
                financial support from non-Federal sources to 
                ensure that the coalition and the programs 
                operated by the coalition are self-sustaining.
          (6) Accountability.--The coalition shall--
                  (A) establish a system to measure and report 
                outcomes--
                          (i) consistent with common indicators 
                        and evaluation protocols established by 
                        the Administrator; and
                          (ii) approved by the Administrator;
                  (B) conduct--
                          (i) for an initial grant under this 
                        subchapter, an initial benchmark survey 
                        of drug use among youth (or use local 
                        surveys or performance measures 
                        available or accessible in the 
                        community at the time of the grant 
                        application); and
                          (ii) biennial surveys (or incorporate 
                        local surveys in existence at the time 
                        of the evaluation) to measure the 
                        progress and effectiveness of the 
                        coalition; and
                  (C) provide assurances that the entity 
                conducting an evaluation under this paragraph, 
                or from which the coalition receives 
                information, has experience--
                          (i) in gathering data related to 
                        substance use and misuse among youth; 
                        or
                          (ii) in evaluating the effectiveness 
                        of community anti-drug coalitions.
          (7) Additional criteria.--The Director shall not 
        impose any eligibility criteria on new applicants or 
        renewal grantees not provided in this chapter.
  (b) Grant Amounts.--
          (1) In general.--
                  (A) Grants.--
                          (i) In general.--Subject to clause 
                        (iv), for a fiscal year, the 
                        Administrator may grant to an eligible 
                        coalition under this paragraph, an 
                        amount not to exceed the amount of non-
                        Federal funds raised by the coalition, 
                        including in-kind contributions, for 
                        that fiscal year.
                          (ii) Suspension of grants.--If such 
                        grant recipient fails to continue to 
                        meet the criteria specified in 
                        subsection (a), the Administrator may 
                        suspend the grant, after providing 
                        written notice to the grant recipient 
                        and an opportunity to appeal.
                          (iii) Renewal grants.--Subject to 
                        clause (iv), the Administrator may 
                        award a renewal grant to a grant 
                        recipient under this subparagraph for 
                        each fiscal year following the fiscal 
                        year for which an initial grant is 
                        awarded, in an amount not to exceed the 
                        amount of non-Federal funds raised by 
                        the coalition, including in-kind 
                        contributions, for that fiscal year, 
                        during the 4-year period following the 
                        period of the initial grant.
                          (iv) Limitation.--The amount of a 
                        grant award under this subparagraph may 
                        not exceed $125,000 for a fiscal year.
                  (B) Coalition awards.--
                          (i) In general.--Except as provided 
                        in clause (ii), the Administrator may, 
                        with respect to a community, make a 
                        grant to 1 eligible coalition that 
                        represents that community.
                          (ii) Exception.--The Administrator 
                        may make a grant to more than 1 
                        eligible coalition that represents a 
                        community if--
                                  (I) the eligible coalitions 
                                demonstrate that the coalitions 
                                are collaborating with one 
                                another; and
                                  (II) each of the coalitions 
                                has independently met the 
                                requirements set forth in 
                                subsection (a).
          (2) Rural coalition grants.--
                  (A) In general.--
                          (i) In general.--In addition to 
                        awarding grants under paragraph (1), to 
                        stimulate the development of coalitions 
                        in sparsely populated and rural areas, 
                        the Administrator may award a grant in 
                        accordance with this section to a 
                        coalition that represents a county with 
                        a population that does not exceed 
                        30,000 individuals. In awarding a grant 
                        under this paragraph, the Administrator 
                        may waive any requirement under 
                        subsection (a) if the Administrator 
                        considers that waiver to be 
                        appropriate.
                          (ii) Matching requirement.--Subject 
                        to subparagraph (C), for a fiscal year, 
                        the Administrator may grant to an 
                        eligible coalition under this 
                        paragraph, an amount not to exceed the 
                        amount of non-Federal funds raised by 
                        the coalition, including in-kind 
                        contributions, for that fiscal year.
                          (iii) Suspension of grants.--If such 
                        grant recipient fails to continue to 
                        meet any criteria specified in 
                        subsection (a) that has not been waived 
                        by the Administrator pursuant to clause 
                        (i), the Administrator may suspend the 
                        grant, after providing written notice 
                        to the grant recipient and an 
                        opportunity to appeal.
                  (B) Renewal grants.--The Administrator may 
                award a renewal grant to an eligible coalition 
                that is a grant recipient under this paragraph 
                for each fiscal year following the fiscal year 
                for which an initial grant is awarded, in an 
                amount not to exceed the amount of non-Federal 
                funds raised by the coalition, including in-
                kind contributions, during the 4-year period 
                following the period of the initial grant.
                  (C) Limitations.--
                          (i) Amount.--The amount of a grant 
                        award under this paragraph shall not 
                        exceed $125,000 for a fiscal year.
                          (ii) Awards.--With respect to a 
                        county referred to in subparagraph (A), 
                        the Administrator may award a grant 
                        under this section to not more than 1 
                        eligible coalition that represents the 
                        county.
          (3) Additional grants.--
                  (A) In general.--Subject to subparagraph (F), 
                the Administrator may award an additional grant 
                under this paragraph to an eligible coalition 
                awarded a grant under paragraph (1) or (2) for 
                any first fiscal year after the end of the 4-
                year period following the period of the initial 
                grant under paragraph (1) or (2), as the case 
                may be.
                  (B) Scope of grants.--A coalition awarded a 
                grant under paragraph (1) or (2), including a 
                renewal grant under such paragraph, may not be 
                awarded another grant under such paragraph, and 
                is eligible for an additional grant under this 
                section only under this paragraph.
                  (C) No priority for applications.--The 
                Administrator may not afford a higher priority 
                in the award of an additional grant under this 
                paragraph than the Administrator would afford 
                the applicant for the grant if the applicant 
                were submitting an application for an initial 
                grant under paragraph (1) or (2) rather than an 
                application for a grant under this paragraph.
                  (D) Renewal grants.--Subject to subparagraph 
                (F), the Administrator may award a renewal 
                grant to a grant recipient under this paragraph 
                for each of the fiscal years of the 4-fiscal-
                year period following the fiscal year for which 
                the initial additional grant under subparagraph 
                (A) is awarded in an amount not to exceed 
                amounts as follows:
                          (i) For the first and second fiscal 
                        years of that 4-fiscal-year period, the 
                        amount equal to 80 percent of the non-
                        Federal funds, including in-kind 
                        contributions, raised by the coalition 
                        for the applicable fiscal year.
                          (ii) For the third and fourth fiscal 
                        years of that 4-fiscal-year period, the 
                        amount equal to 67 percent of the non-
                        Federal funds, including in-kind 
                        contributions, raised by the coalition 
                        for the applicable fiscal year.
                  (E) Suspension.--If a grant recipient under 
                this paragraph fails to continue to meet the 
                criteria specified in subsection (a), the 
                Administrator may suspend the grant, after 
                providing written notice to the grant recipient 
                and an opportunity to appeal.
                  (F) Limitation.--The amount of a grant award 
                under this paragraph may not exceed $125,000 
                for a fiscal year.
          (4) Process for suspension.--A grantee shall not be 
        suspended or terminated under paragraph (1)(A)(ii), 
        (2)(A)(iii), or (3)(C) unless that grantee is afforded 
        a fair, timely, and independent appeal prior to such 
        suspension or termination.
  (c) Treatment of Funds for Coalitions Representing Certain 
Organizations.--Funds appropriated for the substance use and 
misuse activities of a coalition that includes a representative 
of the Bureau of Indian Affairs, the Indian Health Service, or 
a tribal government agency with expertise in the field of 
substance use prevention may be counted as non-Federal funds 
raised by the coalition for purposes of this section.
  (d) Priority in Awarding Grants.--In awarding grants under 
subsection (b)(1)(A)(i), priority shall be given to a coalition 
serving economically disadvantaged areas.

Sec. 1033. Information collection and dissemination with respect to 
                    grant recipients

  (a) Coalition Information.--
          (1) General auditing authority.--For the purpose of 
        audit and examination, the Administrator--
                  (A) shall have access to any books, 
                documents, papers, and records that are 
                pertinent to any grant or grant renewal request 
                under this chapter; and
                  (B) may periodically request information from 
                a grant recipient to ensure that the grant 
                recipient meets the applicable criteria under 
                section 1032(a).
          (2) Application process.--The Administrator shall 
        issue a request for proposal regarding, with respect to 
        the grants awarded under section 1032, the application 
        process, grant renewal, and suspension or withholding 
        of renewal grants. Each application under this 
        paragraph shall be in writing and shall be subject to 
        review by the Administrator.
          (3) Reporting.--The Administrator shall, to the 
        maximum extent practicable and in a manner consistent 
        with applicable law, minimize reporting requirements by 
        a grant recipient and expedite any application for a 
        renewal grant made under this subchapter.
  (b) Data Collection and Dissemination.--
          (1) In general.--The Administrator may collect data 
        from--
                  (A) national substance use and misuse 
                organizations that work with eligible 
                coalitions, community anti-drug coalitions, 
                departments or agencies of the Federal 
                Government, or State or local governments and 
                the governing bodies of Indian tribes; and
                  (B) any other entity or organization that 
                carries out activities that relate to the 
                purposes of the Program.
          (2) Activities of administrator.--The Administrator 
        may--
                  (A) evaluate the utility of specific 
                initiatives relating to the purposes of the 
                Program;
                  (B) conduct an evaluation of the Program; and
                  (C) disseminate information described in this 
                subsection to--
                          (i) eligible coalitions and other 
                        substance use prevention organizations; 
                        and
                          (ii) the general public.
          (3) Consultation.--The Administrator shall carry out 
        activities under this subsection in consultation with 
        the National Community Antidrug Coalition Institute.
          (4) Limitation on use of certain funds for evaluation 
        of program.--Amounts for activities under paragraph 
        (2)(B) may not be derived from amounts under section 
        1038(a) except for amounts that are available under 
        section 1038(b) for administrative costs.

Sec. 1034. Technical assistance and training

  (a) In General.--
          (1) Technical assistance and agreements.--With 
        respect to any grant recipient or other organization, 
        the Administrator may--
                  (A) offer technical assistance and training; 
                and
                  (B) enter into contracts and cooperative 
                agreements.
          (2) Coordination of programs.--The Administrator may 
        facilitate the coordination of programs between a grant 
        recipient and other organizations and entities.
  (b) Training.--The Administrator may provide training to any 
representative designated by a grant recipient in--
          (1) coalition building;
          (2) task force development;
          (3) mediation and facilitation, direct service, 
        assessment and evaluation; or
          (4) any other activity related to the purposes of the 
        Program.

Sec. 1035. Supplemental grants for coalition mentoring activities

  (a) Authority to Make Grants.--As part of the program 
established under section 1031, the Director may award an 
initial grant under this subsection, and renewal grants under 
subsection (f), to any coalition awarded a grant under section 
1032 that meets the criteria specified in subsection (d) in 
order to fund coalition mentoring activities by such coalition 
in support of the program.
  (b) Treatment With Other Grants.--
          (1) Supplement.--A grant awarded to a coalition under 
        this section is in addition to any grant awarded to the 
        coalition under section 1032.
          (2) Requirement for basic grant.--A coalition may not 
        be awarded a grant under this section for a fiscal year 
        unless the coalition was awarded a grant or renewal 
        grant under section 1032(b) for that fiscal year.
  (c) Application.--A coalition seeking a grant under this 
section shall submit to the Administrator an application for 
the grant in such form and manner as the Administrator may 
require.
  (d) Criteria.--A coalition meets the criteria specified in 
this subsection if the coalition--
          (1) has been in existence for at least 5 years;
          (2) has achieved, by or through its own efforts, 
        measurable results in the prevention and treatment of 
        substance use and misuse among youth;
          (3) has staff or members willing to serve as mentors 
        for persons seeking to start or expand the activities 
        of other coalitions in the prevention and treatment of 
        substance use and misuse;
          (4) has demonstrable support from some members of the 
        community in which the coalition mentoring activities 
        to be supported by the grant under this section are to 
        be carried out; and
          (5) submits to the Administrator a detailed plan for 
        the coalition mentoring activities to be supported by 
        the grant under this section.
  (e) Use of Grant Funds.--A coalition awarded a grant under 
this section shall use the grant amount for mentoring 
activities to support and encourage the development of new, 
self-supporting community coalitions that are focused on the 
prevention and treatment of substance use and misuse in such 
new coalitions' communities. The mentoring coalition shall 
encourage such development in accordance with the plan 
submitted by the mentoring coalition under subsection (d)(5).
  (f) Renewal Grants.--The Administrator may make a renewal 
grant to any coalition awarded a grant under subsection (a), or 
a previous renewal grant under this subsection, if the 
coalition, at the time of application for such renewal grant--
          (1) continues to meet the criteria specified in 
        subsection (d); and
          (2) has made demonstrable progress in the development 
        of one or more new, self-supporting community 
        coalitions that are focused on the prevention and 
        treatment of substance use and misuse.
  (g) Grant Amounts.--
          (1) In general.--Subject to paragraphs (2) and (3), 
        the total amount of grants awarded to a coalition under 
        this section for a fiscal year may not exceed the 
        amount of non-Federal funds raised by the coalition, 
        including in-kind contributions, for that fiscal year. 
        Funds appropriated for the substance use and misuse 
        activities of a coalition that includes a 
        representative of the Bureau of Indian Affairs, the 
        Indian Health Service, or a tribal government agency 
        with expertise in the field of substance use prevention 
        may be counted as non-Federal funds raised by the 
        coalition.
          (2) Initial grants.--The amount of the initial grant 
        awarded to a coalition under subsection (a) may not 
        exceed $75,000.
          (3) Renewal grants.--The total amount of renewal 
        grants awarded to a coalition under subsection (f) for 
        any fiscal year may not exceed $75,000.
  (h) Fiscal Year Limitation on Amount Available for Grants.--
The total amount available for grants under this section, 
including renewal grants under subsection (f), in any fiscal 
year may not exceed the amount equal to five percent of the 
amount authorized to be appropriated by section 1038 for that 
fiscal year.
  (i) Priority in Awarding Initial Grants.--In awarding initial 
grants under this section, priority shall be given to a 
coalition that expressly proposes to provide mentorship to a 
coalition or aspiring coalition serving economically 
disadvantaged areas.

Sec. 1036. Authorization for National Community Antidrug Coalition 
                    Institute

  (a) In General.--The Director shall, using amounts authorized 
to be appropriated by subsection (d), make a competitive grant 
to provide for the continuation of the National Community Anti-
drug Coalition Institute.
  (b) Eligible Organizations.--An organization eligible for the 
grant under subsection (a) is any national nonprofit 
organization that represents, provides technical assistance and 
training to, and has special expertise and broad, national-
level experience in community antidrug coalitions under this 
subchapter.
  (c) Use of Grant Amount.--The organization that receives the 
grant under subsection (a) shall continue a National Community 
Anti-Drug Coalition Institute to--
          (1) provide education, training, and technical 
        assistance for coalition leaders and community teams, 
        with emphasis on the development of coalitions serving 
        economically disadvantaged areas;
          (2) develop and disseminate evaluation tools, 
        mechanisms, and measures to better assess and document 
        coalition performance measures and outcomes; and
          (3) bridge the gap between research and practice by 
        translating knowledge from research into practical 
        information.
  (d) Authorization of Appropriations.--The Director shall, 
using amounts authorized to be appropriated by section 1038, 
make a grant of $2,000,000 under subsection (a), for each of 
the fiscal years 2019 through 2023.

Sec. 1037. Definitions

  In this subchapter:
          (1) Administrator.--The term ``Administrator'' means 
        the Administrator appointed by the Director under 
        section 1031(c).
          (2) Community.--The term ``community'' shall have the 
        meaning provided that term by the Administrator.
          (3) Eligible coalition.--The term ``eligible 
        coalition'' means a coalition that meets the applicable 
        criteria under section 1032(a).
          (4) Grant recipient.--The term ``grant recipient'' 
        means the recipient of a grant award under section 
        1032.
          (5) Program.--The term ``Program'' means the program 
        established under section 1031(a).
          (6) Substance use and misuse.--The term ``substance 
        use and misuse'' means--
                  (A) the illegal use or misuse of drugs, 
                including substances for which a listing is in 
                effect under any of schedules I through V under 
                section 202 of the Controlled Substances Act 
                (21 U.S.C. 812);
                  (B) the misuse of inhalants or over the 
                counter drugs; or
                  (C) the use of alcohol, tobacco, or other 
                related product as such use is prohibited by 
                State or local law.
          (7) Youth.--The term ``youth'' shall have the meaning 
        provided that term by the Administrator.

Sec. 1038. Drug-free communities reauthorization

  (a) Authorization of Appropriations.--There are authorized to 
be appropriated to the Office to carry out this subchapter 
$99,000,000 for each of fiscal years 2019 through 2023.
  (b) Administrative Costs.--Not more than 8 percent of the 
funds appropriated for this subchapter may be used by the 
Office or, in the discretion of the Director, an agency 
delegated to carry out the program under section 1031(d) to pay 
for administrative costs associated with carrying out the 
program.
                              ----------                              


OFFICE OF NATIONAL DRUG CONTROL POLICY REAUTHORIZATION ACT OF 2006

           *       *       *       *       *       *       *



TITLE II--THE NATIONAL DRUG CONTROL STRATEGY

           *       *       *       *       *       *       *


[SEC. 203. ANNUAL REPORT REQUIREMENT.

  [(a) In general.--On or before February 1, 2013, and every 3 
years thereafter,, the Director shall submit a report to 
Congress that describes--
          [(1) the strategy of the national media campaign and 
        whether specific objectives of the campaign were 
        accomplished;
          [(2) steps taken to ensure that the national media 
        campaign operates in an effective and efficient manner 
        consistent with the overall strategy and focus of the 
        campaign;
          [(3) plans to purchase advertising time and space;
          [(4) policies and practices implemented to ensure 
        that Federal funds are used responsibly to purchase 
        advertising time and space and eliminate the potential 
        for waste, fraud, and abuse;
          [(5) all contracts entered into with a corporation, 
        partnership, or individual working on behalf of the 
        national media campaign;
          [(6) specific policies and steps implemented to 
        ensure compliance with title IV of this Act;
          [(7) steps taken to ensure that the national media 
        campaign will secure, to the maximum extent possible, 
        no cost matches of advertising time and space or in-
        kind contributions that are directly related to the 
        campaign in accordance with title IV of this Act; and
          [(8) a review and evaluation of the effectiveness of 
        the national media campaign strategy for the past year.
  [(b) Audit.--The Government Accountability Office shall, not 
later than December 31, 2013, and every 3 years thereafter--
          [(1) conduct and supervise an audit and investigation 
        relating to the programs and operations of the--
                  [(A) Office; or
                  [(B) certain programs within the Office, 
                including--
                          [(i) the High Intensity Drug 
                        Trafficking Areas Program;
                          [(ii) the Counterdrug Technology 
                        Assessment Center; or
                          [(iii) the National Youth Anti-drug 
                        Media Campaign; and
          [(2) provide the Director and the appropriate 
        congressional committees with a report containing an 
        evaluation of and recommendations on the--
                  [(A) policies and activities of the programs 
                and operations subject to the audit and 
                investigation;
                  [(B) economy, efficiency, and effectiveness 
                in the administration of the reviewed programs 
                and operations; and
                  [(C) policy or management changes needed to 
                prevent and detect fraud and abuse in such 
                programs and operations.]

           *       *       *       *       *       *       *


                   [TITLE VIII--DRUG-FREE COMMUNITIES

[SEC. 801. REAUTHORIZATION

  [(a) In general.--Section 1024(a) of the Drug-Free 
Communities Act of 1997 (21 U.S.C. 1524(a)) is amended--
          [(1) in paragraph (9), by striking ``and'' after the 
        semicolon;
          [(2) in paragraph (10), by striking the period and 
        inserting a semicolon; and
          [(3) by adding at the end the following:
          [``(11) $109,000,000 for fiscal year 2008;
          [``(12) $114,000,000 for fiscal year 2009;
          [``(13) $119,000,000 for fiscal year 2010;
          [``(14) $124,000,000 for fiscal year 2011; and
          [``(15) $129,000,000 for fiscal year 2012.''.
  [(b) Administration Costs.--Section 1024(b) of the Drug-Free 
Communities Act of 1997 (21 U.S.C. 1524(b)) is amended to read 
as follows:
  [``(b) Administrative Costs.--
          [``(1) Limitation.--Not more than 3 percent of the 
        funds appropriated for this chapter may be used by the 
        Office of National Drug Control Policy to pay for 
        administrative costs associated with their 
        responsibilities under the chapter.
          [``(2) Designated agency.--The agency delegated to 
        carry out this program under section 1031(d) may use up 
        to 5 percent of the funds allocated for grants under 
        this chapter for administrative costs associated with 
        carrying out the program.''.

[SEC. 802. SUSPENSION OF GRANTS.

  [(a) In general.--Section 1032(b) of the Drug-Free 
Communities Act of 1997 (21 U.S.C. 1532(b)) is amended by 
adding at the end the following:
          [``(4) Process for suspension.--A grantee shall not 
        be suspended or terminated under paragraph (1)(A)(ii), 
        (2)(A)(iii), or (3)(E) unless that grantee is afforded 
        a fair, timely, and independent appeal prior to such 
        suspension or termination.''.
  [(b) Report to Congress.--Not later than 60 days after the 
date of enactment of this Act, the Director of the Office of 
National Drug Control Policy shall submit to Congress a report 
detailing the appeals process required by section 1032(b)(4) of 
the Drug-Free Communities Act of 1997, as added by subsection 
(a).

[SEC. 803. GRANT AWARD INCREASE

  [Subsections (b)(1)(A)(iv), (b)(2)(C)(i), and (b)(3)(F) of 
section 1032 of the Drug-Free Communities Act of 1997 (21 
U.S.C. 1532) are amended by striking ``$100,000'' and inserting 
``$125,000''.

[SEC. 804. PROHIBITION ON ADDITIONAL ELIGIBILITY CRITERIA

  [Section 1032(a) of the Drug-Free Communities Act of 1997 (21 
U.S.C. 1532(a)) is amended by adding at the end the following:
          [``(7) Additional criteria.--The Director shall not 
        impose any eligibility criteria on new applicants or 
        renewal grantees not provided in this chapter.''.

[SEC. 805. NATIONAL COMMUNITY ANTI-DRUG COALITION INSTITUTE

  [Section 4 of Public Law 107-82 (21 U.S.C. 1521 note), 
reauthorizing the Drug-Free Communities Support Program, is 
amended--
          [(1) by amending subsection (a) to read as follows:
  [``(a) In general.--The Director of the Office of National 
Drug Control Policy shall, using amounts authorized to be 
appropriated by subsection (d), make a directed grant to 
Community Anti-Drug Coalitions of America to provide for the 
continuation of the National Community Anti-drug Coalition 
Institute.'';
          [(2) by striking subsection (b) and redesignating 
        subsections (c) and (d) as (b) and (c), respectively; 
        and
          [(3) in subsection (c), as redesignated by paragraph 
        (2), by adding at the end the following:
          [``(4) For each of the fiscal years 2008 through 
        2012, $2,000,000.''.]

           *       *       *       *       *       *       *


TITLE XI--MISCELLANEOUS PROVISIONS

           *       *       *       *       *       *       *


[SEC. 1105. MODEL ACTS.

  [(a) In General.--The Director of the Office of National Drug 
Control Policy shall provide for or shall enter into an 
agreement with a non-profit corporation that is described in 
section 501(c)(3) of the Internal Revenue Code of 1986 and 
exempt from tax under section 501(a) of such Code to--
          [(1) advise States on establishing laws and policies 
        to address alcohol and other drug issues, based on the 
        model State drug laws developed by the President's 
        Commission on Model State Drug Laws in 1993; and
          [(2) revise such model State drug laws and draft 
        supplementary model State laws to take into 
        consideration changes in the alcohol and drug abuse 
        problems in the State involved.
  [(b) Authorization of Appropriations.--There is authorized to 
be appropriated to carry out this subsection $1,500,000 for 
each of fiscal years 2007 through 2011.]

           *       *       *       *       *       *       *


[SEC. 1110. REQUIREMENT FOR SOUTHWEST BORDER COUNTERNARCOTICS STRATEGY.

  [(a) In General.--Not later than 120 days after the date of 
enactment of this Act, and every 2 years thereafter, the 
Director of National Drug Control Policy shall submit to the 
Congress a Southwest Border Counternarcotics Strategy.
  [(b) Purposes.--The Southwest Border Counternarcotics 
Strategy shall--
          [(1) set forth the Government's strategy for 
        preventing the illegal trafficking of drugs across the 
        international border between the United States and 
        Mexico, including through ports of entry and between 
        ports of entry on that border;
          [(2) state the specific roles and responsibilities of 
        the relevant National Drug Control Program agencies (as 
        defined in section 702 of the Office of National Drug 
        Control Policy Reauthorization Act of 1998 (21 U.S.C. 
        1701)) for implementing that strategy; and
          [(3) identify the specific resources required to 
        enable the relevant National Drug Control Program 
        agencies to implement that strategy.
  [(c) Specific Content Related to Drug Tunnels Between the 
United States and Mexico.--The Southwest Border 
Counternarcotics Strategy shall include--
          [(1) a strategy to end the construction and use of 
        tunnels and subterranean passages that cross the 
        international border between the United States and 
        Mexico for the purpose of illegal trafficking of drugs 
        across such border; and
          [(2) recommendations for criminal penalties for 
        persons who construct or use such a tunnel or 
        subterranean passage for such a purpose.
  [(d) Consultation with other agencies.--The Director shall 
issue the Southwest Border Counternarcotics Strategy in 
consultation with the heads of the relevant National Drug 
Control Program agencies.
  [(e) Limitation.--The Southwest Border Counternarcotics 
Strategy shall not change existing agency authorities or the 
laws governing interagency relationships, but may include 
recommendations about changes to such authorities or laws.
  [(f) Report to Congress.--The Director shall provide a copy 
of the Southwest Border Counternarcotics Strategy to the 
appropriate congressional committees (as defined in section 702 
of the Office of National Drug Control Policy Reauthorization 
Act of 1998 (21 U.S.C. 1701)), and to the Committee on Armed 
Services and the Committee on Homeland Security of the House of 
Representatives, and the Committee on Homeland Security and 
Governmental Affairs and the Committee on Armed Services of the 
Senate.
  [(g) Treatment of Classified or Law Enforcement Sensitive 
Information.--Any content of the Southwest Border 
Counternarcotics Strategy that involves information classified 
under criteria established by an Executive order, or whose 
public disclosure, as determined by the Director or the head of 
any relevant National Drug Control Program agency, would be 
detrimental to the law enforcement or national security 
activities of any Federal, State, local, or tribal agency, 
shall be presented to Congress separately from the rest of the 
strategy.

[SEC. 1110A. REQUIREMENT FOR NORTHERN BORDER COUNTERNARCOTICS STRATEGY.

  [(a) Definitions.--In this section, the terms ``appropriate 
congressional committees'', ``Director'', and ``National Drug 
Control Program agency'' have the meanings given those terms in 
section 702 of the Office of National Drug Control Policy 
Reauthorization Act of 1998 (21 U.S.C. 1701).
  [(b) Strategy.--Not later than 180 days after the date of 
enactment of this section, and every 2 years thereafter, the 
Director, in consultation with the head of each relevant 
National Drug Control Program agency and relevant officials of 
States, local governments, tribal governments, and the 
governments of other countries, shall develop a Northern Border 
Counternarcotics Strategy and submit the strategy to--
          [(1) the appropriate congressional committees 
        (including the Committee on the Judiciary of the Senate 
        and the Committee on the Judiciary of the House of 
        Representatives);
          [(2) the Committee on Armed Services, the Committee 
        on Homeland Security and Governmental Affairs, and the 
        Committee on Indian Affairs of the Senate; and
          [(3) the Committee on Armed Services, the Committee 
        on Homeland Security, and the Committee on Natural 
        Resources of the House of Representatives.
  [(c) Purposes.--The Northern Border Counternarcotics Strategy 
shall--
          [(1) set forth the strategy of the Federal Government 
        for preventing the illegal trafficking of drugs across 
        the international border between the United States and 
        Canada, including through ports of entry and between 
        ports of entry on the border;
          [(2) state the specific roles and responsibilities of 
        each relevant National Drug Control Program agency for 
        implementing the strategy;
          [(3) identify the specific resources required to 
        enable the relevant National Drug Control Program 
        agencies to implement the strategy; and
          [(4) reflect the unique nature of small communities 
        along the international border between the United 
        States and Canada, ongoing cooperation and coordination 
        with Canadian law enforcement authorities, and 
        variations in the volumes of vehicles and pedestrians 
        crossing through ports of entry along the international 
        border between the United States and Canada.
  [(d) Specific Content Related to Cross-border Indian 
Reservations.--The Northern Border Counternarcotics Strategy 
shall include--
          [(1) a strategy to end the illegal trafficking of 
        drugs to or through Indian reservations on or near the 
        international border between the United States and 
        Canada; and
          [(2) recommendations for additional assistance, if 
        any, needed by tribal law enforcement agencies relating 
        to the strategy, including an evaluation of Federal 
        technical and financial assistance, infrastructure 
        capacity building, and interoperability deficiencies.
  [(e) Limitation.--
          [(1) In general.--The Northern Border 
        Counternarcotics Strategy shall not change the existing 
        agency authorities and this section shall not be 
        construed to amend or modify any law governing 
        interagency relationships.
          [(2) Legitimate trade and travel.--The Northern 
        Border Counternarcotics Strategy shall be designed to 
        promote, and not hinder, legitimate trade and travel.
  [(f) Treatment of Classified or Law Enforcement Sensitive 
Information.--
          [(1) In general.--The Northern Border 
        Counternarcotics Strategy shall be submitted in 
        unclassified form and shall be available to the public.
          [(2) Annex.--The Northern Border Counternarcotics 
        Strategy may include an annex containing any classified 
        information or information the public disclosure of 
        which, as determined by the Director or the head of any 
        relevant National Drug Control Program agency, would be 
        detrimental to the law enforcement or national security 
        activities of any Federal, State, local, or tribal 
        agency.]

           *       *       *       *       *       *       *

                              ----------                              


                           PUBLIC LAW 107-82


AN ACT To extend the authorization of the Drug-Free Communities Support 
 Program for an additional 5 years, to authorize a National Community 
Antidrug Coalition Institute, and for other purposes.

           *       *       *       *       *       *       *


[SEC. 4. AUTHORIZATION FOR NATIONAL COMMUNITY ANTIDRUG COALITION 
                    INSTITUTE.

  [(a) In General.--The Director of the Office of National Drug 
Control Policy shall, using amounts authorized to be 
appropriated by subsection (d), make a directed grant to 
Community Anti-Drug Coalitions of America to provide for the 
continuation of the National Community Anti-drug Coalition 
Institute.
  [(b) Use of Grant Amount.--The organization receiving the 
grant under subsection (a) shall establish a National Community 
Antidrug Coalition Institute to--
          [(1) provide education, training, and technical 
        assistance for coalition leaders and community teams, 
        with emphasis on the development of coalitions serving 
        economically disadvantaged areas;
          [(2) develop and disseminate evaluation tools, 
        mechanisms, and measures to better assess and document 
        coalition performance measures and outcomes; and
          [(3) bridge the gap between research and practice by 
        translating knowledge from research into practical 
        information.
  [(c) Authorization of Appropriations.--There is authorized to 
be appropriated for purposes of activities under this section, 
including the grant under subsection (a), amounts as follows:
          [(1) For each of fiscal years 2002 and 2003, 
        $2,000,000.
          [(2) For each of fiscal years 2004 and 2005, 
        $1,000,000.
          [(3) For each of fiscal years 2006 and 2007, 
        $750,000.
          [(4) For each of the fiscal years 2008 through 2012, 
        $2,000,000.]

           *       *       *       *       *       *       *



[GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT]

 
 
                                [all]